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Preface 
This book is intended as an introductory text for scientists who want to know more 
about the histocompatability. It attempts to present the field of immunology from a 
consistent viewpoint, that of the host’s interaction with an environment containing 
many species of potentially harmful microbes.
The book includes the following topics: 1) HLA Polymorphism in Anthropology. 2)
Distinctive Immunological Functions of HLA-G. 3) Immune Privilege Revisited: The 
Roles of Neuronal MHC Class I Molecules in Brain Development and Plasticity. 4) 
Human Leukocyte Antigen Class II in Stimulated Polymorphnuclear Neutrophils. 5)
Dicer Regulates the Expression of Major Histocompatibility Complex (MHC) Class I
Chain-Related Genes A and B. 6.) Killer Immunoglobulin-Like Receptors and Their
Ligands. 7.) Sequence Analysis of MHC Class II Genes in Cetaceans. 8.) Regulation of 
MHC Class I by Viruses. 9.) Major and Minor Histocompatibility Antigens to Non-
Inherited Maternal Antigens (NIMA). 10.) MHC Class I Quality Control. 
This book would not exist without the efforts of the following authors -  Sundararajulu
Panneerchelvam and Mohd Nor Norazmi; Giada Amodio and Silvia Gregori; Adema
Ribic; Bahaa K. A. Abdel-Salam; Kai-Fu Tang; Roberto Biassoni, Irene Vanni and
Elisabetta Ugolotti; Wei-Cheng Yang, Lien-Siang Chou and Jer-Ming Hu; Shatrah
Othman and Rohana Yusof; Masahiro Hirayama, Eiichi Azuma and Yoshihiro 
Komada; Gustav Røder, Linda Geironson, Elna Follin, Camilla Thuring and Kajsa 
Paulsson  which were extremely helpful to all of us, and kept the book running. 
Dr. Bahaa Kenawy Abuel-Hussien Abdel-Salam 
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HLA Polymorphism in Anthropology




Humans are the most adaptable species among living organisms. Adaptation is the sum of
all processes which allows the organism to cope with environmental stresses, in particular 
climate and topography, for its survival. All living species continuing through time and
space to the present day are endowed with innate biological adaptation. The whole gamut
of biological adaptation of human species is dependent on the sum total of anatomical, 
physiological, immunological and genetic characteristics. But the human species, in addition
to biological adaptation, also possess cultural adaptation. Cultures are customs and 
traditions which help shape the human body and mind. The quest for understanding 
diversity of his own species and the rest of the species through time and space has promoted 
the expansion of the science of biological/physical Anthropology [1].
The irresistible urge for understanding the phenomenon of evolution of Homo sapiens with a 
systematic scientific search to decipher the chronological events of the past led researchers
to the objective reconstruction of the vanished past, postulating that anatomically similar 
modern humans had emerged in Africa 200,000 years ago and dispersed to all regions of the
world. The accumulated evidences which led to such a suggestion encompasses research 
from several scientific disciplines viz., hierarchical taxonomy of primates displaying nested
groupings; comparative anatomy of all primates exhibiting homologies such as arboreal 
adaptation and brachiating anatomy of apes and humans; comparative primate embryology 
exhibiting similar ontogeny; comparative molecular genetics of hominoid chromosome
exhibiting 98% similarity between chimpanzees and humans; adaptive anatomical
structures such as pelvic structure adapted to erect bipedalism and larynx adapted for
speech; presence of vestigial structures mimicking ancient forms, nipples on males; 
paleogeographical evidences such as distribution of fossils of earlier and later forms of 
hominoids and their sequence and pattern and chronological sequence of ancient tools, 
overwhelmingly centred around the African origin of modern humans [2-7].
Biological anthropology, primarily deals with tracing the biological origins by analysing 
change in gene frequency in a population gene pool over a period of time leading to
heritable genetic differences in subsequent generations and ultimately the genetic diversity 
of the human species. In the process, scientists undertake genetic analysis to find reasons
behind the physical differences between people of various groups [1]. The genetic analysis 
assesses frequency of variant allele relating to genetic markers and comparing genetic 
variation among populations with a view to trace evolution. In this article a general
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appraisal of genetic diversity, the causative factors of genetic diversity, their impact on 
evolution [7], and the different molecular genetic markers with emphasis on the human 
leukocyte antigen (HLA) genetic markers, used in the study of tracing past events of human 
migrations are discussed. 
2. Genetic diversity 
Humans across the world exhibit remarkable phenotypic variations coupled with 
behavioural attributes. These variations are due to the combined effect of genetic and 
environmental factors. Researchers assess genetic variation by comparing variation between 
individuals in a group and by comparing variation between individuals in different groups 
(intra and inter population differences). The sources of individual variation are due to 
recombinant events in the genome and mutational events in meiosis leading to polymorphic 
alleles. Variation between groups is due to selective pressure on the genome due to 
differences in the environment and due to the combined outcome of founder effect and 
genetic drift. These differences are the source to trace/validate migration patterns in 
populations [8-15]. There are four major causes for genetic diversity in populations. They are 
(1) random sampling of gametes, (2) mutation, (3) subdivision, migration and genetic 
exchange and (4) natural selection.  
3. Random sampling of gametes 
In finite populations in the absence of any selection, random sampling of gametes effects a 
change in the gene frequency from the previous generation by chance. Random sampling is 
better visualised in finite populations. In real life, all populations are finite. For some 
populations (bacteria), the assumption of infinite size is a good approximation. For some, 
this is completely unrealistic. Hardy–Weinberg equilibrium (HW) assumes that the 
population is infinite. When a population is finite, random genetic drift produces a more 
pronounced effect. Random genetic drift is the random fluctuation of allele frequencies 
resulting in fixation or loss of an allele [10-16]. Wright-Fisher model explains the random 
change of frequency in finite populations. This model assumes a constant number of small 
panmictic populations producing infinite number of gametes evolving through non-
overlapping discrete generations without mutation and without selection. This concept of 
random selection resulting in random genetic drift is explained in Fig.1. Consider that the 
parents are heterozygous for a locus, say, A and a. The parents produce a large number of 
gametes of which A and a will be 0.5 in proportion approximately. This proportion may not 
be 0.5 since reproductive cell death may occur at any stage of the gamete formation and 
besides, in females ¾ of the products are lost as polar bodies. In Fig. 1, the population is 
shown as consisting of 10 (3 AA homozygote; 4Aa heterozygotes and 3 aa homozygotes) 
individuals at t0 generation with (allele frequency) of A = 0.5 and a = 0.5, producing infinite 
gametes and 10 individuals by random selection of gametes in each generation. At 
generation t20 (Fig.1) the gene frequency of A=0.55 and a=0.45 (3 Aa heterozygous 4 AA 
homozygous and 3 aa homozygous) and over generations, the finite sampling process erase 
the heterozygosity in the population. The end result of the random change will be that the 
frequency of A will eventually be 1 and a = 0; - that is the population is becoming 
homozygous [Fig.1].  
 




Fig. 1. Random Selection of Gametes 
Illustration of random selection of gametes in a finite population represented by 10 circles, 
producing infinite number of gametes evolving through non-overlapping discrete 
generations without mutation and without selection. Solid circles (homozygous AA), open 
circle (homozygous a a) and semi-solid circles (heterozygous individuals A a) 
The rate of genetic drift has an inverse relationship to the size of the population. This is to 
say that in an infinite population the loss of heterozygosity is extremely minimal. One 
reason for this is that the pool of reproductive individuals is always smaller than the total 
population. There are other reasons, including individual differences in expected fertility 
and changes in population size. Basic principles show that if the population size fluctuates, 
genetic diversity (heterozygosity) is lost at a rate related to the smallest size. There are two 
specific circumstances that greatly accelerate genetic drift. The first, called a bottleneck, 
occurs when a population size is reduced for a protracted period of time and then rebounds. 
The second, called a founder effect, occurs when all individuals in a population are traced 
back to a small number of founding individuals. Genetic diversity is lost very slowly in 
large populations. Like selection, drift is a process of differential reproductive success; 
however, the key element of genetic drift is that which individuals survive and reproduce is 
unrelated to their phenotype and genotype and it is random. 
4. Mutation 
Mutation is the ultimate source of all variations in a population. Mutations can be beneficial, 
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needs. In this respect, mutations are random. Many mutations are functionally silent either 
due to their presence outside the protein coding region of the genome or when present 
within the coding region does not alter the final protein product [17]. These silent mutations 
are used in deciphering genetic ancestry and demography of populations. Random genetic 
drift due to finite sample size which results in loss of genetic variation is offset by mutations 
generating genetic variation. The balance between these two opposing forces is assessed by 
using Coalescent modelling [18, 19].  
Coalescent theory states that all genes or alleles in a given population are ultimately 
inherited from a single ancestor shared by all members of the population, known as the 
most recent common ancestor (MRCA) [19-21]. If the inheritance relationships are displayed 
in the form of a phylogenetic tree (termed a gene genealogy), the gene or allele of interest is 
said to undergo coalescence to the common ancestor (sometimes termed the coancestor to 
emphasize the coalescent relationship) [Fig 2]. Basic coalescence theory assumes that genes 
do not undergo recombination and models genetic drift as a stochastic process. Because the 
process of gene fixation due to genetic drift is a crucial component of coalescence theory, it 
is most useful when the genetic locus under study is not under natural selection. Coalescent 
modeling helps to understand the structure of whole population by assessing a small 
sample of descendents. It allows quantitating expected sequence diversity, the expected 
number of segregating sites, expected heterozygosity etc. Though the coalescent model 
addresses complex issues of population genetics there underlies the following basic 
components viz., the expected time back to the MRCA, the mutation rate and the outcome of 
the mutation [16-21].  
 
Fig. 2. Coalescent Model 
Tracing the gene geneology of the four sub-divided present day population leading back to 
the MRCA. 
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5. Subdivision, migration and genetic exchange 
The collection of genetically differentiated subpopulations is referred to as population 
substructure [22, 23]. In a large random mating population the genes with multiple alleles 
obey HW equilibrium in the absence of natural selection. Migration into and out of a 
population affects the population genetic structure [23-26]. Consider a hypothetical 
supposition that immigrants from a large population formed a new population in a different 
location. The parental population and the new population after hundreds of generations 
may again subdivide. This gives rise to two additional populations. All the four populations 
(ie. the parental plus the 3 sub-divided populations) will go through hundreds of 
generations. Eventually these populations are known as meta populations – regardless of 
whether they remain completely isolated or they may have been in communication with 
each other through the exchange of individuals.  
Migration between two populations may have effect on genetic variation. However, it will 
be difficult to identify the boundaries of sub-populations and on genetic analyses one may 
confront with samples of individuals that may come from one sub-population or from more 
than one sub-population. The parental and the newly formed sub-populations may 
genetically be different from each other. Even if each of the subpopulations obeys HW and 
linkage equilibrium, a pooled sample from these populations may not match the expected 
and observed data. It is due to the fact that populations are more likely to choose mates 
living nearby and not in a random fashion. Since individuals that live close to one another 
tend to be more genetically similar than those that live far apart, the impacts of local mating 
will mimic those of inbreeding within a single well-mixed population. This is known as 
Walhund effect [27]. 
On genetic analysis the copies of a certain genetic locus coexisting in a sub-population do 
not always coalesce together. With reference to Fig. 3, sub-populations B and C, before 
coalescing at (MRCA), coalesce with D. If the subpopulations have high frequencies of 
certain alleles at a locus, the pooled population will show substantial linkage 
disequilibrium. If all the populations are in contact and random mating takes place it will 
take a considerable time for attaining linkage equilibrium since the reduction in linkage 
disequilibrium is by a factor of 1-r per generation, where r is the recombination fraction 
between two loci, that is the linkage disequilibrium between two linked loci will be reduced 
by ½ per generation. Continued random mating eventually result in linkage equilibrium. 
The genetic exchange between the local sub-populations is termed as gene flow. 
6. F statistics 
Walhund effect is the observation of excess homozygotes or deficiency of heterozygotes in a 
population of pooled subpopulations. Subpopulations fixed for a particular allele in a 
certain locus, is indicative of homozygous individuals in that population for that allele. 
Sewall Wright [11,12,28,29] expressed such effect by defining fixation index. Wright defined 




p  is the average allele frequency of homozygotes in sub-populations. Wright’s F parameter 
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Sewall Wright [11,12,28,29] expressed such effect by defining fixation index. Wright defined 




p  is the average allele frequency of homozygotes in sub-populations. Wright’s F parameter 






Fig. 3. Coalescent model in a subdivided population. Adapted from (16) 
The present day sub-divided populations (also known as meta populations) represented by 
A, B, C, D, E and F tracing back to one single parent population in the past. Selected genetic 
locus coexisting in a sub-population do not always coalesce together. For example, the 
subdivided populations B and C coalesce with sub-divided population D before they 
coalesce with the MRCA despite sub-divided population D being in another group of sub-
divided population. Solid circle represents unchanged allele within the selected gene locus 
of the parent while open circle represents the alternate allele in the selected locus. 
subpopulations, then F = 0 (random population); alternatively if they are fixed for an allele 
then F = 1 (100% homozygosity). In the absence of selection and mutation, genetic drift is the 
primary evolutionary force causing differentiation of the population. Mutation and 
migration may prevent F from reaching 1 by introducing alternative alleles. Low levels of 
migration leads to moderately high level of F value. If the drift and migration is continuing 
through many generations and reaching equilibrium then F attains a constant value and can 




Where N is the effective population size (often referred as Ne) and m is number of migration 
rate. 
7. Natural selection 
Natural selection is the fourth primary mechanism which acts as a whole on populations 
rather than individual organisms that produces changes in the genetic composition of a 
population from one generation to the next and in due course causes evolutionary change 
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[29,30]. Individuals in a population vary in genetic composition and some may have genetic 
variants conferring reproductive fitness making them more adaptable than others. In 
successive generations more offsprings will have better traits leading to changes in the 
frequency of that trait. Mutation often produces deleterious alleles. Selection removes 
deleterious alleles thereby providing stability of biological structures, and it is known as 
negative selection. Since negative selection confers stability by removing deleterious alleles 
it is also known as purifying selection or background selection. T cells which recognise self 
molecules and are eliminated in the thymus, is an example of negative selection. In some 
circumstances, a favorable allele may arise by mutation and may sweep through the entire 
population replacing all other alleles and such a selection is known as positive selection. The 
null allele at Duffy blood group locus conferring resistance to malaria parasite in African 
populations is a well known example for positive selection [26]. 
8. Genetic markers in the study of genetic diversity 
Genetic variation is the fundamental prerequisite for evolution. Evolution is a continuous 
process and hence there should be processes to increase or decrease genetic variation. Genes 
mutate resulting in new alleles and they are the source of variation. Natural selection 
process acts on them furthering evolution. Genetic variation is the result of mutation and 
random association of alleles. Considerable variations are present in natural populations. 
The study of genetic variation assists us to understand the place and time of origin of 
modern humans and their dispersal pattern to all regions of the world. The study of 
migratory pattern using genetic variation requires extensive genetic marker based 
population data. The application of various genetic markers in assessing genetic diversity in 
populations paralleled the development and design of new genetic markers [30]. One can 
distinguish three phases in the use of various genetic markers [31-33]. Blood grouping and 
other serological characteristics based genetic polymorphism data formed the first phase of 
genetic diversity information. With the advent of electrophoresis to separate variant alleles 
in protein markers, the second phase utilized protein markers extending across all the 
populations. The third phase is marked with the use of DNA markers. The DNA marker 
based genetic diversity studies on populations completely replaced the use of 
serological/protein based genetic markers. In the subsequent paragraphs, an overview of 
the utility of DNA molecular genetic markers in Anthropological studies of human 
populations, with special emphasis on the HLA genetic marker is discussed. 
DNA-based genetic diversity studies either use frequency data or direct sequence data. In 
general such studies involve three important steps in deciphering the phylogeography of 
populations. The three steps are (1) assessing inter and intra population differentiation; (2) 
ascertaining gene genealogies by constructing phylogenetic tree and (3) drawing inferences 
about dispersal pattern. The DNA-based molecular genetic markers routinely used in 
human population genetic diversity studies includes mitochondrial DNA (mtDNA), Y 
chromosome markers, single nucleotide polymorphism (SNPs), microsatellites and HLA 
markers.  
9. Mitochondrial DNA 
Human mtDNA is a single double-stranded circular DNA consisting of 16,569 basepairs in 
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9. Mitochondrial DNA 
Human mtDNA is a single double-stranded circular DNA consisting of 16,569 basepairs in 





maternal inheritance, lack of recombination and higher mutation rate than nuclear genes. 
The mtDNA behave as a haploid genome. The maternal inheritance and haploid nature of 
the genome facilitates in identifying relationships in a population. Using sequencing and 
RFLP-based high resolution mapping, Cann et al [34] suggested that Africa is the likely 
source of human mitochondrial gene pool and based on mtDNA sequence divergence 
suggested that the common ancestor of all surviving mtDNA types existed 140,000-200,000 
years ago. Using a different method, Ingmann et al [35] estimated the time since most recent 
common ancestor (TMRCA) as 171 ± 50 thousand years ago (kya). Mitochondrial studies on 
various worldwide populations found further evidence for the African origin hypothesis 
and also estimated TMRCA at about 100,000-200,000 years. mtDNA studies on evolution is 
approached in two ways, namely, lineage based (haplogroups) and population based. 
However the recent trend is to use both haplogroup and population based studies to 
understand the pre-history of human populations. 
10. Y chromosome 
The Y chromosome in the human nuclear genome is haploid as that of mtDNA. The Y 
chromosome is paternally inherited. The human Y chromosome has now been sequenced 
[36]. It consists of the recombining segments, known as pseudoautosomal regions at the Yp 
and Yq ends. The Male sex determining region of Y (MSY) previously known as non-
recombining region of Y (NRY) consists of euchromatic and heterochromatic regions 
accumulate changes due to insertions, deletions, base changes (SNPs) and Alu sequence 
insertions polymorphisms (YAP). The stable YAP and SNPs together are known as unique 
event polymorphisms (UEP) and many of them are bi-allelic markers. The microsatellites 
present in MSY region of Y chromosome accumulate changes, which either increase or 
decrease the copy number of core repeats faster than UEPs. The Y-linked loci in the MSY are 
haploid and the non-recombining nature of this region coupled with accumulated changes 
over thousands of generations are useful in delineating male lineages in populations and 
usefully exploited to study the prehistoric migrations of human populations [37]. Extensive 
genetic studies were undertaken on worldwide populations to ascertain male Y haplotype 
lineages, and their pattern of distribution suggest a recent origin between 60 and 150 
thousand years ago in Africa for all the present day Y chromosomes [37-42]. 
11. Microsatellites 
Microsatellites, also known as short tandem repeats (STRs) are arrays of 2-6 bp length 
tandem repeat motifs present throughout the genome. Changes in the repeat number take 
place due to replication slippage and the rate of change in repeat number is faster than 
SNPs. It is in the order of 10-3. The change in repeat number follows most often stepwise 
mutation model (SMM) that is either increase or decrease by one repeat at a time. It is also 
reported that multistep changes or point mutations are also responsible for change in motif 
number. Being a neutral polymorphic marker, microsatellites are used in genetic mapping 
and studies of the evolutionary connections between species and populations. 
Microsatellites are the preferred markers for high resolution genetic mapping and useful in 
inferring relationships between closely related population groups. In a pilot study, Bowcock 
et al [43] studied 30 dinucleotide loci from 14 aboriginal populations and constructed a 
phylogenetic tree, in which the first split separated Africans from the rest of the populations 
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and Goldstein [44] reanalyzed the data using a new genetic distance and estimated TMRCA 
75,000 -287,000 years. 
12. Single nucleotide polymorphism 
Single nucleotide polymorphism (SNP) is defined as a single base change in the sequence of 
a segment of DNA occurring at a rate of >1% in a large population. SNPs occur in high 
frequency in the human genome and they can be found in coding and non-coding regions 
and they occur with very high frequencies – about 1 in 1,200 bases on average, which results 
in approximately 10 million SNPs in the human genome. SNPs are due to either base change 
or by deletion/insertion of a base. A base change in a coding region either alters the protein 
structure (synonymous mutation) or does not alter the protein structure (non-synonymous 
mutation). SNPs are the major cause of genetic diversity among different individuals 
facilitating large scale genetic association studies as genetic markers. With the advances in 
statistical methodologies in population genetics and the availability of large scale SNP data, 
this marker may facilitate in the study of prehistoric migration and demographic history of 
modern humans [45-47]. 
13. HLA polymorphic markers 
The HLA is a multigene family and spans approximately 4 mega bases [48-50]. Currently 
there are at least 7,130 alleles in the class I and class II HLA loci described by the HLA 
nomenclature and included in the IMGT/HLA database (as of January 2012). The 
IMGT/HLA consortium directly receives the sequences for new alleles from researchers for 
checking and assignment of official name prior to publication to avoid confusion and 
multiple names. The polypeptides produced by these alleles differ by one or more amino 
acid substitutions. The polymorphic nature of the HLA class I and class II loci is a useful tool 
for the study of human evolution. 
Serological and DNA based typing methods are used in HLA typing [51-53]. High 
resolution sequence specific primer (SSP) and sequence based typing (SBT) methods are 
more appropriate since both the methods are able to identify all the alleles so far defined, 
and for SBT, capable of identifying new alleles. 
14. Significance of HLA diversity in evolution 
The rate and number of nucleotide substitutions leading to new alleles in each of the 
functional HLA class I and II loci are quite high compared to neutral loci such as mtDNA 
and Y chromosome markers. Besides that the class I and class II loci exhibit high 
heterozygosity (80-90%) and hence are good genetic markers for phylogenetic study. Some 
of the lineages especially the DRB1 lineages are perpetuated more than 35 million years ago, 
the time of evolutionary divergence of the so-called hominoids (apes) from old world 
monkeys. Though the exact nature of mechanism for the high number of alleles and the 
perpetuation of alleles is not known, it is suggested that high mutation, inter locus genetic 
exchange (gene conversion) coupled with over dominant diversity results in the 
perpetuation of high number of alleles in the HLA locus. In such a selection, not only new 
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15. HLA polymorphism in phylogenetics 
HLA markers are codominant SNP markers enabling heterozygotes to be distinguished 
from homozygotes, and allowing the determination of genotypes and allele frequencies. The 
class I and class II alleles in HLA are closely linked and occur jointly in individuals more 
often than by chance (linkage disequilibrium) [68]. Population migration and genetic drift 
can cause linkage disequilibrium. Linkage disequilibrium decreases by random mating over 
a period of time which is dependent on recombination fraction per generation. The study 
and analysis of remnant linkage disequilibrium, assuming that there is no selection shall 
provide information on the number of generations passed in-between two closely related 
populations from the time of their separation. Haplotype diversity, allele frequency 
variation and linkage disequilibrium analysis in HLA genetic markers are used to reflect the 
amount of variation between closely related populations. Comparison of variation is used to 
assess population genetic substructure. The analysis of variation in the HLA class I and II 
markers increase the power of detecting population substructure because each locus will 
contain an independent history of the population depending on the amounts of random 
drift, mutation, and migration that have occurred. The allele frequency based genetic 
distance help to construct phylogenetic tree to infer the relative estimate of the time that has 
passed since the populations have existed as single cohesive units [69-72]. The HLA marker 
allele frequencies of various populations are also used for cluster analysis using principal 
coordinate analysis (PCA). 
Each population has unique HLA profile with reference to class I and class II HLA gene 
distributions. This has been reported in several studies compiling population data on HLA 
class I and class II genes from various populations of the world and it has significance in 
anthropological studies [73-108]. To highlight the effectiveness of HLA genetic markers in 
phylogenetics, a few studies relevant to genetic relationships among populations are 
described. Serjeantson et al [75] used allele frequency variation and linkage disequilibrium 
studies of HLA A and B loci in 16 Pacific Island populations to trace the phylogeogrphy of 
the populations to elucidate the interrelationships and migrations among peoples of the 
Pacific Islands. Shaw et al  [89] used HLA-A, -B, -DR and -DQ allele frequency and 
haplotype frequency data to show that the aborigines in Taiwan has a distinct profile than 
the Chinese population groups and found Javanese closely related to Taiwan aborigines. 
Using HLA class I (A and B) and HLA class II (DRB1 and DQB1) allele distribution, linkage 
disequilibrium and cluster analysis it was shown that Amerindians are the very first 
American Natives that were already in America when Na Dene (Athabascans, Navajo, 
Apache) and Eskimo speaking people reached it [105]. Recently, Buhler and Sanchez-Mazas 
[108] used sequence based analysis on seven HLA genes in 23,500 individuals from 200 
populations across the world to report on the significant correlation between genetics and 
geography which is in agreement with earlier HLA based studies using allele frequency 
data for population genetic diversity studies. They also concluded that geography plays a 
major role in shaping molecular variability among populations. 
16. HLA genetic diversity studies and effective population size 
The theory of African replacement model of evolution of modern humans generalize that 
the modern humans originated in Africa 200,000 years ago and the transition from archaic to 
modern humans was associated with a narrow bottleneck and the number of individuals in 
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the bottleneck period was small. The theory of coalescence permits us to estimate the 
effective population size (Ne) and based on mtDNA and Y STR markers, the Ne at the time 
of divergence of modern humans is estimated to be 104 (10,000) individuals. In contrast, 
HLA based genetic diversity studies, taking into consideration the occurrence of large 
number of alleles and the perpetuation of HLA lineages more than 35 million years ago, 
previously estimated the effective population size to the order of 105 (100,000) individuals 
without bottleneck [61-63]. However subsequently this hypothesis was revised which 
included a bottleneck but spanning for a shorter period although the effective population 
size is maintained at 105 [64]. However Bergstrom et al (1998) on analysis of intron 
sequences of  more than 135 contemporary human DRB1 alleles  generated after the 
separation of hominoids from old world monkeys suggested that the coalescent time of 
alleles within these allelelic lineages indicate that the effective population size (Ne) is similar 
to estimates based on mtDNA that is 104 [66]. 
17. Conclusion 
The high polymorphism, tight linkage, the random association of alleles and the 
perpetuation of allelic lineages over time make HLA genetic markers an invaluable tool in 
unravelling the human past. The vital information relating to amount, pattern and 
distribution of genetic variation of HLA genetic markers in different populations enable us 
to correlate genetic profile of populations and their past migrations in the determination of 
their origin.   
18. Acknowledgements  
The authors acknowledge the funds provided by the USM Research University Grant 
(1001/PPSK/813053) for the publication of this work. 
19. References  
[1] Kottak C P (Ed) (2006) Anthropology The exploration of Human Diversity. 11th edition, 
Mc Graw Hill company Inc., New York, PP: 3-23  
[2] Smith F H (1992) Models and realities in modern human origins: The African fossil 
evidence, Phil Trans, R Soc Lond B (33): 243-250.  
[3] Cartmill M and Smith F H (Ed) (2009) The human lineage, John Wiley & Sons, PP63-121  
[4] Stringer C B and Andrews P (1988) Genetic and fossil evidence for the origin of modern 
humans, Science (239):1263-1268.  
[5] Cavalli-Sforza L L, Piazza A, Menozzi P and Mountain J (1988) Reconstruction of human 
evolution bringing together genetic, archaeological and linguistic data (origin of 
modern humans/phylogenetic tree/paleoanthropology), Proc Natl Acad Sci USA 
(92): 6002-6006.  
[6] Templeton A R (2002) Out of Africa again and again, Nature 416(7): 45-51 
[7] Dobzhansky T. (1970) Genetics of the Evolutionary Process. Columbia University Press, 
New York.  






15. HLA polymorphism in phylogenetics 
HLA markers are codominant SNP markers enabling heterozygotes to be distinguished 
from homozygotes, and allowing the determination of genotypes and allele frequencies. The 
class I and class II alleles in HLA are closely linked and occur jointly in individuals more 
often than by chance (linkage disequilibrium) [68]. Population migration and genetic drift 
can cause linkage disequilibrium. Linkage disequilibrium decreases by random mating over 
a period of time which is dependent on recombination fraction per generation. The study 
and analysis of remnant linkage disequilibrium, assuming that there is no selection shall 
provide information on the number of generations passed in-between two closely related 
populations from the time of their separation. Haplotype diversity, allele frequency 
variation and linkage disequilibrium analysis in HLA genetic markers are used to reflect the 
amount of variation between closely related populations. Comparison of variation is used to 
assess population genetic substructure. The analysis of variation in the HLA class I and II 
markers increase the power of detecting population substructure because each locus will 
contain an independent history of the population depending on the amounts of random 
drift, mutation, and migration that have occurred. The allele frequency based genetic 
distance help to construct phylogenetic tree to infer the relative estimate of the time that has 
passed since the populations have existed as single cohesive units [69-72]. The HLA marker 
allele frequencies of various populations are also used for cluster analysis using principal 
coordinate analysis (PCA). 
Each population has unique HLA profile with reference to class I and class II HLA gene 
distributions. This has been reported in several studies compiling population data on HLA 
class I and class II genes from various populations of the world and it has significance in 
anthropological studies [73-108]. To highlight the effectiveness of HLA genetic markers in 
phylogenetics, a few studies relevant to genetic relationships among populations are 
described. Serjeantson et al [75] used allele frequency variation and linkage disequilibrium 
studies of HLA A and B loci in 16 Pacific Island populations to trace the phylogeogrphy of 
the populations to elucidate the interrelationships and migrations among peoples of the 
Pacific Islands. Shaw et al  [89] used HLA-A, -B, -DR and -DQ allele frequency and 
haplotype frequency data to show that the aborigines in Taiwan has a distinct profile than 
the Chinese population groups and found Javanese closely related to Taiwan aborigines. 
Using HLA class I (A and B) and HLA class II (DRB1 and DQB1) allele distribution, linkage 
disequilibrium and cluster analysis it was shown that Amerindians are the very first 
American Natives that were already in America when Na Dene (Athabascans, Navajo, 
Apache) and Eskimo speaking people reached it [105]. Recently, Buhler and Sanchez-Mazas 
[108] used sequence based analysis on seven HLA genes in 23,500 individuals from 200 
populations across the world to report on the significant correlation between genetics and 
geography which is in agreement with earlier HLA based studies using allele frequency 
data for population genetic diversity studies. They also concluded that geography plays a 
major role in shaping molecular variability among populations. 
16. HLA genetic diversity studies and effective population size 
The theory of African replacement model of evolution of modern humans generalize that 
the modern humans originated in Africa 200,000 years ago and the transition from archaic to 
modern humans was associated with a narrow bottleneck and the number of individuals in 
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the bottleneck period was small. The theory of coalescence permits us to estimate the 
effective population size (Ne) and based on mtDNA and Y STR markers, the Ne at the time 
of divergence of modern humans is estimated to be 104 (10,000) individuals. In contrast, 
HLA based genetic diversity studies, taking into consideration the occurrence of large 
number of alleles and the perpetuation of HLA lineages more than 35 million years ago, 
previously estimated the effective population size to the order of 105 (100,000) individuals 
without bottleneck [61-63]. However subsequently this hypothesis was revised which 
included a bottleneck but spanning for a shorter period although the effective population 
size is maintained at 105 [64]. However Bergstrom et al (1998) on analysis of intron 
sequences of  more than 135 contemporary human DRB1 alleles  generated after the 
separation of hominoids from old world monkeys suggested that the coalescent time of 
alleles within these allelelic lineages indicate that the effective population size (Ne) is similar 
to estimates based on mtDNA that is 104 [66]. 
17. Conclusion 
The high polymorphism, tight linkage, the random association of alleles and the 
perpetuation of allelic lineages over time make HLA genetic markers an invaluable tool in 
unravelling the human past. The vital information relating to amount, pattern and 
distribution of genetic variation of HLA genetic markers in different populations enable us 
to correlate genetic profile of populations and their past migrations in the determination of 
their origin.   
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1. Introduction 
HLA-G is a non-classical HLA class Ib molecule belonging to the Major Histocompatibility 
Complex (MHC) located on the short arm of chromosome 6. The tissue-restricted 
distribution of HLA-G, the low polymorphism in the coding region, the fact that HLA-G 
primary transcript is alternatively spliced in seven isoforms, and the inhibitory action on 
immune cells, constitute four hallmarks of HLA-G, which distinguish it from other HLA 
class I molecules (Carosella et al., 1999). In healthy conditions, a basal level of HLA-G gene 
transcription is observed in most cells and tissues. However, translation into HLA-G protein 
is restricted to trophoblasts at the fetal-maternal interface (Carosella et al., 2003), and in 
adults, to thymic epitelial, cornea, mesenchymal stem cells (MSCs), nail matrix, pancreatic- 
cells, erythroid and endothelial precursors. HLA-G can be also neo-expressed in 
pathological conditions including malignant transformation, viral infections, inflammatory 
and autoimmune diseases, and allogeneic transplantation (Carosella, 2011). 
HLA-G locus is very low polymorphic and, due to its structure, HLA-G molecule can 
recognize and present only a restricted peptide repertoire compared to classical HLA class I 
molecules (Clements et al., 2005). These peculiarities render HLA-G exclusively oriented 
towards immune inhibition and tolerance. In the late ninety, Rouas-Freiss et al. showed that 
HLA-G expressing trophoblasts were protected from maternal NK cell-mediated cytolysis, 
indicating for the first time HLA-G as a key molecule in fetal-maternal tolerance (Rouas-
Freiss et al., 1997). From this first observation, several groups have worked to define the 
mode of action of HLA-G and in which settings it is involved in promoting tolerance. It is 
now generally accepted that HLA-G is a unique molecule with several immuno-modulatory 
properties: it plays an important role not only in fetal-maternal tolerance, but also in 
modulating immune responses and promoting and maintaining peripheral tolerance in 
healthy and pathological conditions. HLA-G can indeed act on both the innate and the 
adaptive branches of immunity and regulate short- and long-term immune-responses. 
2. HLA-G molecule  
The alternative splicing of HLA-G primary transcript results in seven different isoforms, 
four of which are membrane bound (HLA-G1 to –G4) and three are soluble (HLA-G5 to –
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Fig. 1. HLA-G isoforms, monomers and dimers 
A. The alternative splicing of a unique primary transcript yields 7 protein isoforms: 
truncated isoforms are generated by excision of one or two exons encoding globular () 
domains, whereas translation of intron 4 (i4) or intron 2 (i2) yields soluble isoforms that lack 
the transmembrane domain. B. HLA-G molecules can form homodimers through the 
generation of Cys42-Cys42 disulfide bonds.  
In addition, a soluble HLA-G1 isoform (shed HLA-G1) can be generated by the membrane 
HLA-G1 proteolytic cleavage that is dependent on metalloproteinase activity (Park et al., 
2004), and is regulated by Nitric Oxide (NO) concentration (Diaz-Lagares et al., 2009) and 
Tumor Necrosis Factor (TNF)-/NFkB pathway activation (Zidi et al., 2006). Soluble and 
membrane-bound HLA-G isoforms have similar functions. HLA-G1, HLA-G5, and shed 
HLA-G1 are the most described isoforms in healthy tissues (Paul et al., 2000) and their 
structure is similar to that of classical HLA class I molecules: a heavy chain of three globular 
domains non-covalently associated with 2-microglobulin (2m) and a nona-peptide 
(Clements et al., 2005). The other HLA-G isoforms contain the 1 domain but lack one or 
two of the other globular domains, and are not associated with 2m and the peptide. The 
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presence of the 3 domain is important to HLA-G functions since it represents a binding site 
for HLA-G receptors (Clements et al., 2005; Clements et al., 2007). 
HLA-G possesses two unique cysteine residues, in position 42 of the 1 domain and in 
position 147 of the 2 domain. Through these residues, HLA-G may dimerize by intra-
molecular disulfide bonds (Boyson et al., 2002). Membrane-bound or soluble HLA-G dimers 
were detected both in vitro and in vivo (Apps et al., 2007; Boyson et al., 2002; Gonen-Gross et 
al., 2005)  (Fig. 1B). Dimerization of HLA-G is one of its key features since dimers bind to 
HLA-G receptors with  higher affinity and slower dissociation rates compared to monomers 
(Shiroishi et al., 2006a) and, as a consequence, dimers, but not monomers, carry most of the 
HLA-G functions (Gonen-Gross et al., 2003; Li et al., 2009). 
HLA-G acts through three inhibitory receptors: immunoglobulin-like transcript (ILT)2 
(CD85j/LILRB1), ILT4 (CD85d/LILRB2), the killer cell immunoglobulin-like receptor 
(KIR)2DL4 (CD158d), and the co-receptor CD8 (Colonna et al., 1997; Colonna et al., 1998; 
Rajagopalan and Long, 1999) (Fig. 2).  
 
Fig. 2. HLA-G receptors 
Inhibitory receptors known to bind HLA-G. Basic structural organization and expression 
patterns are shown. The HLA-G structural configuration that these receptors are known to 
bind are indicated as ‘+’ (reported binding) and ‘–’ (reported absence of binding or minor 
binding). 
ILT2 is expressed by B cells, some T cells (both CD4+ and CD8+), a sub-population of NK 
cells, and all monocytes/Dendritic Cells (DCs) (Colonna et al., 1997), whereas ILT4 is only 
expressed by mono/macrophages and DCs (Colonna et al., 1998). KIR2DL4 is expressed by 
some CD8+ T and NK cells (Goodridge et al., 2003). 
Even if ILT2 and ILT4 recognize other HLA Class I molecules, HLA-G is their ligand of 
highest affinity and they bind HLA-G dimers even more strongly (Shiroishi et al., 2006a; 
Shiroishi et al., 2003). ILT2 and ILT4 can recognize different HLA-G structures: ILT2 binds 
only 2m-associated HLA-G1/G5 isoforms, whereas ILT4 also recognizes their 2m-free 
counterparts (Gonen-Gross et al., 2005; Shiroishi et al., 2006b). Finally, significantly higher 






Fig. 1. HLA-G isoforms, monomers and dimers 
A. The alternative splicing of a unique primary transcript yields 7 protein isoforms: 
truncated isoforms are generated by excision of one or two exons encoding globular () 
domains, whereas translation of intron 4 (i4) or intron 2 (i2) yields soluble isoforms that lack 
the transmembrane domain. B. HLA-G molecules can form homodimers through the 
generation of Cys42-Cys42 disulfide bonds.  
In addition, a soluble HLA-G1 isoform (shed HLA-G1) can be generated by the membrane 
HLA-G1 proteolytic cleavage that is dependent on metalloproteinase activity (Park et al., 
2004), and is regulated by Nitric Oxide (NO) concentration (Diaz-Lagares et al., 2009) and 
Tumor Necrosis Factor (TNF)-/NFkB pathway activation (Zidi et al., 2006). Soluble and 
membrane-bound HLA-G isoforms have similar functions. HLA-G1, HLA-G5, and shed 
HLA-G1 are the most described isoforms in healthy tissues (Paul et al., 2000) and their 
structure is similar to that of classical HLA class I molecules: a heavy chain of three globular 
domains non-covalently associated with 2-microglobulin (2m) and a nona-peptide 
(Clements et al., 2005). The other HLA-G isoforms contain the 1 domain but lack one or 
two of the other globular domains, and are not associated with 2m and the peptide. The 
 
Distinctive Immunological Functions of HLA-G 
 
21 
presence of the 3 domain is important to HLA-G functions since it represents a binding site 
for HLA-G receptors (Clements et al., 2005; Clements et al., 2007). 
HLA-G possesses two unique cysteine residues, in position 42 of the 1 domain and in 
position 147 of the 2 domain. Through these residues, HLA-G may dimerize by intra-
molecular disulfide bonds (Boyson et al., 2002). Membrane-bound or soluble HLA-G dimers 
were detected both in vitro and in vivo (Apps et al., 2007; Boyson et al., 2002; Gonen-Gross et 
al., 2005)  (Fig. 1B). Dimerization of HLA-G is one of its key features since dimers bind to 
HLA-G receptors with  higher affinity and slower dissociation rates compared to monomers 
(Shiroishi et al., 2006a) and, as a consequence, dimers, but not monomers, carry most of the 
HLA-G functions (Gonen-Gross et al., 2003; Li et al., 2009). 
HLA-G acts through three inhibitory receptors: immunoglobulin-like transcript (ILT)2 
(CD85j/LILRB1), ILT4 (CD85d/LILRB2), the killer cell immunoglobulin-like receptor 
(KIR)2DL4 (CD158d), and the co-receptor CD8 (Colonna et al., 1997; Colonna et al., 1998; 
Rajagopalan and Long, 1999) (Fig. 2).  
 
Fig. 2. HLA-G receptors 
Inhibitory receptors known to bind HLA-G. Basic structural organization and expression 
patterns are shown. The HLA-G structural configuration that these receptors are known to 
bind are indicated as ‘+’ (reported binding) and ‘–’ (reported absence of binding or minor 
binding). 
ILT2 is expressed by B cells, some T cells (both CD4+ and CD8+), a sub-population of NK 
cells, and all monocytes/Dendritic Cells (DCs) (Colonna et al., 1997), whereas ILT4 is only 
expressed by mono/macrophages and DCs (Colonna et al., 1998). KIR2DL4 is expressed by 
some CD8+ T and NK cells (Goodridge et al., 2003). 
Even if ILT2 and ILT4 recognize other HLA Class I molecules, HLA-G is their ligand of 
highest affinity and they bind HLA-G dimers even more strongly (Shiroishi et al., 2006a; 
Shiroishi et al., 2003). ILT2 and ILT4 can recognize different HLA-G structures: ILT2 binds 
only 2m-associated HLA-G1/G5 isoforms, whereas ILT4 also recognizes their 2m-free 
counterparts (Gonen-Gross et al., 2005; Shiroishi et al., 2006b). Finally, significantly higher 





interaction may have relatively lower affinity compared to that of ILT4 (Allan et al., 1999). 
Interestingly, HLA-G can directly influence the expression rate of its receptors both at 
mRNA level and at the protein level (LeMaoult et al., 2005). Thus, HLA-G is unique in its 
ability to be expressed in different isoforms and to act through inhibitory receptors. 
3. Mechanisms underlying HLA-G expression 
Even if theoretically any tissue might express HLA-G, its physiological expression is 
restricted to few tissues such as trophoblasts, thymic epithelium, cornea, MSC and 
pancreatic -cells (Carosella, 2011). Nonetheless, in pathological conditions, HLA-G 
expression can be induced and/or up-regulated. So far the reason why HLA-G can be 
expressed in some, but not in all tissues has not been fully elucidated. However, several 
factors such as immune-modulatory cytokines and hormones, were described to potentially 
affect transcriptional mechanisms responsible for HLA-G expression (Moreau et al., 2009).  
In contrast to classical HLA class I molecules, HLA-G expression is not influenced by the 
transcription factor NF-kB (Gobin et al., 1998) or by classical pro-inflammatory cytokines 
such as Interferon (IFN)- (Gobin et al., 1999), since responsive elements for IFN- are 
missed in HLA-G promoter (Gobin et al., 1999; Steimle et al., 1995). In contrast, HLA-G 
transcriptional rate is increased by the presence of a number of anti-inflammatory cytokines 
including IFN-(Lefebvre et al., 2001), Interleukin (IL)-4, IL-5, IL-6 (Deschaseaux et al., 
2011), and IL-10 (Moreau et al., 1999)  and can be modulated by Granulocyte Macrophage 
Colony-Stimulating Factor (GM-CSF) (Onno et al., 2000; Yang et al., 1996), Transforming 
Growth Factor (TGF)-, or Granulocyte Colony-Stimulating Factor (G-CSF).  
In addition to cytokines, hormones like glucocorticoids (dexamethasone) and progesterone 
were shown to increase the secretion of both HLA-G5 and HLA–G6 by trophoblasts (Akhter 
et al., 2011; Moreau et al., 2001; Yie et al., 2006a; Yie et al., 2006b). HLA-G expression can be 
also influenced by Adenosine Triphosphate (ATP) and by the tryptophan catalayzing 
enzyme indoleamine 2 3-dioxygenase (IDO). ATP acts as a potent inhibitor of HLA-G1 and 
HLA–G5 production from LPS-activated PBMCs via down-regulation of IL-10 (Rizzo et al., 
2009). IDO, known to be involved in the generation of tolerogenic microenvironments by 
tryptophan depletion and in the generation of T regulatory (Treg) cells (Chung et al., 2009; 
Munn et al., 2002), was shown to differentially modulate HLA-G expression in monocytes 
and myeloid DCs. IDO blocked HLA-G cell-surface expression on monocytes (Gonzalez-
Hernandez et al., 2005), but it induced HLA-G expression and shedding in myeloid DCs 
(Lopez et al., 2006). Overall, a number of immune mediators can influence HLA-G 
expression. It has to be taken in account that these molecules can be up-regulated in 
conditions, such as inflammation, in which HLA-G expression is needed to control or 
dampen the immune response.  
In addition to soluble factors, it has been recently reported that “transient” HLA-G 
expression can be acquired via trogocytosis, a cell-to-cell contact-dependent uptake of 
membranes and associated molecules from one cell by another (reviewed in (Davis, 2007; 
LeMaoult et al., 2007a). Trogocytosis of HLA-G was shown for activated CD4+ and CD8+ T 
cells (LeMaoult et al., 2007b), activated NK cells (Caumartin et al., 2007), and monocytes 
(HoWangYin et al., 2011). For CD4+ T cells, the most important consequence of HLA-G 
acquisition, is that the newly-expressing cells became transiently tolerogenic (LeMaoult et 
al., 2007a), as discussed below. Thus, trogocytosis generates HLA-G positive cells, which 
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display, but do not express HLA-G. The ability of different cells to transiently acquire HLA-
G expression broadens the immuno-modulatory activity of HLA-G. 
4. HLA-G immunological function 
The functions of HLA-G are exclusively oriented towards immune inhibition and tolerance. 
HLA-G exerts its inhibitory functions on several immune cells through direct binding to the 
inhibitory receptors ILT2, ILT4, and KIR2DL4 (Shiroishi et al., 2006b). 
4.1 Short-term immuno-modulation mediated by HLA-G 
HLA-G:ILT2 interaction modulates NK cell activity (Rouas-Freiss et al., 1997). HLA-G-
expressing target cells are indeed resistant to the lysis mediated by NK cells (Riteau et al., 
2001). Although the mechanisms underlying this effect are not completely elucidated, it has 
been recently defined that HLA-G:ILT2 interaction disrupts the immunological synapse (IS), 
a supramolecular structure responsible for both T and NK cell activation and function 
(Favier et al., 2010), leading to inhibition of NK cytolysis. HLA-G binds to KIR2DL4 on NK 
cells (Shiroishi et al., 2006b). However, it still remains unclear which are the effects mediated 
by this interaction. Ligation of KIR2DL4 activates cytokine production but not cytotoxicity 
(Rajagopalan et al., 2001), and it has been recently proposed that activation of KIR2DL4 by 
soluble HLA-G activates a pro-inflammatory/pro-angigenic responses, consistent with a 
role in promoting vascularization during early pregnancy (Rajagopalan et al., 2006). HLA-G 
can also bind CD8, which is expressed by a subpopulation of NK cells leading to Fas ligand 
expression, and induction of apoptosis (Contini et al., 2003). 
The interaction between HLA-G and CD8+ T cells impairs the antigen-specific cytotoxic T 
lymphocyte (CTLs) activity (Le Gal et al., 1999). HLA-G has a dose-dependent effect on the 
generation of allo-CTL responses, while it seems to not affect pre-existing allo-CTLs (Kapasi 
et al., 2000). Furthermore, during later stages of T cell activation, HLA-G:CD8 interaction 
promotes TCR-independent apoptosis of CD8+ T cells through the same mechanisms 
described for NK cells (Fournel et al., 2000). 
During the early phase of CD4+ T cell activation, HLA-G:ILT2 interaction induces a cell cycle 
blockade at the G1 phase (Bahri et al., 2006), and inhibits allo-reactive T-cell proliferation 
(Naji et al., 2007a). Interestingly, it has been proposed that HLA-G isoforms have different 
impact on the cytokine secretion profile of CD4+ T cells. HLA-G1 was indeed shown to 
promote T helper (h)2 polarization of naïve T cells (Kanai et al., 2001b; Kapasi et al., 2000) 
whereas HLA-G5 induces tumor necrosis factor (TNF)-, IFN-, and IL-10 (Kanai et al., 
2001a). Morandi et al. recently described that HLA-G5 has an additional effect on CD4+ T 
cells since it down-regulates expression and function of CCR2, CXCR3, and CXCR4 on 
different subsets of activated CD4+ T cells, impairing their migratory capability (Morandi et 
al., 2010).  
The immunological functions of HLA-G on B cells are poorly described. It has been shown 
that in patients who underwent renal transplantation, serum levels of soluble HLA-G are 
negatively associated with anti-HLA antibodies and with graft rejection, suggesting that 
soluble HLA-G may possibly act to inhibit the immune humoral responses against HLA 
(Qiu et al., 2006). Further investigation is needed to better highlight the role of HLA-G in 
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Myeloid antigen presenting cells (APCs) express both ILT2 and ILT4, which render them 
targets of HLA-G-mediated modulation. In the presence of HLA-G, myeloid APCs fail to 
stimulate allo-proliferative T cell responses in vitro (LeMaoult et al., 2004) and reduce NK-
mediated cytotoxicity (Gros et al., 2008). Moreover, HLA-G inhibits the up-regulation of 
HLA Class II, CD80 and CD86 on myeloid DCs in response to LPS or allo-activation signals 
in vitro (Ristich et al., 2007) (Gros et al., 2008). Thus, HLA-G inhibits the functions and 
differentiation of myeloid APCs, leading to improper T lymphocyte activation and to impair 
NK cytotoxic activity. However, HLA-G does not block myeloid APCs functions, but 
induces them to differentiate into tolerogenic cells. Several reports indeed show that HLA-G 
treatment up-regulates the expression of cytokines, chemokines, and chemokine receptors 
by myeloid APCs (Apps et al., 2007; Gros et al., 2008; Li et al., 2009; Liang et al., 2008). The 
first evidence that HLA-G promotes the induction of tolerogenic APCs comes from studies 
conducted by the group of Horuzsko demonstrating that HLA-G treatment of monocyte-
derived DCs that highly express ILT2 and ILT4 results in cells with tolerogenic-like 
phenotype and the potential to induce T-cell anergy (Ristich et al., 2005). Results obtained in 
a murine model support this notion by showing that HLA-G inhibited maturation of DCs 
(Horuzsko et al., 2001) and that in ILT4 transgenic mice, the HLA-G:ILT4 interaction 
impaired DC maturation in vivo, leading to delayed skin allograft rejection (Liang et al., 
2002). Thereby, HLA-G by interacting with ILT receptors present on myeloid APCs induces 
their differentiation into regulatory cells.  
4.2 Long-term tolerogenic properties of HLA-G 
Myeloid APCs are not only the cells more sensitive to HLA-G-mediated modulation, but 
they also commonly express HLA-G. Myeloid APCs may express all HLA-G isoforms (Le 
Friec et al., 2004), but cell-surface HLA-G1 and secreted HLA-G5 have been described the 
most. In pathological contexts including transplantation, cancer, viral infections, and 
inflammatory diseases, the expression of HLA-G on myeloid cells can be up-regulated 
(Carosella et al., 2008). Recently, in liver-transplanted patients, the presence of HLA-G-
expressing myeloid DCs has been correlated with tolerance and graft acceptance 
(Castellaneta et al., 2011). Similarly, in cancer (reviewed in (Amiot et al., 2011) as well as in 
viral infections (reviewed in (Fainardi et al., 2011), myeloid APCs expressing HLA-G were 
reported, and often correlated with  poor clinical outcomes. Myeloid APCs not only express 
membrane-bound HLA-G1 but they may also secrete or shed HLA-G molecules, 
contributing to the generation of a tolerogenic microenvironment. Such a microenvironment 
may alter the functions not only of lymphocytes, but also of the HLA-G-expressing myeloid 
APCs themselves, in a tolerogenic feedback loop. HLA-G can indeed directly promote its 
expression and the expression of its receptors on myeloid APCs (LeMaoult et al., 2005). 
Thus, myeloid APCs may be viewed as suppressor cells capable of inhibiting other immune 
effectors, and also of generating regulatory cells including Treg cells. 
Treg cells are critical players for preservation of immune homeostasis and for 
establishment and maintenance of peripheral tolerance. Treg cells belonging to different T 
cell subsets, including CD4+ and CD8+, NKT, and  T cells. The best characterized Treg 
populations are the forkhead box P3 (FOXP3)-expressing, CD4+CD25+ Tregs (FOXP3+ 
Tregs) (Sakaguchi et al., 2010), and the CD4+ IL-10-producing Tr1 cells (Akdis et al., 2004; 
Barrat et al., 2002; Groux et al., 1997; Roncarolo et al., 2006). FOXP3+ Tregs and Tr1 cells 
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are distinct populations of Treg cells that play a non-redundant role in maintaining 
tolerance, and are distinguished from one another by their distinct phenotype and 
cytokine profiling. FOXP3+ Treg cells are characterized by the constitutively-high 
expression of CD25 and the transcription factor FOXP3 (Sakaguchi, 2005), and their 
development and function is strictly dependent on FOXP3 (Bacchetta et al., 2007; Gavin et 
al., 2007). Tr1 cells can be induced in the periphery upon chronic antigen (Ag) stimulation 
in the presence of IL-10 (Roncarolo et al., 2006), and are currently identified by their 
unique cytokine profile consisting of high levels of IL-10, TGF-β, and low levels of IL-2 
and IFN-γ and the absence of IL-4 after stimulation (Bacchetta et al., 1994; Groux et al., 
1997). Once activated through their specific TCR, Tr1 cells secrete IL-10 and TGF- that 
directly inhibit effector T cell proliferation and expression of HLA class II and co-
stimulatory molecules on APCs, which indirectly suppress effector T-cell activation. More 
recently, we demonstrated that Tr1 cells specifically kill myeloid cells via a Granzyme B-
dependent mechanism (Magnani et al., 2011). 
HLA-G-expressing APCs were shown to be capable of priming naïve T cells to become Treg 
cells. Indeed, APC lines over-expressing membrane-bound HLA-G1 induced the 
differentiation of CD4+ and CD8+ T cells able to inhibit allogeneic responses (LeMaoult et al., 
2004). Resulting HLA-G-induced Treg cells included CD4low and CD8low T cells that 
suppress via soluble factors (Naji et al., 2007a; Naji et al., 2007b). These results are in 
agreement with those obtained in patients who received a combined liver-kidney transplant, 
in which high plasma levels of HLA-G5 correlated with an increased percentage of 
suppressor T cells (Le Rond et al., 2004; Naji et al., 2007b). They are also in line with results 
showing that high HLA-G5 plasma levels in the peripheral blood of stem cell-transplanted 
patients are associated with the expansion in peripheral blood of CD4+CD25+CD152+ T cells 
with suppressive activity (Le Maux et al., 2008). 
We recently identified and characterized a new subset of human DCs that arises in the 
presence of IL-10 and endogenously expresses cell-surface HLA-G (Gregori et al., 2010). DC-
10 are characterized by the outstanding ability to produce IL-10 and by the expression of 
high levels of membrane-bound HLA-G1 and other tolerogenic signaling molecules such as 
ILT2, ILT3, and ILT4 (Fig. 3).  
DC-10 are potent inducers of adaptive allo-specific Tr1 cells (Gregori et al., 2010). 
Furthermore, allergen-specific Tr1 cells can be generated in vitro by stimulating human T 
cells with autologous tolerogenic DC-10 pulsed with allergen (Pacciani et al., 2010). 
Interestingly, the expression of membrane-bound HLA-G1 and that of its receptors are up-
regulated by IL-10 on both DC-10 and T cells, and the expression of high levels of 
membrane-bound HLA-G1, ILT4, and IL-10 by DC-10 is critical to the generation of Tr1 cells 
by DC-10 (Rossetti et al., 2011). 
5. HLA-G expressing regulatory cells  
In addition to myeloid cells that can constitutively or transiently express HLA-G, T cells or 
other immune cells can express or secrete HLA-G. 
A subpopulation of CD4+ HLA-G1+ and CD8+ HLA-G1+ T cells has been described (Feger et 
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Fig. 3. A unique subset of human tolerogenic DC: DC-10 
A. DC-10 are present in vivo and characterized by the expression of the surface markers 
CD14, CD16, CD83. They also express high levels of HLA-G1 and its receptor ILT4. B. DC-10 
can be differentiated in vitro starting from the CD14+ fraction of PBMCs cultured for 7 days 
in the presence of GM-CSF, IL-4 and IL-10.  
are increased at sites of inflammation, such as in the central nervous system of patients with 
neuro-inflammatory disorders and in muscle tissue in patients with idiopathic myositis 
(Feger et al., 2007; Huang et al., 2009a; Wiendl et al., 2005). CD4+ HLA-G1+ T cells represent 
a population of naturally occurring Treg cells distinct from nTreg cells, since they lack CD25 
and FOXP3 expression. HLA-G+ Treg cells showed reduced proliferation in response to 
allogeneic (mDCs) and polyclonal stimulation (CD3/CD28), and have a cytokine profiling 
different from Tr1 cells. CD4+ HLA-G+ and CD8+ HLA-G+ Treg cells inhibit the proliferation 
of autologous HLA-G- T cells through HLA-G1/sHLA-G1 (Feger et al., 2007) and soluble 
factors, including IL-10 (Huang et al., 2009b). A population of induced HLA-G+ T cells has 
been also described, these allo-specific CD4+ and CD8+ T cells were shown to express HLA-
G1 and to secrete HLA-G5 (Le Rond et al., 2004; Lila et al., 2001). Moreover, we 
demonstrated that up-regulation of HLA-G on CD4+ T cells is critically required for DC-10 
mediated induction of adoptive Tr1 cells (Gregori et al., 2010). 
Adult bone marrow MSCs can also express HLA-G and have been included in the list of 
regulatory cells. MSCs are multipotent cells that play an important role in tissue 
regeneration and also have strong immuno-modulatory properties (reviewed in (Uccelli et 
al., 2008)). MSCs express low levels of HLA Class I molecules, do not express HLA class II or 
co-stimulatory molecules, and therefore do not induce T-cell activation. It has been 
demonstrated that MSCs constitutively express HLA-G5 (Selmani et al., 2009). Even though 
HLA-G expression decrease during MSCs expansion in vitro, recent studies clearly identified 
it as a key contributor to MSCs immune-tolerogenic functions (Nasef et al., 2007; Rizzo et al., 
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2008; Selmani et al., 2008). In addition to a direct suppressive function through HLA-G5, 
MSCs can induce via a cell-to-cell contact mechanism CD4+ CD25high Foxp3+ Treg cells 
(Selmani et al., 2008). 
6. HLA-G and its polymorphisms 
Very few polymorphisms have been identified in the coding region of the HLA-G locus. The 
heavy chain encoding region exhibits 33 Single Nucleotide Polymorphisms (SNPs) but only 
13 amino acid variations are observed. This peculiarity is important in determining the 
biological function of HLA-G, since a reduced variability leads to a limited peptide 
repertoire and presentation capability (Clements et al., 2005), and can influence the 
polymerization rate. Moreover, the 5’ Up-stream Regulatory Region (5’ URR), containing the 
promoter, and the 3’ untranslated region (UTR) exhibit numerous nucleotide variations that 
may influence HLA-G expression (Donadi et al., 2011; Larsen and Hviid, 2009) and 
consequently its tissue distribution in healthy and pathological conditions (Fig. 4). 
 
Fig. 4. HLA-G locus and its polymorphisms  
Schematic representation of HLA-G locus. The major polymorphisms observed at the 5’URR 
and at 3’UTR regions are indicated. URR: Up-stream regulatory region; UTR: Untraslated 
region. 
6.1 5’ up-stream regulatory region (URR) 
Because of the presence of regulatory elements, polymorphisms at the 5’ URR might have a 
relevant impact in the regulation of HLA-G expression (Fig. 4). The region up-stream from 
the transcriptional start site of HLA-G contains 27 different polymorphisms but only 13 of 
them are within or very close to known transcription factor binding sites or regulatory 
elements (Hviid et al., 1999; Ober et al., 2003; Tan et al., 2005). Interestingly, all the 27 
polymorphisms are in strong linkage disequilibrium (LD) and define 13 unique promoter 
haplotypes (Ober et al., 2003; Tan et al., 2005). Among the 5’ URR polymorphisms, only the -
725C/G/T single nucleotide polymorphism (SNP) has been associated with HLA-G 
expression. Ober et al. demonstrated that the presence of G in position -725 significantly 
increases HLA-G transcription rate in JEG-3 cell line (Ober et al., 2006) and, when it is 
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An additional interesting SNP located in 5’ URR is the -201 A/G SNP since it resides into the 
enhancer A region (Hviid et al., 1999). However, it still remains to be clarified if this 
polymorphism has any impact on the expression of certain HLA-G alleles.  
6.2 3’untraslated region (UTR) 
The exon 7 of the HLA-G locus is always absent in the mature messenger(m)RNA. 
Moreover, due to the presence of a stop codon in the exon 6 of HLA-G, the exon 8 is not 
translated. Thus, exon 8 is considered the 3’ UTR of the mature RNA. This region contains 
several regulatory elements (Kuersten and Goodwin, 2003), including polyadenylation 
signals, AU-rich elements (Alvarez et al., 2009), and several polymorphic sites that may 
potentially influence mRNA stability, turnover, mobility and splicing pattern. 3’UTR 
polymorphisms that can influence HLA-G expression are: i) the insertion (INS) or deletion 
(DEL) of a 14bp fragment (14bp INS/DEL) that has been associated with mRNA stability; ii) 
the SNP at position +3142, which may be a target for certain microRNAs (miRNAs), small 
RNA sequences which once bound to a complementary mRNA lead to its translational 
repression or degradation and gene silencing (Bartel, 2009); iii) additional six SNPs landed 
in putative binding sites for miRNAs (Castelli et al., 2009) (Fig.4). 
The first identified 3’UTR HLA-G polymorphism is the 14bp INS/DEL and has been studied 
the most. The insertion of the 14bp fragment, results in the formation of a cryptic breakpoint in 
the mRNA that loose the first 92bp of exon 8 (Hviid et al., 2003). Rousseau et al. demonstrated 
that HLA-G transcript with the 92bp deleted seems to be more stable than the complete 
mRNA fragment generated by the 14bp DEL (Rousseau et al., 2003), suggesting that 14bp INS 
might be associated with high levels of HLA-G expression.  Nonetheless, several groups have 
demonstrated that 14 bp INS/INS genotype is associated with lower serum and plasma level 
of sHLA-G1/HLA-G5 compared to those observed in 14bp INS/DEL and 14bp DEL/DEL 
genotypes (Chen et al., 2008; Hviid et al., 2004; Hviid et al., 2006), an observation that 
constitutes the “14bp paradox”. Consistently, conflicting results have been obtained in 
different studies concerning the association of the 14bp HLA-G genotypes with autoimmune 
diseases, pathological pregnancy, recurrent spontaneous abortions, and pre-eclampsia. 
Notably, the presence of 14bp DEL has been found to be predictive for the incidence of GvHD 
after unrelated (La Nasa et al., 2007) and HLA-identical sibling (Sizzano et al., in press) Human 
Stem Cell Transplantation (HSCT) for beta-thalassemia. 
Several SNPs at 3’UTR of HLA-G locus have been identified (Castelli et al., 2009). Among 
them, the +3142 C/G SNP has been proposed to be critically involved in HLA-G regulation 
since it is associated with asthma (Tan et al., 2005). The G variant of a G/C SNP at position 
+3142 of the 3’UTR has been hypothesized to increase the affinity of the resulting mRNA for 
miR-148a, miR-148b and miR-152 (Veit and Chies, 2009). Among these miRNAs, only miR-
152 has been demonstrated responsible for HLA-G post-transcriptional regulation. Indeed, 
over-expression of miR-152 in JEG-3 cell lines resulted in decreasing HLA-G expression and 
increased susceptibility to NK cell–mediated cytolysis (Zhu et al., 2010). 
In silico analysis of the 3’UTR of the HLA-G locus revealed the presence of additional six 
SNPs that are landed in putative binding sites for miRNAs (Castelli et al., 2009). 
Interestingly the 14bp INS/DEL and the 7 SNPs arrange in different combinations to 
generate eight distinct haplotypes of 3’UTR HLA-G region (Castelli et al., 2010) (Table 1). 
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Therefore, it has been hypothesized that the expression of HLA-G might be influenced by a 
combination of specific polymorphisms. Our group is currently investigating the impact of 
the HLA-G 3’UTR haplotypes on HLA-G expression. Preliminary results indicate that 
different 3’UTR HLA-G haplotypes are associated with variable levels of HLA-G1 
expression on myeloid APCs.  
 
Table 1. 3’UTR HLA-G haplotypes 
7. Conclusions and perspectives 
Since the discovery of HLA-G, research has established its role in modulating immune 
responses and inducing tolerance. While a great deal of progress has been made in 
understanding the mechanisms underlying immune modulation by HLA-G, several 
questions remain to be clarified. First, HLA-G can promote the differentiation of regulatory 
cells and HLA-G-expressing cells act as regulatory cells, however additional studies are 
required to better define their role in promoting tolerance. Second, although it is generally 
accepted that 5’ URR and 3’ UTR are involved in HLA-G expression, further investigation 
are needed to elucidate the molecular mechanisms involved in HLA-G regulation. Third, 
3’UTR HLA-G haplotypes have been identified, future studies are warranted to define 
whether they can influence the transcriptional rate of HLA-G isoforms and their functions. 
Answering these questions will not only bring us closer to understanding how HLA-G 
function, but also how to exploit or modulate its suppressive activity for targeted therapy 
against a wide variety of diseases. 
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1. Introduction 
1.1 MHC class I molecules: Molecular hallmarks of individuality  
Ever since its initial discovery in 1948 by George Snell, major histocompatibility (MHC) 
complex became the focus of intense research that, due to its diverse roles, gradually 
extended far beyond transplantation biology. MHC class I molecules are found on virtually 
all nucleated cells of jawed vertebrates and are the most polymorphic molecules described 
to date (Cresswell et al. 2005, Solheim 1999). Their polymorphism is so high that, with the 
exception of identical twins, two individuals with the exact same set of MHC molecules 
(both class I and II) do not exist.  
1.2 Structure, function and properties of MHC class I molecules 
MHC class I molecules are normally composed of three subunits: transmembrane heavy 
chain, small β-2-microglobulin subunit and the presenting antigenic peptide [Figure 1; 
(Cresswell et al. 2005, Solheim 1999)]. MHC class I molecules are assembled in the 
endoplasmatic reticulum and are generally dependent on the presence of all three subunits 
for proper cell surface expression. The MHC class I heavy chain is a glycoprotein with 
reported molecular weight of 42-48 kDa. It consists of three extracellular domains (α1-3), 
and short transmembrane and cytoplasmic regions (Figure 1). α1 and α2 domains form the 
peptide binding groove and are the regions responsible for the high polymorphism of MHC 
class I molecules. α3 domain carries the signature of the immunoglobulin superfamily, the 
immunoglobulin fold.  
β-2-microglobulin is the smaller, 11-13 kDa subunit, without a transmembrane domain. It is 
non-covalently attached to the MHC class I heavy chain on the cell surface. β-2-
microglobulin is encoded by a gene settled outside of the MHC cluster and it is structurally 
also immunoglobulin-like (Figure 1). MHC class I molecules are divided in two groups: 
classical and non-classical MHC class I. Classical MHC class I molecules are highly 
polymorphic, usually form trimers on the cell surface and are mainly associated with 
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They are not as polymorphic as the classical MHC class I and some of them do not require β-
2-microglobulin or the binding of peptide in order to reach the cell surface (Arosa et al. 
2007). Non-classical MHC class I are also implicated in a wide range of immune and non-
immune processes, from presentation of glycolipids to regulation of pheromone signalling 
(Arosa et al. 2007, Fishman et al. 2004). 
 
Fig. 1. Structure of MHC class I molecules.  
Ribbon structure of MHC class I molecule: MHC class I molecule (HLA-A2, in this case) is 
composed of heavy chain (red), β-2-microglobulin (violet blue) and the presenting peptide 
(dark blue). Immunoglobulin fold structure of the α3 domain of the heavy chain and the β-2-
microglubulin is visible. Image courtesy of Wikimedia Commons. 
1.3 MHC class I signaling in immune and non-immune systems 
The main function of classical MHC class I molecules is the presentation of foreign, “non-
self” peptides to cytotoxic T-cells. This process initiates the canonical MHC class I/T-cell 
receptor signaling pathway (Figure 2). Cytotoxic T-cells become activated through this 
pathway after they recognize the MHC class I-presented peptide as foreign and potentially 
hazardous. The signalling cascade brought about by MHC class I/TCR interaction induces 
cytoskeletal rearrangements and cytokine production in T-cells activated by it (for more 
details, the reader should refer to general immunology textbooks). Although this is the 
canonical MHC class I signalling pathway, the TCR complex is not the only receptor for the 
MHC class I molecules. MHC class I proteins are able to interact with a large number of 
receptors within the immune system, both in cis and in trans, such as killer-cell 
immunoglobulin-like receptors (KIRs), leukocyte immunoglobulin-like receptors (LILRs), 
etc., causing a wide range of responses (Parham 2005).   
Immune Privilege Revisited: The Roles  




Fig. 2. Canonical MHC class I/T-cell receptor pathway.  
TCR receptor complex is depicted with its main components: T-cell receptor (TCR) and 
accessory CD3 molecules (ε,γ,ζ and δ). CD8 is a co-receptor specific for MHC class I 
molecules. After T-cell receptor (TCR) complex recognizes the peptide presented by MHC 
class I as foreign, TCR receptor complex subunits rearrange within the membrane in a more 
spatially constricted configuration. CD3 subunits become phosphorylated (orange circles) 
by lymphocyte-specific protein kinase (Lck) and zeta-chain associated protein kinase 70 
(ZAP70). ZAP70 also phosphorylates linker of activated T-cell kinase (LAT) before T-cell 
activation.  
Outside of the immune system, MHC class I molecules have been implicated mainly in 
regulation of trafficking and internalization of hormone receptors. Interactions with insulin 
receptor (IR), γ-endorphin receptor, luteinizing hormone receptor and many others have 
been reported (Arosa et al. 2007). The best characterized non-immune interaction of MHC 
class I is with the IR. It has been suggested that MHC class I molecules are involved in 
glycosylation of IR and its proper transport to the cell surface, but most evidence has been 
provided for the role of MHC class I in insulin-induced IR internalization (Olsson et al. 1994, 
Ramalingam et al. 1997, Stagsted 1998, Stagsted et al. 1993a, Stagsted et al. 1990, Stagsted et 
al. 1993b). A number of studies have suggested that MHC class I associates with IR after 
insulin binding thereby causing its internalization and removal from the cell surface. 
Functional significance of these findings is still debated; however, certain MHC class I genes 
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1.4 Immune privilege and neuronal expression of MHC class I molecules  
The concept of immune privilege refers to the ability of certain organs (eyes, brain, testicles 
and the uterus while harbouring a foetus) to evade inflammatory responses during antigen 
presentation (Hong and Van Kaer 1999). Tissues transplanted to the central nervous system 
(CNS) show prolonged survival compared to tissues grafted to other locations in the body, 
such as skin (Carson et al. 2006, Galea et al. 2007). Furthermore, a number of pathogens are 
able to evade the immune responses by “hiding” in the CNS structures (Carson et al. 2006, 
Galea et al. 2007). This immune privilege of the CNS is thought to be a consequence of the 
blood-brain barrier (BBB), considered impermeable to the cells of the immune system 
(Carson et al. 2006, Galea et al. 2007). A classical inflammatory response would be 
devastating for immune privileged structures due to their special properties and it is 
believed that immune privilege is an active process that has developed throughout the 
evolution (Hong and Van Kaer 1999). However, the concept of CNS immune privilege has 
been extensively challenged in the last few decades. Increasing evidence suggests not only 
that immune cells are able to cross the blood-brain barrier under normal conditions, but that 
they might be indispensable to normal functioning of the CNS (Kipnis et al. 2004). 
Furthermore, the notion of the CNS being completely devoid of neuronal MHC class I 
expression due its immune privileged status has been questioned with strong experimental 
evidence over the past decade. The new line of research on the interactions between the 
immune and the nervous system is slowly debunking the myth of classical CNS immune 
privilege. Strong experimental evidence is pointing to a novel concept: CNS functions highly 
depend on its proper interactions with the immune system.   
2. Neuronal MHC class I molecules in brain development and plasticity 
Based on the immune privileged status of the CNS, expression of MHC class I by neurons 
has always been considered either low or non-existent. Based on experimental evidence, it 
was believed that neurons were able to express MHC class I only after induction by 
cytokines (Neumann et al. 1995). However, a study by Corriveau et al. in 1998 demonstrated 
high neuronal MHC class I expression in normal, developing and adult brains. Since then, a 
number of studies confirmed that neurons do express MHC class I molecules in normal, 
non-pathological conditions (Datwani et al. 2009, Goddard et al. 2007, Huh et al. 2000, 
McConnell et al. 2009, Ribic et al. 2010, Rolleke et al. 2006). Furthermore, MHC class I have 
been implicated in proper development and maintenance of neuronal circuitry in various 
brain regions, especially in the development of the visual system (Huh et al. 2000, Ribic et al. 
2011), and in modulation of synaptic plasticity in hippocampus and the cerebellum 
(Goddard et al. 2007, Huh et al. 2000, McConnell et al. 2009, Ribic et al. 2010). 
2.1 MHC class I molecules and the mammalian visual system development 
2.1.1 Mammalian visual system 
Synaptic plasticity is the ability of neurons to change the strength of their synaptic 
connections in response to various stimuli. Plasticity is one of the fundamental properties of 
CNS. This process occurs in various forms with distinct properties and is thought to be 
essential for development and maintenance of brain circuits. The developing visual system 
is one of the main models of two forms of plasticity: visual activity-independent and visual 
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input-driven or activity-dependent plasticity. There are two main stages of visual system 
development. The early stage encompasses the development of the eyes and the brain and 
the initial development of the neuronal connections between them. It is believed that at this 
early stage, both growth of neuronal processes and pathfinding are independent of retinal 
activity, as opposed to the later stage. The second stage involves proper development of 
connections in and between the thalamus and the visual cortex, regions responsible for the 
processing of the visual input. The thalamic dorsal lateral geniculate nucleus (LGN) is the 
first relay structure of visual input and is organized into segregated, eye-specific, neuronal 
layers that form upon early spontaneous activity from retinal ganglion cells in the eye 
[Figure 3, (Shatz 1996)].  
 
Fig. 3. Schematic structure of the mammalian visual system.   
Retinal ganglion cells from both eyes project to the thalamic dorsal lateral geniculate nucleus 
(dLGN). Partial crossing of the two pathways occurs in the optic chiasm. Neurons of the 
lateral geniculate nucleus project to the visual cortex in the occipital lobes where neurons 
form eye-specific patches, ocular dominance columns (ODCs).  
Neurons of the LGN send their projections to the primary visual cortex (V1), where their 
activity is required for the development of eye-specific patches of neurons in layer IV, i.e., 
the ocular dominance columns (ODCs) (Sur and Rubenstein 2005).  
Although the development of both LGN and V1 is dependent on spontaneous retinal 
activity, visual activity is also required for their proper maturation. Blocking retinal activity 
of one eye during the development of the visual circuits while leaving the other one intact 
leads to the perturbation of the segregation of LGN neurons into eye-specific layers (Shatz 
1996). In the visual cortex, ODCs do not form properly if one eye is deprived of input. As a 
consequence of visual deprivation, the ODCs increase the fraction of neurons responsive to 
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al. 2003, Sur and Rubenstein 2005). Furthermore, neurons receiving afferents from the intact 
eye tend to expand their synaptic space and occupy more territory within the visual cortex. 
On the other hand, neurons receiving afferents from the deprived eye shrink their territory 
[Figure 4; (Berardi et al. 2003)]. 
 
Fig. 4. Effects of monocular deprivation on visual cortex development.  
Normal development of the visual cortex is based on the competition between the two eyes 
which confers balanced development of LGN neurons and their connections with the visual 
cortex neurons in ODCs (upper panel). If one eye is deprived of visual input throughout the 
development of the visual system, LGN neurons receiving afferents from the deprived eye 
shrink and prune their connections in the visual cortex (lower panel). This also causes 
shrinkage of ODCs in the visual cortex that receive input from the deprived eye (in the 
figure: left eye). On the other hand, ODCs receiving input from the intact eye, expand their 
territory within the visual cortex (in the figure: right eye). 
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2.1.2 The roles of MHC class I molecules in visual system development  
In the mouse dLGN and visual cortex, MHC class I molecules are associated with mainly 
excitatory, glutamate-activated synapses (Datwani et al. 2009, Glynn et al. 2011, Needleman 
et al. 2010). Immunoelectron microscopy of mouse visual cortex has demonstrated that 
MHC class I molecules may be situated on both sides of the synapse (Needleman et al. 
2010). Expression levels of MHC class I proteins decrease with development of mouse 
cortex, being very prominent in the early stages of cortical development (Needleman et al. 
2010). First studies dealing with neuronal expression of MHC class I revealed an essential 
role for MHC class I genes in the segregation of retinal inputs and proper formation of 
neuronal layers within the LGN (Corriveau et al. 1998, Huh et al. 2000). MHC class I-
deficient mice display an aberrant development of retinal projections and impairments in 
the formation of eye-specific regions in the LGN, caused by an excess of inappropriate 
synapses that are normally removed during LGN development in wild-type mice (Huh et al. 
2000). These studies implicated MHC class I in weakening, removal and pruning of 
synapses, and it is believed that MHC class I molecules limit plasticity in the developing 
visual system (Syken et al. 2006). β-2-microglobulin deficient mice show an increased 
density of synapses in the visual cortex, consistent with the role of MHC class I in synapse 
pruning (Glynn et al. 2011). A recent study has shown that classical MHC class I molecules 
are mediating these effects (Datwani et al. 2009). Mutant mice lacking two classical MHC 
class I genes (H2-Kb and H2-Db) replicate the phenotype observed in the visual system of β-
2-microglubulin/TAP-deficient mice used in previous studies (Datwani et al. 2009). 
Interestingly, mice that lack the expression of TCR complex subunit CD3-ζ also display 
similar defects in visual system development (Corriveau et al. 1998, Huh et al. 2000, Xu et al. 
2010). Furthermore, a study that investigated the retinal phenotype of CD3-ζ knock-out mice 
revealed an important observation-the phenotype observed in the dLGN and visual cortex 
of both CD3-ζ and MHC class I-deficient mice may be just a consequence of retinal defects 
observed in these mice (Xu et al. 2010).MHC class I genes are also expressed in the retina 
(Huh et al. 2000) and time will show if this assumption holds true.  
Majority of the above mentioned studies have been performed in mice and cats (Corriveau 
et al. 1998, Huh et al. 2000). The number of class I genes is highly variable between species; 
moreover, orthologous relationships are found only within same order of mammals such as 
within primates, but never between primates and rodents (Kumanovics et al. 2003, Gunther 
and Walter 2001). Mouse and rat MHC clusters are comprised of over 30 functional classical 
and non-classical genes (Gunther and Walter 2001, Kumanovics et al. 2003). Despite the 
orthologous relationship, MHC class I genes are still very variable between primates. Strict 
orthologues of classical human MHC class I genes are present only in the great apes, 
whereas orthologues of the non-classical genes are found in Old World (baboons, macaques) 
and New World monkeys. This, coupled with known differences in CNS anatomy and 
function between rodents and primates, poses a question of possible interspecies differences 
in the function of neuronal MHC class I genes. It is known that MHC class I genes are highly 
expressed in the visual cortex of the marmoset monkey (a New World primate) and that their 
expression closely follows the synapse development in the visual cortex, increasing with 
postnatal age (Ribic et al. 2011). Neuronal MHC class I gene expression appears activity-
dependent in all species examined (Corriveau et al. 1998, Huh et al. 2000, Ribic et al. 2011), but 
the expression profile seems to be highly dependent on both the experimental paradigm and 
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On the other hand, neurons receiving afferents from the deprived eye shrink their territory 
[Figure 4; (Berardi et al. 2003)]. 
 
Fig. 4. Effects of monocular deprivation on visual cortex development.  
Normal development of the visual cortex is based on the competition between the two eyes 
which confers balanced development of LGN neurons and their connections with the visual 
cortex neurons in ODCs (upper panel). If one eye is deprived of visual input throughout the 
development of the visual system, LGN neurons receiving afferents from the deprived eye 
shrink and prune their connections in the visual cortex (lower panel). This also causes 
shrinkage of ODCs in the visual cortex that receive input from the deprived eye (in the 
figure: left eye). On the other hand, ODCs receiving input from the intact eye, expand their 
territory within the visual cortex (in the figure: right eye). 
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2.1.2 The roles of MHC class I molecules in visual system development  
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2000). These studies implicated MHC class I in weakening, removal and pruning of 
synapses, and it is believed that MHC class I molecules limit plasticity in the developing 
visual system (Syken et al. 2006). β-2-microglobulin deficient mice show an increased 
density of synapses in the visual cortex, consistent with the role of MHC class I in synapse 
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Fig. 5. Expression of MHC class I proteins in the visual cortex of the common marmoset.  
MHC class I proteins (green) colocalize with the neuronal marker MAP2 (red) in layer IV 
neuronal cell bodies of the common marmoset primary visual. Image adapted from Ribic et 
al., 2011. 
Unavailability of transgenic non-human primate models has hindered the answers to the 
question of potential interspecies variability in neuronal MHC class I function. However, 
having in mind the high evolution rate of these molecules, differential interspecies function 
seems highly plausible. 
2.2 MHC class I molecules and hippocampal plasticity 
2.2.1 The hippocampus 
Hippocampus is a part of the brain situated in the medial temporal lobe and implicated in 
learning and memory processes. It is organized as a series of connected cell layers: the 
dentate gyrus, hilus, and cornu ammonis 1, 2 and 3 (CA1-3, Figure 6), which form the so 
called “trisynaptic circuit”. Due to its relatively simple structure, hippocampus is one of the 
best studied circuits within the brain. The dentate gyrus is composed of granule cells that 
receive input from the entorhinal cortex and send projections to the hilus and the CA3 
pyramidal neurons region. The dentate gyrus to hilus and CA3 projections are known as the 
mossy fiber pathway (Figure 6). The CA3 pyramidal neurons innervate the CA1 cell layer, 
and the CA1 pyramidal neurons in turn send their axons to the entorhinal cortex. The CA3 
to CA1 connections are also called Schaffer collaterals. Both mossy fiber pathway and 
Schaffer collaterals have received a great deal of attention over the past decades due to 
neuronal long-term plasticity properties within these two hippocampal regions. Prolonged 
correlated presynaptic (neurotransmitter release) and postsynaptic (activation of 
neurotransmitter receptors) activity is thought to underlie one form of long-term plasticity, 
long-term potentiation [LTP; (Cooke and Bliss 2006, Malenka and Bear 2004)]. LTP results in 
increased synapse strength between participating neurons (Cooke and Bliss 2006, Malenka 
and Bear 2004). In contrast to LTP, prolonged uncorrelated presynaptic and postsynaptic 
activity results in long-term depression (LTD), a form of plasticity thought to precede the 
weakening of synapses and their pruning (Collingridge et al. 2010, Malenka and Bear 2004). 
Although both LTP and LTD are experimental phenomena, they are considered cellular 
mechanisms of memory formation and storage and both have been extensively studied 
using hippocampus as a model system (Collingridge et al. 2010, Malenka and Bear 2004).  
LTP and LTD in Schaffer collaterals are considered the classical examples of long term 
plasticity (Malenka and Bear 2004). Both LTP and LTD have various forms of induction and 
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maintenance, but the most investigated forms are dependent on the activation of NMDAR 
(N-methyl D-aspartate receptors), as well as changes in Ca2+ concentrations (Malenka and 
Bear 2004). Both LTP and LTD occur in the visual cortex during developmental activity-
dependent plasticity, where they regulate the strengthening of appropriate and removal of 
inappropriate synapses (Berardi et al. 2003, Heynen et al. 2003, Katz and Crowley 2002, 
Thompson 2000).  
 
Fig. 6. Schematic structure of the hippocampus.  
Granule cells in the dentate gyrus receive input from the entorhinal cortex (EC, orange) and 
send their projections to the CA3 pyramidal neurons [mossy fiber pathway (mf), red]. CA3 
neurons innervate CA1 pyramidal neurons [Schaffer collaterals (sc), green], which in turn 
send their projections back to the entorhinal cortex (blue). 
2.2.2 The roles of MHC class I proteins in hippocampal plasticity 
MHC class I proteins in mice have been shown to localize postsynaptically on the somata 
and dendrites of the dentate gyrus granule neurons and the CA1-CA3 pyramidal neurons 
(Corriveau et al. 1998, Goddard et al. 2007). Both LTP and LTD at the Schaffer collaterals are 
aberrant in mice lacking MHC class I molecules (Huh et al., 2000). Schaffer collateral LTP in 
these mice is significantly enhanced, while LTD is completely absent (Huh et al. 2000). These 
findings parallel the effects of MHC class I in the visual system: LTP reflects strengthening 
of the neuronal connections and the absence of MHC class I causes strengthening of 
synapses that would otherwise be weakened by LTD. However, the enhancement of LTP in 
MHC class I deficient mice is not dependent on NMDAR receptors (Huh et al. 2000). In 
primates, at least a subset of neuronal MHC class I molecules is presynaptic and expressed 
exclusively in the mossy fibers within the hippocampal formation (Ribic et al. 2010). 
Blocking their function in vitro interferes with normal synaptic transmission (Ribic et al. 
2010). 
So far, presynaptic localization of neuronal MHC class I molecules in mice has only been 
detected in the spinal cord and at the neuromuscular junction (Oliveira et al. 2004, Thams et 
al. 2009). Future studies will no doubt reveal if there are any functional differences 
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Fig. 7. MHC class I (MHCI) protein is localized to the presynaptic side of the mossy fiber-
CA3 synapse in the common marmoset monkey hippocampus.  
MHC class I signal (A, green) significantly overlaps with that of piccolo (B, red), a marker of 
the presynaptic active zone (C and G, white arrowheads). Almost no overlap is detected 
between MHC class I (D) and the postsynaptic marker PSD95 (E, F and H).  
2.3 Molecular mechanisms of neuronal MHC class I action 
The main unanswered question is how are neuronal MHC class I molecules mediating all 
these effects? A few studies have shown that MHC class I may recruit receptors other than 
TCR in the CNS. Mice lacking PirB, known interaction partner of MHC class I molecules in the 
immune system, also show similar defects in developmental synapse removal (Syken et al).  
It has been hypothesized that MHC class I may engage in trans-synaptic interactions and 
hence exert presynaptic effects that have been observed (Goddard et al. 2007, Syken et al. 
2006). As the phenotype of CD3ζ knock-out mice resembles the phenotype of MHC class I 
deficient mice, it is safe to assume that they may be involved in the same signaling pathway 
(Xu et al. 2010, Huh et al. 2000). Furthermore, MHC class I molecules may affect the function 
of synapses through their effects on neurotransmitter receptors, such as glutamate receptors 
(Fourgeaud et al. 2010). A recent study indicated that MHC class I proteins may regulate 
trafficking of NMDAR receptors, which parallels their previously described roles in insulin 
receptor signaling (Arosa et al. 2007, Fishman et al. 2004, Fourgeaud et al. 2010). 
Interestingly enough, insulin is mediating a non-NMDAR dependent form of LTD in the 
hippocampus (Ahmadian et al. 2004, Collingridge et al. 2010, Ge et al. 2010, Wang and 
Linden 2000). Receptor internalization seems to be the main role of MHC class I in the 
vomeronasal organ of mice, where non-classical MHC class I molecules appear to be 
involved in internalization of vomeronasal receptors (Olson et al. 2006, Dulac and Torello 
2003, Loconto et al. 2003). In the primate hippocampus, blockade of neuronal MHC class I in 
vitro slows down basal synaptic transmission at the mossy fiber-CA3 synapses (Ribic et al. 
2010). The mossy fiber-CA3 synapse displays a number of peculiarities in comparison to the 
majority of CNS synapses. It is e.g. characterized by a low basal transmission which is 
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maintained by activation of a number of receptors that have inhibitory effects on synaptic 
transmission (Nicoll and Schmitz 2005). As previously mentioned, given that the best 
characterized non-immune function of MHC class I is regulation of trafficking and 
internalization of various receptors (Olsson et al. 1994, Stagsted 1998, Stagsted et al. 1990, 
Ramalingam et al. 1997), it is likely that neuronal MHC class I molecules in the marmoset 
hippocampus are needed for proper internalization of one or several of those receptors 
(Figure 8). One may speculate that blocking the interaction of MHC class I with such  
 
Fig. 8. Schematic representation of potential mode of action of MHC class I at the mossy 
fiber-CA3 synapse.  
Mossy fiber-CA3 synapse normally displays lower levels of basal activity compared to other 
synapses in the central nervous system (representative electrophysiological trace of 
recorded spontaneous excitatory postsynaptic currents (EPSCs) of a marmoset CA3 neuron 
is shown in the lower part of the image). This is mainly due to large number of receptors 
(magenta) that have inhibitory effect on synaptic transmission (Nicoll and Schmitz, 2005). It 
is possible that MHC class I is needed for proper internalization and removal of one of these 
receptors from the cell surface. MHC class I would presumably bind to the receptor with its 
α1 and α2 domains. (D) If anti-MHC class I antibodies that bind to α1 and α2 domains are 
applied in the vicinity of the cell while the cell’s activity is recorded using patch clamp 
technique, frequency of spontaneous EPSCs is decreased (trace in the lower part of the 
image). It is possible that antibodies block interaction of MHC class I with putative 
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receptors by application of anti-MHC class I antibodies would prolong inhibitory signaling 
and exert the inhibitory effects on synaptic transmission. Future studies need to elucidate 
the exact molecular pathways that neuronal MHC class I molecules are involve in, as well as 
their potential involvement in insulin-induced hippocampal LTD.  
3. Nervous and immune systems-shared molecules and mechanisms 
A vast number of studies in the past decades have shown that the immune and the nervous 
system are interconnected more than previously thought. Recent discoveries have 
highlighted a number of roles performed by immune molecules in the CNS-molecules and 
pathways previously thought to be exclusively acting within the immune system. From 
MHC class I molecules in synapse development (Corriveau et al. 1998, Huh et al. 2000, Ribic 
et al. 2010), CD3ζ in retinal function and dendrite development (Baudouin et al. 2008, Xu et 
al. 2010), to DAP12 in astrocyte-neuron signaling (Roumier et al. 2004), a new picture of 
immune privilege emerges-a picture in which the immune system is actively involved in 
proper brain development and maintenance of neuronal circuitry. This concept has 
important implications for a number of diseases associated with MHC cluster, such as 
schizophrenia and autism (Torres et al. 2006, Kipnis et al. 2004, Needleman et al. 2010). 
Current research efforts are focused on elucidating the consequences of prenatal immune 
insult on the brain development, so called “maternal immune activation”. Both 
schizophrenia and autism have been genetically linked to MHC cluster and to prenatal 
immune insult (Soumiya et al. 2011, Buehler 2011, Escobar et al. 2011, Patterson 2011, Fatemi 
et al. 2011, Parker-Athill and Tan 2010, Boksa 2010, Currenti 2010, Li et al. 2009, Patterson 
2009, Smith et al. 2007, Cohly and Panja 2005, Patterson 2002, Stubbs and Magenis 1980). 
Future studies will no doubt elucidate the interactions between the nervous and immune 
systems in more detail, as well as shed more light on the vast polymorphism of MHC class I 
molecules, especially in the light of their neuronal functions.  
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receptors by application of anti-MHC class I antibodies would prolong inhibitory signaling 
and exert the inhibitory effects on synaptic transmission. Future studies need to elucidate 
the exact molecular pathways that neuronal MHC class I molecules are involve in, as well as 
their potential involvement in insulin-induced hippocampal LTD.  
3. Nervous and immune systems-shared molecules and mechanisms 
A vast number of studies in the past decades have shown that the immune and the nervous 
system are interconnected more than previously thought. Recent discoveries have 
highlighted a number of roles performed by immune molecules in the CNS-molecules and 
pathways previously thought to be exclusively acting within the immune system. From 
MHC class I molecules in synapse development (Corriveau et al. 1998, Huh et al. 2000, Ribic 
et al. 2010), CD3ζ in retinal function and dendrite development (Baudouin et al. 2008, Xu et 
al. 2010), to DAP12 in astrocyte-neuron signaling (Roumier et al. 2004), a new picture of 
immune privilege emerges-a picture in which the immune system is actively involved in 
proper brain development and maintenance of neuronal circuitry. This concept has 
important implications for a number of diseases associated with MHC cluster, such as 
schizophrenia and autism (Torres et al. 2006, Kipnis et al. 2004, Needleman et al. 2010). 
Current research efforts are focused on elucidating the consequences of prenatal immune 
insult on the brain development, so called “maternal immune activation”. Both 
schizophrenia and autism have been genetically linked to MHC cluster and to prenatal 
immune insult (Soumiya et al. 2011, Buehler 2011, Escobar et al. 2011, Patterson 2011, Fatemi 
et al. 2011, Parker-Athill and Tan 2010, Boksa 2010, Currenti 2010, Li et al. 2009, Patterson 
2009, Smith et al. 2007, Cohly and Panja 2005, Patterson 2002, Stubbs and Magenis 1980). 
Future studies will no doubt elucidate the interactions between the nervous and immune 
systems in more detail, as well as shed more light on the vast polymorphism of MHC class I 
molecules, especially in the light of their neuronal functions.  
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1. Introduction 
1.1 Polymorphonuclear neutrophils (PMN) 
Polymorphnuclear neutrophils (PMN) possess a very short half-life in the circulation 
because they constitutively undergo apoptosis (Gasmi et al., 1996; Stringer et al., 1996; 
Moulding et al., 1998). Under certain conditions PMN play an important role in the effectors 
arm of host immune defense through the clearance of immune complexes, the phagocytosis 
of opsonized particles, and the release of inflammatory mediators (Shen et al., 1987; Petroni 
et al., 1988; Lloyd et al., 1992). During the recent years the image of PMN has changed 
considerably. Traditionally considered to be the first line defense against bacterial infection.  
It became increasingly clear that PMN also participate in chronic inflammatory disease and 
regulation of the immune response when appropriately activated (Iking-Konert et al., 2002). 
Persistent Staphylococcus aureus-mediated local infection induces the local activation and 
transdifferentiation of PMN to cells with dendritic-like characteristics (Wagner et al., 2006).   
1.2 Interleukin (IL) 
Interleukin is involved in processes of cell activation, cell differentiation, proliferation and 
cell to cell interactions. Each IL acts on a specific group of cells that express the correct 
receptor for the IL. The same IL can be produced by different cell types and an individual IL 
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transdifferentiation of PMN to cells with dendritic-like characteristics (Wagner et al., 2006).   
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reported to express IL-2R� and to be activated by IL-2 for tumoricidal activity (Espinoza-
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and their possession of IL-2R is unknown. The direct effect of IL-2 on PMN, especially the 
mechanisms involved in the activation of PMN, is unknown, although the ability of other 
immune cells to respond to IL-2 is well studied. Preliminary studies have shown that PMN 





More importantly it have identified that PMN express surface receptors for IL-2, but only IL-
2Rß and not IL-2Rα is present (Djeu et al., 1993). 
1.2.2 Interleukin (IL)-4 
IL-4 production has been found to occur in thymocytes, mature T-cells, certain malignant T-
cells, mast-cells and basophiles and occasionally, in transformed B-cells (Holter, 1997). It has 
an effect on B-cells, T-cells, monocytes, mast-cells, endothelial cells, and fibroblasts (Paul, 
1991). Directly and/or indirectly, IL-2 has a prominent role in the regulation of IL-4 
producing cells (Holter, 1997). IL-4 binds to a high-affinity cell-surface receptor (IL-4R) to 
exert its effects (Idzerda et al., 1990). It promotes the growth and differentiation of activated 
human B-lymphocytes and shares many biological functions with IL-13 (Aversa et al., 1993). 
1.2.3 Interleukin (IL)-15 
IL-15 is a pleiotropic cytokine which shares biological activities with IL-2. IL-15 uses both β- 
and γ-chains of the IL-2 receptor for binding and signaling. The IL-15 receptor (IL-15R) 
complex also includes a specific α subunit ( IL-15Rα) , distinct from the IL-2Rα chain. IL-15R 
is expressed on various cells of the immune response, including T- and B-cells, NK cells and 
more recently, peripheral blood neutrophils (Girard et al., 1999). 
IL-15 plays an important role in both innate and adaptive immunity. It induces T-cell 
proliferation and cytokine production, stimulates the locomotion and chemotaxis of T-cells 
and delays its apoptosis. IL-15 has been shown to stimulate the growth and cytotoxicity of 
NK cells and to induce antibody-dependent cell-mediated cytotoxicity. It was also 
demonstrated that this cytokine induces macrophages function and B-cell proliferation 
(Girard et al., 1999). Recent investigation has shown that IL-15 potentiated several 
antimicrobial functions of normal PMN involved in the innate immune response against 
invading pathogens (Casatella  and McDonald, 2000). IL-15 was observed to enhance 
phagocytosis, NF-ќB activation, and IL-8 production and to delay apoptosis of these cells. In 
addition, IL-15 has been shown to prime the metabolic burst of PMN in response to N-
formyl-methionyl-eucyl- phenylalanine (fMLP) (Casatella and McDonald, 2000; Girard et al., 
1996; McDonald et al., 1998; Mastroianni et al., 2000). 
The main source of IL-15 are macrophages / monocytes and lymphocytes as well as 
neutrophils (Casatella and McDonald, 2000; Muro and Taha, 2001; Zissel and Baumer, 2000). 
1.3 Human leukocyte antigen (HLA) class II 
For surface molecules, there are several reports that PMN from a variety of species can 
express HLA class II (Vachiery et al., 1999; Radsak et al., 2000; Iking-Konert et al., 2001a; 
Iking-Konert et al., 2002; Tyler et al., 2006). Under certain stimulation murine neutrophils 
present Class II restricted antigen (Shauna et al., 2008). Coexpression of HLA class II would 
potentially endow PMN with the capacity to influence the adaptive immune system through 
antigen presentation. Previous investigations with mouse, human, and goat PMN defined 
conditions whereby HLA class II expression was observed following stimulation with IFN-
γ, granulocyte macrophage-colony stimulating factor (GM-CSF), or IL-3 (Gosselin et al., 
1993; Smith et al., 1995; Mudzinski et al., 1995; Reinisch et al., 1996) or in human patients, 
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with Wegener’s granulomatosis (Haensch et al., 1999; Iking-Konert et al., 2001b). In some 
cases, PMN expression of HLA II was reported as constitutive (Okuda et al., 1979; Vachiery 
et al., 1999), and human PMN were also shown to function as accessory cells for primed T-
cell activation with protein antigens and superantigens (Okuda et al., 1980; Fanger et al., 
1997; Iking-Konert et al., 2001a; Tyler et al., 2006). Bovine PMN expressed detectable levels 
of HLA class II on their surface, only when cocultured with peripheral blood mononuclear 
cells (PBMC). This observation suggested that PMN may up-regulate endogenous HLA 
class II expression or passively acquire HLA class II protein from other leukocytes. 
To better understand the role of IL-2 in the activation of PMN and to explore the possibility 
that the activation of PMN by IL-2 may reflect the interaction between T-cells and PMN. 
These findings provide useful insight for understanding some mechanisms of T-cell and 
PMN interactions and the possible role of PMN in IL-2 immunotherapy. There is evidence 
that HLA class II-positive PMN are able to present the superantigen staphylococcus 
enterotoxin E (SEE) to T-cells in an HLA class II-dependent manner (Fanger et al., 1997). 
Moreover, PMN pulsed with peptide was shown to activate antigen-specific memory T-cells 
(Reali et al., 1996). In addition, PMN stimulated with GM-CSF and IFN-γ has the capacity to 
present antigen to naive T-cells (Fanger et al., 1997). Those PMN with antigen-presenting 
capacity are thought to be a relatively mature population (Mudzinski et al., 1995). There is a 
large production of proinflammatory cytokines from both T-cells and monocytes following 
superantigen activation: T-cells produce IL-1β, IFN-γ, TNF-α, and IL-2 (Jupin et al., 1988; See 
et al., 1992a; Lagoo et al., 1994). While monocytes produce both IL-1β and IFN-γ (See and 
Chow 1992; See et al., 1992; Trede et al., 1994). It has shown that human PMN can be 
induced to express HLA class II molecules both in vitro and in vivo. Specifically, in vitro 
incubation of human PMN from healthy donors with either GM-CSF, IFN-γ, or IL-3 resulted 
in low-level expression of HLA-DR (Gosselin et al., 1993; Smith et al., 1995). In rheumatoid 
arthritis, there is an evidence for T-cells activation, where PMN act as dendritic-like cells at 
the site of inflammation (Iking-Konert et al., 2005).  
1.4 Aim of the study 
The aim of this study was to insure that IL-2, IL-4 or IL- 15 stimulated PMN might be 
involved in T-cell proliferation by acquiring HLA class II antigens. 
2. Materials and methods 
2.1 Immunocytochemistry 
Blood was taken by venous puncture using 7·5 ml heparin-coated tubes (Sarstedt; 
Nümbrecht, Germany) and was analyzed within 2 hours 
The IL-2R of PMN could be detected by immunofluorescence. Freshly isolated PMN by two 
hypotonic/hypertonic lyses steps with 0.2%/1.6% saline were fixed on slides (2 X 105 cells / 
slide) by a cytoSpin 4 centrifuge (Shandon; Frankfurt, Germany) and ice-cold methanol. 
Cells were incubated with 5% goat serum (Sigma; Saint Louis, MO, USA) in PBS followed by 
2 g anti-CD25-FITC (Becton Dickinson; San Jose, USA), 2g anti-CD122-FITC (Serotec; 
Oxford, UK). Anti-mouse IgG-FITC and anti-CD66-FITC (Immunotech. Marseille, France) 
were used as positive and negative control respectively. The slides were examined by 
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IL-2R was detected on PMN by direct and indirect extracellular fluorescence-activated cell 
sorter (FACS). In direct sets of experiments cells in whole blood were stained with 2μg anti-
CD122-FITC and 2μg anti-CD25 (Serotic; Oxford, UK) as a markers for IL-2Rβ chain and IL-
2Rα chain. Primary an unlabeled antibody for IL-2Rβ chain was added to cells before 
staining with anti-CD122-FITC.  Anti-mouse IgG-FITC and anti-CD66-FITC (Immunotech.; 
Marseille, France) were used as a negative and a positive control, respectively. 
For HLA class II detection cells in whole blood were double labeled with 2g anti-CD66b-
FITC (Immunotech.; Marseille, France) as a PMN marker and 2g PE-labeled antibodies to 
HLA DP-DQ-DR (Serotec; Oxford, UK), respectively, using standard procedures. They were 
analyzed by FACSCalibur and CellQuest software (Becton-Dickinson, Heidelberg, 
Germany). Results are expressed as percentage of positive cells in the respective gate or 
quadrant. 
2.3 Cells purification and cultivation 
For co-culture, cells were isolated by PolymorphPrep® (Nycomed; Oslo, Norway). PMN, 
Monocytes and T-cells fraction was further purified by adsorption to CD15, CD14 and CD3 
beads (Miltenyi Biotech; Bergisch Gladbach, Germany), respectively, by magnetic cell 
separation using the devices supplied by Milteny Biotech (Bergisch-Gladbach, Germany). 
Highly purified PMN (1 x 106 /ml) were cultivated in AIM V (Gibco BRL; Paisley, 
Scotland)) with 2.5% autologous normal human serum, NHS (inactivated at 56C for 30 
min.).  T-cells and monocytes were cultured in RPMI 1640 (Gibco BRL; Paisley, Schottland) 
supplemented with 10% FCS (PAN Biotech GmbH; Aidenbach, Germany), 100U/ml 
penicillin/streptomycin (Gibco BRL; Paisley, Schottland), 2mM L-glutamine (Gibco BRL; 
Paisley, Schottland)), and 10mM HEPES (Gibco BRL; Paisley, Scottland). All the three types 
of cells were incubated at 37C and 5 % CO2 for the times indicated. 
2.4 Stimulation of PMN 
Highly purified PMN were placed into 24-well plate (NuncTm; Roskilde, Danmark)), 
2ml/well, and incubated in the presence or absence of 10ng/ml IL-2 (Sigma; St Louis, MO, 
USA)) for about 48 hours at 37C with 5% CO2. 
2.5 RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR) 
Total cellular RNA was isolated using the RNeasy kit from Qiagen (Hilden, Germany). For 
RT, 2 mg of RNA was incubated with 50 pmol random primer, 1 U RNase inhibitor, 10 pmol 
dNTP and 20 U Moloney Murine Leukemia Virus (MMuLV) reverse transcriptase (all 
purchased from Boehringer Mannheim, Germany) for 60 min at 37u, followed by 15 min at 
94u. PCR for HLA class II was carried out in a Perkin-Elmer (UÈ berlingen, Germany) 
thermocycler as follows: 10 pmol dNTP was added to 5 ml of cDNA, followed by 50 pmol of 
the primers and 1 U Taq DNA polymerase in 2 mM MgCl2. After preheating to 94u for 10 
min, 30 cycles for HLA class II were performed (30 seconds at 94u, 30 seconds at 60u,  
60 seconds at 72u) followed by a final extension step at 72u for 10 min. The HLA-DR  
primer was used: sense: 5k-CGGATCCTTCGTGTCCCCAC-3k; antisense: 5k-
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CTCCCCAACCCCGTAGTTGTGTCTGCA-3k, amplifying a 270-bp fragment (Nadler et al., 
1994). This primer were synthesized by ARK Scientific Biosystems (Darmstadt, Germany). 
The PCR products were analyzed by gel electrophoresis (1.5% agarose) and staining with 
Sybr green (Molecular Probes; Leiden, the Netherlands). As a size marker, DNA molecular 
weight marker VI (Boehringer: Mannheim, Germany) was used. For sequencing, the PCR 
product was extracted by using the QIAquick gel extraction kit (Qiagen; Hilden, Germany); 
sequencing was performed using the ABI PRISM2 Big Dye2 Terminator Cycle Sequencing 
Ready Reaction Kit (PE Applied Biosystems; Warrington, UK). Data were measured and 
analyzed by Fluorescent Image Analyzer (FLA)-2000 (Becton Dickinson, San Jose, USA). 
2.6 Coculture expreiments 
Unstimulated and stimulated PMN (1x103) or monocytes (1x10) in 100l were added per 
well of a 96-well concave-bottom plate (Greiner; Nuertingen, Germany). Then, 1x104 T cells 
(100l) were added to each well together with 25ng Staphylococcal aueurs Enterotoxins A 
(Sigma; München, Germany). The effect of IL-2 stimulation was blocked by ant-IL-2R 
(Serotec; Oxford, UK). After coincubation for 4 days at 37C with 5% CO2, proliferation was 
tested by adding 1 mCi of 3H-thymidine (Amer-sham Life Science; Braunschweig, Germany) 
for 6-8 hours [3H]TdR incorporation into DNA was measured and expressed as counts per 
minute (cpm). The values represent the meanSD of 6-12 parallel wells. 
2.7 Statistical analysis 
Data were analyzed by student's t test. And a P value of 0.05 was a considered as the limit of 
significance. 
3. Results 
3.1 Visualization of the IL-2R chain by immunocytochemistry 
Isolated PMN by a hypotonic solution were examined by confocal laser microscopy. The IL-
2R chain was not detectable (Fig. 1c).  However the IL-2R chain was seen in all cells (Fig. 
2c). Mouse IgG-FITC was used as a negative control (Fig. 1a and 2a), while CD66b-FITC was 
used as a positive control (Fig. 1b and 2b), respectively. 
    
Fig. 1. Detection of IL-2R chain on PMN: The negative and positive controls were in panels 
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The PCR products were analyzed by gel electrophoresis (1.5% agarose) and staining with 
Sybr green (Molecular Probes; Leiden, the Netherlands). As a size marker, DNA molecular 
weight marker VI (Boehringer: Mannheim, Germany) was used. For sequencing, the PCR 
product was extracted by using the QIAquick gel extraction kit (Qiagen; Hilden, Germany); 
sequencing was performed using the ABI PRISM2 Big Dye2 Terminator Cycle Sequencing 
Ready Reaction Kit (PE Applied Biosystems; Warrington, UK). Data were measured and 
analyzed by Fluorescent Image Analyzer (FLA)-2000 (Becton Dickinson, San Jose, USA). 
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(100l) were added to each well together with 25ng Staphylococcal aueurs Enterotoxins A 
(Sigma; München, Germany). The effect of IL-2 stimulation was blocked by ant-IL-2R 
(Serotec; Oxford, UK). After coincubation for 4 days at 37C with 5% CO2, proliferation was 
tested by adding 1 mCi of 3H-thymidine (Amer-sham Life Science; Braunschweig, Germany) 
for 6-8 hours [3H]TdR incorporation into DNA was measured and expressed as counts per 
minute (cpm). The values represent the meanSD of 6-12 parallel wells. 
2.7 Statistical analysis 
Data were analyzed by student's t test. And a P value of 0.05 was a considered as the limit of 
significance. 
3. Results 
3.1 Visualization of the IL-2R chain by immunocytochemistry 
Isolated PMN by a hypotonic solution were examined by confocal laser microscopy. The IL-
2R chain was not detectable (Fig. 1c).  However the IL-2R chain was seen in all cells (Fig. 
2c). Mouse IgG-FITC was used as a negative control (Fig. 1a and 2a), while CD66b-FITC was 
used as a positive control (Fig. 1b and 2b), respectively. 
    
Fig. 1. Detection of IL-2R chain on PMN: The negative and positive controls were in panels 





    
Fig. 2. Detection of IL-2R chain on PMN: The negative and positive controls were in panels 
A and B, respectively, while the panel C showed the CD122 (magnification: 1 X400). 
3.2 Direct immunofluorescence analysis of IL-2R 
In order to investigate constitutive expression of IL-2R, we tested the presence of the two IL-
2R chains (IL-2 and IL-2) on the PMN cell surface by FACS. In line with previous data by 
others, the  chain (CD25) could not be detected (< 1 % positive cells), while PMN expressed 
CD122, though rather small amounts (Fig. 3).  
  
    
Fig. 3. Detection of IL-2R on PMN: (A) Forward-scatter (FSC) versus side-scatter (SSC) of 
whole blood flow cytometry showed different populations of leukocytes. R1 was set for 
PMN identified by expression of CD66b (B) filled peak. PMN expressed only IL-2R chain 
(D), while IL-2R chain was absent (C) (filled peaks: antibody; line isotype control).  
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When comparing cells of different donors, the mean fluorescence intensity varied (a 
summary of 6 donors is shown in Table 1). 
 













Table 1. Expression IL-2R chain (CD122) on PMN of different donors. 
3.3 Indirect immunofluorescence for the IL-2R chain 
By indirect labeling, using first an unlabeled antibody to IL-2R, followed by a FITC-labeled 
antibody to mouse IgG, the signal for the IL-2R chain could be amplified. Of note is that 
nearly all cells were positive (Fig. 4). 
 
Fig. 4. Indirect extracellular detection of IL-2R chain: (A) the forward-side scatter analysis 
of whole blood flow cytometry showed different populations of leukocytes. PMN were 
identified in R1. (B) M2 is the percentage of CD66b–positive cells (filled peak). (C) PMN 
expressed IL-2R chain as detected by anti-CD122 (filled peak); the line is the negative 
control using mouse IgG in place of anti-CD122. 
3.4 In vitro expression of HLA class II on PMN stimulated with IL-2 
To test effects of IL-2 on HLA class II expression, the induction of HLA class II in highly 
purified PMN 48 hours cultured with IL-2 increased recording 20% (Fig. 5c). Freshly 
isolated PMN had 2% (Fig. 5a). PMN cultured with medium alone for 48 hours had also 
small amount (4%) of HLA class II (Fig. 5b). 
3.5 Effect of IL-2 on HLA class II gene up-regulation on PMN 
In another set of experiments, highly purified PMN exposed to IL-2 for various hours 
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Fig. 5. Direct flow cytometry of the HLA class II induction in highly purified PMN:  
A) Unstimulated PMN (0 hour). B) Unstimulated PMN (48 hours). C) Stimulated PMN with 





Fig. 6. RT-PCR detection of HLA class II mRNA in PMN activated with IL-2: PMN  were 
incubated with IL-2 for 6 hours. The M VI was the used marker (154-2176 bp).  Freshly 
isolated PMN were in Lane (1). Lane (2) showed the stimulated PMN after 6 hours, while 
the unstimulated PMN after 6 hours was in lane (3).  
values were corrected for the input of the PCR-product by using -actin as a housekeeping 
gene (Fig. 6a), it was seen that HLA class II RNA increased only when PMN were cultivated 
for 6 hours. The increase was more pronounced in the presence of IL-2 (Fig. 6b). 
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3.6 In vitro expression of HLA class II on PMN stimulated with IL-4 
The majority of healthy donors PMN expressed CD66b (Fig. 7a, b & c). In the first set of 
experiments the effect of IL-4 on the expression of HLA class II was tested, where we found 
that PMN on whole blood showed expression of HLA class II recording 7.77% (Fig.7c) by 
using IL-4, as stimulators. In contrast, fresh and unstimulated cells cultured with medium 
only counting 1.05% (Fig.7a) and 2.71 % (Fig.7b), respectively. 
 
Fig. 7. Direct flow cytometry of the HLA Class II induction in whole blood PMN.  
A) Unstimulated PMN (0 hour). B) Unstimulated PMN (24 hours). C) Stimulated PMN with 
IL-4 (24 hours).  
3.7 In vitro expression of HLA class II on PMN stimulated with IL-15 
 
 
                           (a)                                                 (b)                                                 (c) 
Fig. 8. Flow cytometric analysis of HLA class II expression on PMN treated with IL-15  
(20ng / ml). PMN in whole blood were labeled with CD66b-FITC as a specific marker for 
PMN and HLA class II-PE. (A) Fresh PMN. (B) PMN cultured for 48hrs in medium. 
(C) PMN cultured for 48hrs in medium with IL-15. 
To test effects of IL-15 on HLA class II expression, in a first set of experiments the induction 
of HLA class II in PMN 24hrs co-cultured with IL-15 was very minor. Although, after 48hrs 
this induction increased recording 11% (Fig. 8c). Freshly PMN had 11% also (Fig. 8a). while 
PMN cultured with medium alone had smaller amout (06%) of HLA class II (Fig. 8b).   
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3.8 Interaction of HLA class II positive PMN with peripheral T-cells 
The question was addressed, whether PMN stimulated to express HLA class II antigen, 
would be able to induce T-cell proliferation. For these experiments highly purified PMN 
were cultivated with IL-2 for 24 hours and then cocultivated with highly purified isolated T-
cells in the absence or presence of Staphylococcus enterotoxin A (SEA), a well-known 
superantigen. 
It was imperative to rule out the participation of professional antigen presenting cells, such 
as dendritic cell, monocytes or B-cells. Therefore great care was taken for purification of the 
cells, which was controlled cytofluorometry. Using this method, less than 1% contaminating 
cells could be detected in either the PMN or the T-cell preparation. 
In a first set of experiments PMN in various numbers and for comparison monocytes were 
cocultivated with the T-cells and SEA and proliferation of T-cells was measured after 4 days. 
The experiment showed that about 10 times more PMN than monocytes were required to 
achieve comparable proliferation and that 100 monocytes were barely sufficient to induce T-
cell proliferation above controls (T-cells alone or T-cells with SEA without PMN or 





Fig. 9. Cells were cocultured with PMN or monocytes in the numbers indicated and in the 
presence of SEA. After 4 days proliferation of T-cells was measured by incorporation of [3H] 
–thymidine, where proliferation was seen with at least 100 monocytes or 1000 PMN.  
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Based on the initial experiments, in the following 1000 PMN were used, because this would 
rule out participation of monocytes assuming a 1% contamination.  
We could show that the T-cell proliferation was dependent not only on the number of PMN, 
but also on the presence or absence of SEA, and also dependent on the prestimulation of the 












Fig. 10. Effects of bacterial Superantigens SEA on the proliferation of T-cells  cocultured with 
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Moreover, the T-cell proliferation could – at least to some extent – be inhibited, when the 
PMN had been cultivated with IL-2 in the presence of an antibody to the IL-2 receptor  
(Fig. 11). 
 
Fig. 11. Inhibition effect of anti-IL-2R on the proliferation of T-cells cocultured with 1 x 103 
PMN stimulated with IL-2 and bacterial superantigens SEA. 
The above data indicated that a high level of IL-2 in our body increases immunity by its 
effect on PMN to act as antigen presenting cells by the expression of HLA class II and 
consequently increased T-cells proliferation (cell mediated immunity).  
The differences between the groups in the sets of experiments related to the interaction of 
HLA class II positive PMN with peripheral T-cells were calculated by t-test using p < 0.05 as 
limit. 
4. Discussion 
PMN are important effectors cells in host defense and inflammation. They are considered 
short-lived cells undergoing spontaneous apoptosis in vivo as well as in culture (Savill, 
1997). In recent years it has become increasingly evident that culturing PMN in the presence 
of cytokines extends their life span (Colotta et al., 1992; Klebanoff et al., 1992; Lee et al., 1993; 
Biffl et al., 1996). 
Previous data by others suggested that PMN express a receptor for IL-2. The present study 
confirms these data and provides evidence that PMN express constitutively IL-2R. As 
shown for monocytes and NK cells only the IL-2R chain is expressed, but not IL-R 
(Espinoza-Delgado et al., 1990). This was in accordance with the present 
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immunofluorosence results, where we detected only Il-2R chain on resting PMN and 
confirmed my choosing of IL-2 as an activator of PMN. 
Increasing evidence suggests that human PMN have an important role to play in regulating 
specific immune responses and in antigen presentation (Fanger et al., 1997; Radsak et al., 
2000). In this study we have demonstrated that HLA Class II antigen was also detected, at 
the protein level by cytofowmetry, and also at the gene level by RT-PCR. These observations 
therefore agree well with the findings of others who have detected these antigens on the 
surface of activated neutrophils (Matsumoto et al., 1987; Radsak et al., 2000). The detection 
of these molecules therefore provides strong support for the hypothesis that human PMN 
can actively synthesize immunoregulatory molecules (Newburger et al., 2000) and have the 
potential to act as APCs (Fanger et al., 1997; Radsak et al., 2000). The observation that PMN 
may also express HLA class II antigens when appropriately stimulated (Gosselin et al., 1993 
and Fanger et al., 1997), high lighted the possibility that PMN might function as accessory 
cells for T-cell activation. HLA class II expression was found on PMN of patients with active 
Wegener's disease (Haensch, et al., 1999). The close correlation of HLA class II expression to 
disease activity prompted the present study with the objective of investigating whether or 
not HLA class II-positive PMN might activate or support activation of T lymphocytes. 
Induction of the above membrane-bound molecules was higher when PMN were stimulated 
in whole blood. The explanation of this phenomena may be due to the loss of some PMN IL-
2R and IL-15R and other activities during their isolation procedure. 
The absence or low detection of MHC class II on human PMN stimulated with IL-2, IL-4 and 
IL-15 could be due to: 1) The relatively long time (44 hrs) required for class II induction, 
which is beyond the period of PMN survival in most culture systems.  2) IL-2 and IL-15 
receptor numbers may vary with the individual. 3) Synthetic capacity of the PMN may vary. 
4) The capacities of cytokine receptors to signal may not be the same. 5) It may also be 
possible that the PMN themselves produce factors that inhibit class II induction. 6) Synthetic 
capacity of the PMN may vary. 7) The capacities of cytokine receptors to signal may not be 
the same. 8) It may also be possible that the PMN themselves produce factors that inhibit 
class II induction (Gosselin et al., 1993). 
When comparing the number of monocytes and PMN required inducing T-cell proliferation, 
it was observed that 10 times more PMN than monocytes were necessary to yield the same 
extent of T-cell proliferation. However, the cell preparation used in this work never 
contained more than 1% of contaminating cells and certainly not the 10% of monocytes that 
would be required to affect the results. The observation that ten times more PMN than 
monocytes were required to induce a similar extent of T-cell proliferation has to be 
considered together with the observation that only a proportion of PMN acquired HLA class 
II. Thus, when only fully equipped PMN are considered, the ability to process and to 
present antigen is similar to that of monocytes. Whether HLA class II-positive PMN 
participate in the immune defense or play a role in pathophysiological events, is a matter of 
speculation. The fact that only a minor proportion of PMN acquire HLA class II might lead 
to the conclusion that a possible accessory function of PMN would be rather weak. One has, 
however, to bear in mind that PMN are numerous in the peripheral blood, and that even a 
low percentage of PMN expressing HLA class II would exceed both circulating monocytes 
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Because of the notion that the presence of Staphylococcus entrotoxin coincides with relapses of 
Wagner's granulomatosis (Cohn-Terveart et al., 1999), we tested whether PMN was able to 
also present Staphylococcus enterotoxin A  is a superantigen, so-called because it binds outside 
of the peptide-binding groove of the HLA class II and the antigen-specific domain of the T-
cell receptor, and consequently activates a large portion of T-cells, preferentially those with 
a V beta 2 domain (Simpson et al., 1995). In accordance with previous studies (Fanger et al., 
1997; Radsak et al., 2000), co-culture of PMN with T-cells and SE resulted in T-cell 
proliferation. Taken together, our data demonstrate that by synthesizing and expressing of 
HLA class II antigens, PMN acquire the capacity to present superantigens to T-cells. 
5. Conclusion 
In conclusion, PMN possession of IL-2R β and γ chains that have the ability to bind with IL-
2, IL-4 and IL-15 prompted us to use IL-2, IL-4 and IL-15 as stimuli for PMN. They 
stimulated PMN to express HLA class II which is the main antigen presenting molecules. 
PMN expressed HLA class II present SEA to T-cells causing their proliferation. T-cells 
proliferations lead to antigen destruction, B-cells activation and consequently 
immunoglobulin production, and activation of phagocytic cells. 
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Because of the notion that the presence of Staphylococcus entrotoxin coincides with relapses of 
Wagner's granulomatosis (Cohn-Terveart et al., 1999), we tested whether PMN was able to 
also present Staphylococcus enterotoxin A  is a superantigen, so-called because it binds outside 
of the peptide-binding groove of the HLA class II and the antigen-specific domain of the T-
cell receptor, and consequently activates a large portion of T-cells, preferentially those with 
a V beta 2 domain (Simpson et al., 1995). In accordance with previous studies (Fanger et al., 
1997; Radsak et al., 2000), co-culture of PMN with T-cells and SE resulted in T-cell 
proliferation. Taken together, our data demonstrate that by synthesizing and expressing of 
HLA class II antigens, PMN acquire the capacity to present superantigens to T-cells. 
5. Conclusion 
In conclusion, PMN possession of IL-2R β and γ chains that have the ability to bind with IL-
2, IL-4 and IL-15 prompted us to use IL-2, IL-4 and IL-15 as stimuli for PMN. They 
stimulated PMN to express HLA class II which is the main antigen presenting molecules. 
PMN expressed HLA class II present SEA to T-cells causing their proliferation. T-cells 
proliferations lead to antigen destruction, B-cells activation and consequently 
immunoglobulin production, and activation of phagocytic cells. 
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1. Introduction 
RNAi constitutes a key component of the innate immune response to viral infection in both 
plants and invertebrate animals, and has been postulated to function as the genome or 
intracellular immune system (Fire A., 2005; Plasterk RH., 2002; Umbach JL. & Cullen BR., 
2009). Knockdown of Dicer, the key component of the RNAi pathway, elicits DNA damage 
and induces the expression of MHC class I chain-related gene A and B (MICA and MICB), 
two ligands of the NKG2D receptor expressed by natural killer cells and activated CD8+ T 
cells (Tang KF. et al, 2008b). In this chapter, I discuss the possible molecular mechanisms by 
which decreased Dicer expression elicits DNA damage and induces the expression of MICA 
and MICB. MICA and MICB are frequently up-regulated in epithelial tumors of diverse 
tissue origins (Gasser S. & Raulet DH., 2006). Dicer is down-regulated in most tumor tissues 
(Merritt WM. et al, 2008; Wu JF. et al, 2011), and DNA damage response is activated in 
human tumors and precancerous lesions (Bartkova J. et al, 2005, 2006; DiTullio RA Jr. et al, 
2002; Gorgoulis VG. et al, 2005). Therefore, the possible roles of Dicer, DNA damage, and 
MICA and MICB in tumorigenesis are also discussed.  
2. RNA interference and the intracellular immune system 
Experimental introduction of antisense RNA into cells was once used to interfere with the 
function of endogenous genes (Izant JG. & Weintraub H., 1984; Nellen W. & Lichtenstein 
C., 1993). However, Fire and colleagues found in 1991 that plasmid-encoded sense RNA is 
sufficient to cause interference (Fire A. et al, 1991); Guo and Kemphues reported in 1993 
that, in addition to antisense RNA, sense RNA and double-stranded RNA (dsRNA) 
interfere with the function of endogenous genes (Guo S. & Kemphues KJ., 1995). In 1998, 
Fire and colleagues found that double-stranded RNA is substantially more effective at 
producing interference than either strand individually (Fire A. et al, 1998). After injection 
into adult animals, purified single strands had at most a modest effect, whereas double-
stranded mixtures caused potent and specific interference (Fire A. et al, 1998). This 
phenomenon is now termed RNA interference (RNAi). Historically, RNAi was also 
known as other names, including posttranscriptional gene silencing (PTGS) and co-
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virus resistance in plants (Lindbo JA. & Dougherty WG., 1992), and“quelling” in 
Neurospora (Cogoni C., 1996) and algae (Wu-Scharf D. et al, 2000). It was postulated that 
the main functions of the RNAi pathway include antiviral defense, heterochromatic 
silencing, and transposon regulation (Martienssen RA. et al, 2008; Umbach JL. & Cullen 
BR., 2009). Therefore, Plasterk and Fire proposed that RNAi is the genome or intracellular 
immune system (Fire A., 2005; Plasterk RH., 2002).  
3. Dicer is the key component of the RNAi pathway 
RNAi is characterized by the presence of RNAs of about 22 nucleotides in length that are 
homologous to the gene being suppressed (Hamilton AJ. & Baulcombe DC., 1999; 
Hammond SM. et al, 2000; Zamore PD. et al, 2000). These 22-nucleotide sequences, called 
short interfering RNAs (siRNAs), serve as guide sequences that instruct a multicomponent 
nuclease, RNA-Induced Silencing Complex (RISC), to destroy the homologous messenger 
RNAs (Hammond SM. et al, 2000). Dicer, the key component of the RNAi pathway, was 
identified by Bernstein and colleagues (Bernstein E. et al, 2001). They demonstrated that 
immunoprecipitated Dicer can generate 22-nucleotide RNAs from dsRNA substrates, and 
that inhibition of Dicer expression significantly reduces processing of long dsRNA in whole-
cell lysates or in Dicer immunoprecipitates (Bernstein E.et al, 2001). In addition to the 
extrogenous siRNAs, Dicer is also responsible for the biogenesis of endogenous siRNAs. In 
Schizosaccharomyces pombe, Dicer processes endogenous dsRNA derived from 
centromeric repeats. The small RNAs are then associated with Ago1, Chp1, and Tas3 to form 
the RNA-induced initiation of transcriptional gene silencing (RITS) complex that is required 
for heterochromatin assembly in fission yeast (Verdel A. et al, 2004). Deletion of Dicer 
results in the aberrant accumulation of complementary transcripts from centromeric 
heterochromatic repeats. This is accompanied by transcriptional de-repression of transgenes 
integrated at the centromere, loss of histone H3 lysine-9 methylation, and impaired 
centromere function (Volpe TA. et al, 2002). The Drosophila endogenous siRNAs are 
derived from transposons, heterochromatic sequences, and stem-loop structures containing 
RNAs. Normal accumulation of these endogenous siRNAs requires the siRNA-generating 
ribonuclease, Dicer, and the RNA interference effector protein, Ago2; mutations in Dicer 
causes an increase in these transcripts (Czech B. et al, 2008; Ghildiyal M. et al, 2008; 
Kawamura Y. et al, 2008; Okamura K. et al, 2008). SiRNAs are target-dependent amplified in 
some organisms. DsRNA is cut into siRNAs, the double-stranded siRNAs are converted into 
single-stranded siRNAs by the slicer activity of Ago2, the sense strands are degraded, and 
the antisense strands anneal to their targets and induce target degradation. Alternatively, 
the antisense RNAs may serve as primers, inducing dsRNA synthesis by the RNA-
dependent RNA polymerase (RdRP); Dicer then cuts the dsRNAs to generate secondary 
siRNAs (Plasterk RH., 2002). Whether there are endogenous siRNAs in organisms lacking 
RdRP activity was investigated by means of deep sequencing. Two groups found that 
endogenous siRNAs derived from pseudogenes, natural antisense transcripts, and 
transposable elements exist in mouse oocytes (Tam OH. et al, 2008; Watanabe T. et al, 2008). 
In addition to producing siRNA, Dicer is also required for the biogenesis of other types of 
small RNAs. Hutvagner and colleagues presented evidence that in Drosophila, a 
developmentally regulated microRNA (miRNA) precursor, pre-let-7, is cleaved by an RNA 
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interference-like mechanism to produce mature let-7 miRNA (Hutvágner G. et al, 2001). In 
cultured human cells, knockdown of Dicer leads to accumulation of the let-7 precursor. This 
is the first evidence that the RNA interference and miRNA pathways intersect (Hutvágner 
G. et al, 2001). In addition to the biogenesis of siRNAs and miRNAs, Dicer is also required 
for the degradation of unstable RNAs containing AU-rich elements (AREs) in 3-prime 
untranslated regions (UTRs) (Jing Q. et al, 2005). Morever, Dicer also functions in 
fragmenting chromosomal DNA during apoptosis. Nakagawa and colleagues reported that 
inactivation of the Caenorhabditis elegans Dicer gene compromises apoptosis and blocks 
apoptotic chromosome fragmentation (Nakagawa A. et al, 2010). Dicer is cleaved by the 
Ced3 caspase to generate a C-terminal fragment with deoxyribonuclease activity, which 
produces 3-prime hydroxyl DNA breaks on chromosomes and promotes apoptosis 
(Nakagawa A. et al, 2010). 
4. Dicer is essential for heterochromatin formation 
Depletion of Dicer disrupts heterochromatin formation in Schizosaccharomyces pombe, 
Arabidopsis thaliana, Caenorhabditis elegans, Tetrahymena thermophila, and Drosophila 
melanogaster (Grewal SI., 2010; Lejeune E. & Allshire RC., 2011; Martienssen RA. et al, 2008; 
Riddle NC. & Elgin SC., 2008). However, whether Dicer is involved in heterochromatin 
formation in mammalian cells is still controversial. Kanellopoulou and colleagues reported 
that knockout of Dicer in mouse ES cells disrupts centromeric heterochromatin formation, 
with reduced histone H3K9 di-methylation and tri-methylation, reduced DNA methylation, 
and increased levels of centromeric repeat RNAs. The decondensation of heterochromatin is 
accompanied by markedly reduced levels of the 25-30 nt centromeric small dsRNAs, 
suggesting that Dicer-dependant small RNAs are required for the formation of centromeric 
heterochromatin (Kanellopoulou C. et al, 2005). Two groups found that the retinoblastoma-
like 2 protein (Rbl2) is the target of miR-290 family miRNAs, and that Rbl2 can inhibit the 
expression of DNA methyltransferases (Dnmts), including Dnmt1, Dnmt3a and Dnmt3b 
(Benetti R. et al, 2008; Sinkkonen L. et al, 2008). Dicer deficiency in mice leads to decreased 
DNA methylation. DNA-methylation defects correlate with decreased expression of Dnmts 
and miR-290 family miRNAs, and can be reversed by transfection with miR-290 family 
miRNAs. These results indicate that the DNA hypomethylation in Dicer knockout cells is 
the consequence of low levels of miR-290 family miRNAs (Benetti R. et al, 2008; Sinkkonen 
L. et al, 2008). However, Benetti and colleagues found that Dicer is not required for histone 
tri-methylation. They observed that Dicer-null cells have a normal density of H3K9me3 and 
H4K20me3 marks and of HP1-binding at pericentric repeats, and that these heterochromatic 
histone marks are significantly increased at telomeric chromatin in Dicer-null cells 
compared to wild-type controls. They also found that the active chromatin mark, AcH3K9, 
is decreased at Dicer-null telomeres compared to wild-type telomeres, and that the density 
of this mark was not significantly decreased at pericentric chromatin. These results suggest 
that Dicer knockout cells have a higher degree of chromatin compaction and silencing at 
telomeric chromatin (Benetti R. et al, 2008). Hannon’s group reported that although loss of 
Dicer affects the abundance of transcripts from centromeres in mouse ES cells, the histone 
modification status at pericentric repeats and methylation of centromeric DNA are not 
affected in Dicer knockout ES cells (Murchison EP. et al, 2005). Cobb and colleagues 
reported that the maintenance of constitutive and facultative heterochromatin seemed to be 
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5. Decreased Dicer expression elicits DNA damage  
The timing of DNA replication is tightly regulated and correlates with chromatin state. 
Highly condensed heterochromatin replicates late in S phase, while less condensed 
euchromatin tends to replicate early (Donaldson AD., 2005). Although the replication times 
of many single copy loci, including a 5 Mb contiguous region surrounding the Rex1 gene, 
are unchanged in Dicer mutant ES cells, the temporal control of satellite DNA replication is 
sensitive to loss of Dicer (Jørgensen HF. et al, 2007). Misregulation of the timing of DNA 
replication may cause stalled and collapsed replication forks, which in turn elicit a DNA 
damage response (Sancar A. et al, 2004). Loss of Dicer in Drosophila cells not only results in 
decondensation of heterochromatin but also leads to accumulation of extrachromosomal 
circular (ecc) repeated DNAs. Ligase IV, an essential regulator of nonhomologous end-
joining and perhaps other DNA damage-repair machinery, participates in eccDNA 
formation (Peng JC. & Karpen GH., 2007). This suggests that, while heterochromatin 
decondensation increases the access of DNA repair and recombination proteins to repeated 
DNA, activation of DNA damage response may also contribute to the formation of eccDNA 
in Dicer mutant cells. RNAi is postulated to function as the genome's immune system, 
defending against molecular parasites such as transposons and viruses, and loss of Dicer 
may activate transposition (Fire A., 2005; Plasterk RH., 2002). Transposition generates 
double strand DNA breaks and elicits a DNA damage response (Gasior SL. et al, 2006). 
Chromatin structure is essential for maintaining genome integrity (Peng JC. & Karpen GH., 
2008). For example, Drosophila cells that lack the Su(var)3-9 H3K9 methyltransferase have 
significantly elevated frequencies of spontaneous DNA damage in heterochromatin. 
Accumulated DNA damage in these mutants correlates with chromosomal defects, such as 
translocations and loss of heterozygosity. Based on the observation that S-phase in Su(var)3-
9 mutants is significantly shorter than that in wild type cells, the authors proposed that 
accumulation of DNA damage in Su(var)3-9 mutants is the consequence of defective DNA 
replication (Peng JC. & Karpen GH., 2009). The regions of repetitive DNA may be 
incompletely replicated or defective in chromatin reassembly because of a shortened S 
phase. Alternatively, repeated DNA in heterochromatin may undergo faster replication, 
resulting in more replication errors. However, the demonstration that DNA damage is 
detected in G1, S, and G2 stages in Su(var)3-9 mutants suggests that defective DNA 
replication is not the only cause of the increased DNA damage. HP1β, whose localization 
requires H3K9me, is needed for efficient DNA damage detection in mammalian cells 
(Ayoub et al, 2008). Therefore, another explanation for the increased frequencies of DNA 
damage in Su(var)3-9 mutant cells may be that proper DNA damage detection and 
subsequent DNA repair response are impaired (Peng JC. & Karpen GH., 2009). We also 
demonstrated that 5-Aza-2'-deoxycytidine (5-aza-dC), a DNA methyltransferase inhibitor, 
induces DNA damage in human cells (Tang KF. et al, 2008a).  
To test whether loss of Dicer can induce DNA damage, we knocked down Dicer in HEK293T 
cells and human hepatoma HepG2 cells and measured markers for DNA damage. 
Immunostaining assays for the phosphorylated form of histone H2AX (γ-H2AX), a widely 
used marker for double-strand DNA breaks (Foster ER. & Downs JA., 2005), and for the 
replication protein A 70 (RPA70), a protein that becomes phosphorylated and forms 
intranuclear foci upon exposure of cells to DNA damage (Zou Y. et al, 2006), revealed that a 
much higher percentage of Dicer knockdown cells display intense γ-H2AX foci and RPA foci 
compared to control cells (Tang KF. et al, 2008b). Using a comet assay to directly assess DNA 
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damage, we confirmed that knockdown of Dicer resulted in accumulation of DNA breaks 
(Tang KF. et al, 2008b). Consistent with our results, Peng and Karpen reported a significant 
increase in spontaneous DNA damage in heterochromatic DNAs of Dicer mutant Drosophila 
cells (Peng JC. & Karpen GH., 2009). Mudhasani and colleagues reported that loss of Dicer 
activates a DNA damage checkpoint, up-regulates p19(Arf)-p53 signaling, and induces 
senescence in primary cells (Mudhasani R. et al, 2008). 
In Figure 1, I summarize the possible mechanisms on how loss of Dicer leads to DNA 
damage. First, loss of Dicer reduces the level of endogenous siRNAs, resulting in 
heterochromatin decondensation. Heterochromatin decondensation may induce DNA 
damage via the following mechanisms: (i) loss of H3K9 methylation compromises DNA 
damage detection and subsequent DNA repair response, leading to DNA damage 
accumulation; (ii) disruption of DNA replication timing induces DNA damage; and (iii) 
mobilization of transposon and retrotransposon creates DNA double-strand breaks. Second, 
loss of Dicer stabilizes dsRNA derived from transposons and retrotransposons, causing a 
high level of transposition and generating DNA double-strand breaks. Third, loss of Dicer 
compromises miRNA biogenesis. Some miRNAs, such as the miR290 family, can suppress 
the expression of DNA methyltransferases or histone modifiers; loss of such miRNAs may 
cause heterochromatin decondensation, which in turn results in DNA damage. Loss of 
miRNAs that target to components of the DNA damage repair pathway may cause 
insufficient DNA damage repair, leading to DNA damage accumulation. These molecular 
events may act synergically or additively in Dicer mutant cells to induce DNA damage. 
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6. DNA damage response induces the expression of ligands for the NKG2D 
receptor 
Natural killer (NK) cells, components of the innate immune system, can kill certain 
transformed or virus-infected cells lacking MHC class I, yet spare the cells expressing MHC 
class I. The ability to attack cells missing ‘self’ markers predicted the existence of both 
inhibitory and activating receptors on NK cells (Lanier LL., 2008). Unlike T and B cells, 
which possess a single antigen receptor that dominates cellular development and activation, 
NK cells do not possess one dominant receptor, but instead have a vast array of receptors to 
initiate effector functions. None of the receptors alone, with the exception of CD16, is able to 
elicit cytolytic activity or cytokine secretion (Lanier LL., 2008). The NKG2D receptor 
complex is one of the activating NK receptors. It is a hexamer, with one NKG2D homodimer 
associated with two DAP10 homodimers. A single gene encodes NKG2D, which is a C-type 
lectin-like superfamily member, and a type II transmembrane-anchored glycoprotein 
expressed as a disulfide-bonded homodimer on the surface of NK cells, γδ T cells, and CD8+ 
T cells (Lanier LL., 2008). Engagement of NKG2D by its ligands leads either to the direct 
activation of killing and cytokine secretion by NK cells or to a costimulation of cytotoxic T-
lymphocyte cytotoxicity (Lanier LL., 2008; Stern-Ginossar N. & Mandelboim O., 2009). In 
humans, NKG2D ligands are divided into two families: the MHC class I polypeptide-related 
chain (MIC) protein family, which contains MICA and MICB; and the cytomegalovirus 
UL16-binding proteins (ULBP) family, which consists of five members (ULBP1, ULBP2, 
ULBP3, ULBP4, and REAT1G) (Stern-Ginossar N. & Mandelboim O., 2009). 
Gasser and colleagues found that NKG2D ligands are up-regulated in non-tumor cell lines 
by genotoxic stress and stalled DNA replication, conditions known to activate a major DNA 
damage checkpoint pathway (Gasser S. et al, 2005). The DNA damage checkpoints employ 
damage sensor proteins, such as ATM, ATR, the Rad17-RFC complex, and the 9-1-1 
complex, to detect DNA damage and to initiate signal transduction cascades that employ 
Chk1 and Chk2 Ser/Thr kinases and Cdc25 phosphatases. The signal transducers activate 
p53 and inactivate cyclin-dependent kinases to inhibit cell cycle progression from G1 to S 
(the G1/S checkpoint), DNA replication (the intra-S checkpoint), or G2 to mitosis (the G2/M 
checkpoint) (Sancar A. et al, 2004). The up-regulation of NKG2D ligand induced by 
genotoxic stress was prevented by pharmacological or genetic inhibition of ATR, ATM, or 
Chk1, indicating that up-regulation of NKG2D ligands is a consequence of DNA damage 
response (Gasser S. et al, 2005). Induction of DNA damage leads to p53 activation. The role 
of p53 in the up-regulation of NKG2D ligands was addressed by Textor and colleagues. 
They found that induction of wild-type p53, but not mutant p53, strongly up-regulated 
mRNA and cell surface expression of ULBP1 and ULBP2, and that the intronic p53 
responsive elements in these two novel p53 target genes are responsible for the up-
regulation of ULBP1 and ULBP2 (Textor S. et al, 2011). The biological and medical 
implications of these findings have been addressed by several groups. Soriani and 
colleagues demonstrated that treatment with low doses of therapeutic agents such as 
doxorubicin, melphalan, and bortezomib commonly used in the management of patients 
with multiple myeloma leads to up-regulation of NKG2D ligands, and that the drug-
induced expression of NKG2D ligands was abolished after treatment with the ATM and 
ATR pharmacologic inhibitors (Soriani A. et al, 2009). We showed that treatment with 5-
Aza-2'-deoxycytidine (5-aza-dC), a DNA methyltransferase inhibitor, induces DNA 
Dicer Regulates the Expression of Major  
Histocompatibility Complex (MHC) Class I Chain-Related Genes A and B 
 
79 
damage-dependant up-regulation of NKG2D ligands (Tang KF. et al, 2008a). Cerboni and 
colleagues demonstrated that in response to superantigen, alloantigen, or a specific 
antigenic peptide, the expression of NKG2D ligands on the surface of T lymphocytes is 
induced, and that the induction of NKG2D ligand expression is the consequence of DNA 
damage (Cerboni C. et al, 2007). In addition, they demonstrated that activated T cells became 
susceptible to autologous NK lysis via NKG2D/NKG2DLs interaction and granule exocytosis, 
suggesting that NK lysis of T lymphocytes via NKG2D may be one of the mechanisms limiting 
T-cell responses (Cerboni C. et al, 2007). HIV up-regulates cell-surface expression of NKG2D 
ligands, including ULBP1, ULBP2, and ULBP3, but not MICA or MICB, in infected cells both 
in vitro and in vivo. HIV-1-induced up-regulation of NKG2D ligands contributes to HIV-1-
induced CD4+ T-lymphocyte depletion. Recently, two groups demonstrated that the HIV-1 
Vpr protein activates the DNA damage response, which specifically induces surface 
expression of ULBP1 and ULBP2 (Richard J. et al, 2010; Ward J. et al, 2009).  
7. Decreased Dicer expression elicits up-regulation of MICA and MICB 
The DNA damage pathway regulates expression of innate immune system ligands for the 
NKG2D receptor. Human NKG2D ligands are up-regulated by genotoxic stress and 
stalled DNA replication. Dicer knockdown elicits DNA damage in human cells. These 
observations prompted us to test whether NKG2D ligands were up-regulated in Dicer 
knockdown cells. Quantitative RT-PCR and flow cytometry revealed markedly increased 
levels of MICA and MICB mRNAs and proteins in Dicer knockdown cells compared with 
mock-transfected or control siRNA-transfected cells. In contrast, inhibiting the expression 
of Dicer did not significantly alter the levels of ULBP1, ULBP2, and ULBP3 mRNAs. Up-
regulation of MICA and MICB by Dicer knockdown is prevented by pharmacologic or 
genetic inhibition of DNA damage pathway components, including ATM, ATR, or Chk1. 
This finding suggests that up-regulation of MICA and MICB is the result of DNA damage 
response activated by Dicer knockdown. Dicer knockdown cells also exhibited greater 
sensitivity to lysis by NKL, a cell line derived from an aggressive form of human natural 
killer cell leukemia. Lysis was partially inhibited by anti-NKG2D antibody, which 
indicated that up-regulated NKG2D ligands make the cells more susceptible to lysis by 
NK cells. This result suggests that Dicer-deficient cells may be cleared by NK or other 
immune cells (Tang KF. et al, 2008b).  
Although we have shown that up-regulation of MICA and MICB in Dicer knockdown cells 
is the result of DNA damage response activation, further studies are necessary to determine 
whether other mechanisms are also involved in the regulation of MICA and MICB in Dicer 
knockdown cells. Stern-Ginossar and colleagues reported that one of the human 
cytomegalovirus encoded miRNAs, hcmv-miR-UL112, specifically down-regulates MICB 
expression during viral infection, leading to decreased binding of NKG2D and reduced 
killing by NK cells (Stern-Ginossar N. et al, 2007). The hcmv-miR-UL112 binding site in the 
MICB 3’-untranslated region is conserved among different MICB alleles and a similar site 
exists in the MICA 3’-untranslated region, suggesting that these sites are targeted by cellular 
microRNAs (Stern-Ginossar N. et al, 2007). To test this hypothesis, Stern-Ginossar and 
colleagues expressed MICB with or without its 3’-UTR in primary human foreskin fibroblast 
(HFF) cells. MICB expression was much higher when it was expressed without its 3’-UTR. 
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expression. These results indicated that the 3’-UTRs of MICA and MICB inhibit expression 
of the corresponding proteins. Knockdown of Drosha, an enzyme essential for miRNA 
biogenesis (Lee Y. et al, 2003), relieved the inhibitory effects, suggesting that cellular 
microRNAs do indeed regulate MICA and MICB expression. Further studies demonstrated 
that miR-20a, miR-93, miR106b, miR-372, miR-373, and miR-520d are involved in the 
regulation of MICA and MICB expression (Stern-Ginossar N. et al, 2008). Yadav and 
colleagues reported that miR-520b acted on both the MICA 3’-UTR and the promoter 
region, causing a decrease in the levels of the MICA transcript and protein. However, an 
antisense oligonucleotide inhibitor of miR-520b increased the expression of a reporter 
construct containing the MICA 3’-UTR (Yadav D. et al, 2009). Dicer is the key enzyme 
involved in miRNA biogenesis, and knockdown of Dicer reduces levels of miRNAs. 
Therefore, it is conceivable that reduced levels of miRNAs may contribute to the up-
regulation of MICA and MICB in Dicer knockdown cells. 
Interferon-alpha promotes expression of MICA in tumor cells (Zhang C. et al, 2008). Some 
siRNAs are found to activate protein kinase R (PKR) and induce global up-regulation of 
interferon-stimulated genes (Marques JT. & Williams BR., 2005; Sledz CA. et al, 2003). 
Because dsRNAs are natural substrates of Dicer, knockdown of Dicer may stabilize 
endogenous dsRNAs. Elevated levels of endogenous dsRNAs may activate the interferon 
pathway. Therefore, it seems possible that up-regulation of MICA and MICB is the 
consequence of nonspecific activation of the interferon pathway in Dicer knockdown cells. 
Our results indicated that the phosphorylation status of PKR and the expression of 
interferon-stimulated genes are not changed in Dicer knockdown cells compared to control 
cells (Tang KF. et al, 2008b). However, we cannot exclude the possibility that complete 
depletion of Dicer may yield levels of endogenous dsRNAs high enough to activate the 
interferon pathway, and eventually up-regulate the expression of MICA and MICB.  
The expression of MICA and MICB is tightly correlated with cell proliferation status. 
Highly confluent HCT116 cells grown to quiescence contain small amounts of MICA and 
MICB mRNAs and display low MIC surface protein expression. In rapidly proliferating 
cells, MICA and MICB mRNAs and surface proteins are strongly induced (Venkataraman 
GM. et al, 2007). Knockout of Dicer in hepatocytes leads to increased cell proliferation 
(Sekine S. et al, 2009), and Dicer knockdown lung adenocarcinoma (LKR13) cells grow 
faster than control cells (Kumar MS. et al, 2007). Therefore, it is possible that up-
regulation of MICA and MICB is the consequence of increased cell proliferation induced 
by down-regulation of Dicer. 
Further studies are necessary to elucidate why loss of Dicer leads to up-regulation of MICA 
and MICB. Some possible mechanisms, summarized in Figure 2, are as follows: (i) decreased 
Dicer expression elicits DNA damage , which in turn induces up-regulation of MICA and 
MICB; (ii) loss of Dicer impairs biogenesis of miRNAs, some miRNAs, such as miR-20a, 
miR-93, miR106b, miR-372, miR-373, miR-520 and miR-520d, can repress the expression of 
MICA and MICB transcriptionally and posttranscriptionally; (iii) loss of Dicer may result in 
increased cell proliferation, and increased proliferation induces the transcription of MICA 
and MICB; and (iv) loss of Dicer stabilizes endogenous dsRNAs, and increased levels of the 
dsRNAs activate the interferon pathway, which in turn induces the expression of MICA and 
MICB.  
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Fig. 2. Molecular mechanisms linking decreased Dicer expression to increased MICA and 
MICB expression 
8. Dicer, DNA damage, and tumorigenesis 
Compared with normal tissue, miRNAs are generally down-regulated in tumor tissue (Lu J. 
et al, 2005). Levels of Dicer mRNA and protein are decreased in 60% of ovarian-cancer 
specimens. Low Dicer expression is significantly associated with advanced tumor stage and 
poor prediagnosis (Merritt WM. et al, 2008). We found that compared to the adjacent non-
cancerous liver tissues, Dicer mRNA and protein are reduced in hepatocellular carcinoma 
tissues in 34 of 36 patients (Wu JF. et al, 2011). Signs of a DNA damage response, including 
histone H2AX and Chk2 phosphorylation, p53 accumulation, focal staining of p53 binding 
protein 1, are widely found in clinical specimens from different stages of human tumors and 
precancerous lesions, but not in normal tissues (Bartkova J. et al, 2005, 2006; DiTullio RA Jr. 
et al, 2002; Gorgoulis VG. et al, 2005). Decreased Dicer expression elicits DNA damage 
(Mudhasani R. et al, 2008; Peng JC. & Karpen GH., 2009; Tang KF. et al, 2008b). Therefore, 
the following questions are intriguing: Is there an association between DNA damage and 
Dicer down-regulation in cancer tissues? If the answer is yes, what is the causal relationship 
between DNA damage and Dicer down-regulation in the process of carcinogenesis? What is 
the role of Dicer in carcinogenesis? 
Kumar and colleagues found that loss of Dicer promotes tumorigenesis (Kumar MS. et al, 
2007). They showed that Dicer knockdown cancer cells had a more pronounced transformed 
phenotype. In animals, Dicer knockdown cells formed tumors with accelerated growth; the 
tumors were also more invasive than control tumors. Furthermore, conditional deletion of 
Dicer enhanced tumor development in a K-Ras–induced mouse model of lung cancer 
(Kumar MS. et al, 2007). Sekine and colleagues disrupted Dicer in hepatocytes using a 
conditional knockout mouse model and found that Dicer elimination induces hepatocyte 
proliferation and overwhelming apoptosis. Unexpectedly, they found that two-thirds of the 
mutant mice spontaneously developed hepatocellular carcinomas (HCCs) at 1 year of age. 
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minor subset of Dicer-deficient hepatocytes gives rise to HCCs suggests the requirement of a 
“second hit” that promotes hepatocarcinogenesis in Dicer-deficient hepatocytes (Sekine S. et 
al, 2009). Based on these observations, I propose a simple model to explain how Dicer 
knockout leads to hepatocarinogenesis (Figure 3). Dicer depletion induces DNA damage via 
the mechanisms described in Figure 1, and DNA damage response leads to cell apoptosis or 
senescence. DNA damage may also result in DNA mutation such that cells containing 
oncogenic mutations may escape from apoptosis and senescence, eventually forming cancer.  
 
Fig. 3. Molecular mechanisms of Dicer knockout-induced tumorigenesis 
Oncogene activation leads to augmented numbers of active DNA replicons and to 
alterations in DNA replication fork progression. These alterations activate DNA damage 
response, and eventually cell senescence or apoptosis. Genetic analyses indicate that early in 
tumorigenesis (before genomic instability and malignant conversion), human cells activate 
an ATR/ATM-regulated DNA damage response network that delays or prevents cancer. 
Mutations compromising this DNA damage response network might allow cell 
proliferation, survival, increased genomic instability and tumor progression (Bartkova J. et 
al, 2005, 2006; Di Micco R. et al, 2006). 
Comparison of the mechanisms of oncogene-induced carcinogenesis (Figure 4) and Dicer 
depletion induced carcinogenesis suggests that Dicer is a tumor suppressor gene. However, 
Kumar and colleagues demonstrated that Dicer functions as a haploinsufficient tumor 
suppressor gene (Kumar MS. et al, 2009). Deletion of a single copy of Dicer in tumors from 
Dicerfl/+ animals reduced survival compared with controls. Moreover, tumors from 
Dicerfl/fl animals always maintained one functional Dicer allele; forced deletion of Dicer 
inhibited tumorigenesis. Analysis of human cancer genome copy number data reveals 
frequent deletion of Dicer. However, the gene has not been reported to undergo 
homozygous deletion (Kumar MS. et al, 2009).  
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Fig. 4. Molecular mechanisms of oncogene-induced tumorigenesis 
9. MIC molecules, DNA damage and tumorigenesis 
Although evolved in parallel with the human MHC class I genes, MIC molecules (MICA 
and MICB) are quite different from MHC class I molecules. The characteristics of MIC 
molecules include the lack of association with beta-2-microglobulin, stable expression 
without conventional class I peptide ligands, and the absence of a CD8 binding site. The 
MIC genes are highly polymorphic. Around 60 alleles of MICA and 25 alleles of MICB 
have so far been identified (Bahram S. et al, 1994; Eagle RA. & Trowsdale J., 2007;). T cells 
with variable region V-delta-1 gamma/delta T-cell receptors are distributed throughout 
the human intestinal epithelium and may function as sentinels that respond to self-
antigens. MIC molecules are expressed on the surface of the intestinal epithelium cells, 
and are recognized by intestinal epithelial T cells expressing diverse V-delta-1 
gamma/delta TCRs. These data suggest that MIC molecules may regulate the protective 
responses by the V-delta-1 gamma/delta T cells in the epithelium of the intestinal tract 
(Groh V. et al, 1998). Cytomegalovirus (CMV) infection induces MIC expression and a 
concurrent down-regulation of MHC class I molecules on fibroblasts and endothelial cells 
(Groh V. et al, 2001). Functional analysis of T-cell cytotoxicity against CMV-infected 
fibroblasts showed that early after infection when MIC expression was low, antibodies to 
MHC class I, but not to MIC or NKG2D, could block T cell-mediated cytolysis (Groh V. et 
al, 2001). As MIC expression increased, antibody masking of MIC or NKG2D reduced 
target-cell lysis; anti-MHC class I antibodies further reduced cytolysis. This study 
suggests that MIC molecules are involved in the immune clearance of virus-infected cells 
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Fig. 3. Molecular mechanisms of Dicer knockout-induced tumorigenesis 
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Dicer Regulates the Expression of Major  




Fig. 4. Molecular mechanisms of oncogene-induced tumorigenesis 
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MHC class I, but not to MIC or NKG2D, could block T cell-mediated cytolysis (Groh V. et 
al, 2001). As MIC expression increased, antibody masking of MIC or NKG2D reduced 
target-cell lysis; anti-MHC class I antibodies further reduced cytolysis. This study 
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cells, and natural killer cells. Engagement of NKG2D activates cytolytic responses of 
gamma/delta T cells and NK cells against transfectants and epithelial tumor cells 
expressing MICA (Bauer S. et al, 1999). These results indicate that MICA and MICB play 
important roles in anti-viral and anti-tumor immune response.  
DNA damage response is activated in clinical specimens from different stages of human 
tumors and precancerous lesions, but not in normal tissues (Bartkova J. et al, 2005, 2006; 
DiTullio RA Jr. et al, 2002; Gorgoulis VG. et al, 2005). Activation of the DNA damage 
response results in cell cycle arrest, senescence, and apoptosis. It was proposed that tumor 
progression requires the appearance of mutations that misregulate the DNA damage 
response pathway, such as p53 mutations, which allay the cell cycle block and allow tumor 
outgrowth (Gasser S. & Raulet DH., 2006; Halazonetis TD., 2004). DNA damage induces up-
regulation of NKG2D ligands (including MICA and MICB). Some components of the DNA 
damage checkpoints, including ATM and ATR (two proteins involved in DNA damage 
detection), and Chk1 (a protein that transduces the DNA damage signal to effector proteins), 
are essential for the up-regulation of NKG2D ligands (Gasser S. et al, 2005; Tang KF. et al, 
2008b). p53 is one of the effector proteins of the DNA damage checkpoints, but is not 
required for up-regulation of NKG2D ligands, as indicated by DNA damage-induced 
expression of the ligands in p53-deficient cell lines (Gasser S. et al, 2005). The fact that other 
components of the DNA damage response, such as ATR and Chk1, are rarely mutated in 
tumors might explain why NKG2D ligands are frequently up-regulated in cancer cells 
(Gasser S. & Raulet DH., 2006; Halazonetis TD., 2004). These findings suggest a possible role 
of the immune system, via the DNA damage response and NKG2D, in the elimination of 
precancerous cells and cancer cells.  
In addition to promoting anti-tumor immune response, MICA and MICB can also suppress 
tumor immune surveillance. MICA associates with endoplasmic reticulum protein-5 (ERP5) 
on the surface of tumor cells, and the association is required for MICA shedding. Detailed 
analysis indicated that ERP5 and membrane-anchored MICA form transitory, mixed 
disulfide complexes, from which soluble MICA is released after proteolytic cleavage near 
the cell membrane. The secreted form of MIC molecules may bind to NKG2D receptor and 
inhibit the killing activity of effector cells (Kaiser BK. et al, 2007). NKG2D binding of MIC 
can induce endocytosis and degradation of NKG2D. In cancer patients, NKG2D expression 
was markedly reduced in both CD8+ tumor-infiltrating T cells and in peripheral blood T 
cells, and the reduction of NKG2D expression is associated with increased level of 
circulating tumor-derived soluble MICA. Down-regulation of NKG2D severely impairs the 
function of tumor antigen-specific effector T cells (Groh V. et al, 2002). MICA can also 
mediate strong suppressive effects on T cell proliferation. Responsiveness to MICA-
mediated suppression involves a receptor other than NKG2D. This finding might explain 
the observation that strong in vivo NKG2D ligand expression, such as in tumor cells, 
sometimes fails to support effective immune responses (Kriegeskorte AK. et al, 2005).  
10. Conclusion 
Dicer is misregulated in tumor tissues, and decreased Dicer expression induces the 
expression of MICA and MICB. MICA and MICB play important roles in anti-tumor 
immune response, and are frequently up-regulated in epithelial tumors of diverse tissue 
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origins. These observations suggest that the intracellular immune system and the innate 
immune system have a good synergistic or additive effect in tumor immune surveillance. In 
addition, decreased Dicer expression elicits DNA damage, which in turn induces cell 
apoptosis and senescence. However, disruption of Dicer in hepatocytes promotes 
hepatocarcinogenesis. Therefore, the role and mechanism of Dicer in tumorigenesis need 
further investigation. 
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1. Introduction 
In immunology, the concept of alloreactivity is universally linked to the mechanism of T-cell 
recognition, where the T cell receptors (TCR) may interact with peptides mounted on major 
histocompatibility complex (MHC) molecules. The mechanisms responsible for the generation 
of TCR specificity and thus for the T cell activation depend on the repertoire of the genes 
coding for T cell receptor following the gene rearrangements of their variable regions and on 
the development and maturation of T-cells (Felix & Allen, 2007). Alloreactivity is not only 
important in the regulation of the adaptive immune responses, but it is also involved in the 
function of a major component of the innate immune system represented by the Natural killer 
(NK) cells (Ciccone et al., 1988, 1992; Kärre et al., 1986), and the rationale of this phenomena 
has been shown useful in some leukemia treatments (Ruggeri et al., 2005). NK cells are known 
to play a major role in the rejection of viral-infected or tumour-transformed cells (Herberman 
et al., 1975; Kiessling et al., 1975) following the “missing self” mechanism (Ljunggren & Kärre, 
1990). Their function is controlled by a multifaceted collection of receptors able to deliver 
either inhibitory or activating signals. Differently than T lymphocytes, NK cells display 
receptors encoded by germline loci, and some of them are able to interact specifically with 
particular alleles of the MHC class I. 
In humans and in primates these molecules are the killer immunoglobulin-like receptors 
(KIR) that display a clonal and stochastic distribution on the cell surface and are encoded by 
a multigene family. In particular, NK cells are known to express at least a one dominant self 
class I inhibitory receptor responsible for the self-tolerance (Moretta et al., 1996, Biassoni et 
al., 2009a). The activation of NK cells is based on continuous surveillance for MHC class I 
expression on autologous cells by inhibitory KIR cell surface receptors and by a balance of 
functions depending by integration of activating and inhibitory receptors responses 
(Biassoni, 2009b). All conditions that alter the surface expression level of the MHC class I on 
target cell, such as virus infection or tumour-transformation, are sufficient to trigger NK-
mediated cytolysis. 
In humans, higher primates and cattle, the inhibition of NK cell function depends by the 
expression of KIR encoded by a multigene family evolved in the last 135 million years from 
the two KIR3DL and KIR3Dx ancestral gene loci (Parham et al., 2011). Humans and higher 
primates have generated the KIR repertoire from the ancestral KIR3DL gene, while in cattle 
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conserved in primates genomes as remnant of genes evolution during speciation. The 
human KIR genes map on chromosome 19q13.42, in the telomeric region of Leukocyte 
Receptor complex (LRC). Rodents and other species conversely evolved a completely 
different set of MHC class I-specific NK receptors, the Ly49 multigene family, which encode 
for type II transmembrane proteins belonging to the C-type lectin molecules. 
Also the CD94/NKG2A receptor, conserved during speciation, is involved in the negative-
control of NK cell function. In humans and in mice, it is specific for the HLA-E or Qa-1 
molecules able to bind conserved peptides derived from the processing of different MHC 
class I leader sequences. Thus, CD94/NKG2A receptors sense the expression of different 
HLA class I molecules at once, indirectly monitoring the overall presence and level of 
expression of MHC class I alleles, making it particularly sensitive to any modification 
induced in transformed cells (Borrego et al., 2006). 
KIR and HLA loci are both highly polymorphic and within this review we discuss the vast 
polymorphism of the KIR gene complex, which rivals that of the HLA complex. Indeed, one 
of the purposes of this chapter is to summarize our current knowledge of how KIR and their 
ligand diversities may influence the outcome of a number of key human diseases. For this 
reason, it is imperative for the accurate and reliable typing to determine the 
presence/absence of specific KIR genes, since the interactions of specific KIR and specific 
ligands have important roles in several diseases. 
2. Killer immunoglobulin-like receptors (KIR) 
KIR receptors vary in length from 306 to 456 amino acid residues and are characterized by 
immunoglobulin-like (Ig-like) domains on their extracellular regions, by a transmembrane 
and cytoplasmic region that are functionally relevant as they define the type of signal which 
is transduced by a defined NK cell (Colonna & Samaridis, 1995; D'Andrea et al., 1995; 
Wagtmann et al., 1995). 
KIR proteins are classified by the number of extracellular Ig-like C2-type domains (2D or 
3D) by the presence of a long (L) or short (S) cytoplasmic tail represented as KIR2DL and 
KIR2DS, respectively (Anfre’ et al., 2001). Inhibitory KIR have a transmembrane region 
containing only hydrophobic amino acids and a long cytoplasmic tail (KIR2DL and KIR3DL) 
containing Immune Tyrosine-based Inhibitory Motifs (ITIM) involved in negative signalling. 
Upon ligand recognition ITIM are phosphorylated and lead to the association with the 
intracellular Src homology-2 (SH2) domain-containing phosphatases 1 or 2 (SHP1 or SHP2), 
which are responsible for turning off locally all triggering signalling pathways induced by 
activating NK cell receptors. 
In contrast, some KIR are known to induce triggering of NK cell functions displaying a 
transmembrane region characterized by a positively charged amino acid (lysine) involved in 
the association with ITAM-bearing subunits and by a short cytoplasmic tail (KIR2DS, 
KIR3DS). Intracytoplasmic signalling and activation induced by these receptors are linked to 
the DAP12 receptor-associated signalling molecules that form a multichain immune 
recognition receptor (Sigalov, 2010). Different from all the other members of the KIR family, 
KIR2DL4 exhibits low polymorphism and high conservation, being one of the KIR 
framework genes. Although, it is characterized by a long cytoplasmic tail containing a single 
N-terminal ITIM, a feature shared with KIR3DL2 and KIR3DL3, KIR2DL4 transduces weak 
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triggering signals mainly associated with cytokine releases rather than cytolysis (Cantoni et 
al., 1998; Faure & Long, 2002; Kikuchi-Maki et al., 2003; Rajagopalan et al., 2001; Selvakumar 
et al., 1996). The activating function depends by the association with FcRI-chain, as 
signalling adapter molecule, instead of the DAP12, due to the positively charged arginine 
residue present in the transmembrane region (Kikuchi-Maki et al., 2005). 
2.1 Organization of Killer immunoglobulin-like gene loci 
The KIR genes are polymorphic, although highly homologous and are found in a region of 
150 kb on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The KIR 
loci and the genes coding for the Human Leukocyte Antigens (HLA) class I molecules reside 
on different chromosomes so they segregate independently and probably constitute the 
most diverse loci in the human genome. Indeed, the polygenic region coding for KIR has 
underwent rapid evolution and selection through mechanisms of homologous 
recombination, domain shuffling, and point mutations (Rajalingam et al., 2004); finally its 
diversity is achieved from the polymorphism of KIR genes and by the numbers of genes 
present in a haplotype. In detail, there are at least fifteen KIR genes and 2 pseudogenes 
(KIR3DP1, KIR2DP1) exhibiting substantial allelic diversity (Figure 1). Among them we may 
find 4 frameworks KIR genes/pseudogene present in nearly all individuals (KIR2DL3, 
KIR3DP1, KIR2DL4, KIR3DL2). Overall, KIR genes encode eight inhibitory receptors 
(KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2), six 
activating molecules (KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1, KIR2DS1, KIR2DS4), and two 
pseudogenes (KIR2DP1, KIR3DP1). Genes coding for KIR molecules, vary in length from 4 
to 16 kb and may contain from four to nine exons, and with signal peptides encoded by 
sequences present in the first two exons. KIR genes are classified as belonging into either 
Type I (Cw Group I, 80 Asn) (KIR2D), Type II (Cw Group II, 80 Lys) (KIR2D), or KIR3D 
grouping. These depend on the presence of pseudoexon-3, partial or complete deletion of 
coding regions, and by the homology of the sequences encoding the immunoglobulin like 
(Ig-C2) domains. In detail, KIR3D genes encode proteins with three extra-cellular Ig-like 
domains (termed D0, D1 and D2), while KIR2D receptors are encoded by either  
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Panel A: Inhibitory KIR named on the bottom and the relative HLA-ligand recognized by the same 
receptors (shown on the top). D0, D1 and D2 Ig-like domain structures are shown. Cell membrane is 
shown as an open rectangle. Small black-filled parallelograms represent ITIM in the cytoplasmic tail of 
the receptors. 
Panel B: Activating KIR named on the bottom and the relative HLA-ligand recognized by the same 
receptors (shown on the top). D0, D1 and D2 Ig-like domain structures are shown. Cell membrane is 
shown as an open rectangle. Small black-filled parallelogram represent ITIM in the cytoplasmic tail of 
the KIR2DL4. Small black-filled ovals represent ITAM in the cytoplasmic tail of the associated chains. 
These signal transducing molecules are associated with the receptors through a polar interaction, inside 
the hydrophobic tranmembrane environment, involving either lysine (K) or arginine (R) present in the 
cytoplasmic tail of triggering KIR with an aspartic acid residue (D) in the cytoplasmic tail of the 
signalling transducing molecules. 
I80>T80: indicates the affinity of interaction with KIR3DL1 
Fig. 2. Structural representation of either inhibitory (A) or activating (B) KIR. 
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Type I KIR2D genes characterized by the presence of pseudoexon 3 and displaying two 
extra-cellular domains with a D1 and D2 conformation or Type II KIR2D genes, which 
encode two extra-cellular domain proteins with a D0 and D2 conformation having deleted 
the corresponding region of exon 4 (Figure 2). Type I KIR2D genes (KIR2DP1, KIR2DL1-3 
and KIR2DS1-5 genes) are all characterized by eight exons and by the presence of 
pseudoexon 3, that it is inactivated due to a nucleotide substitution located on the intron 2-
exon 3 splice-site. The nucleotide sequences of pseudoexon 3 share a high-degree of 
nucleotide identity with to KIR3D exon 3 corresponding sequences. Within the Type I 
KIR2D group of genes, KIR2DL1 and KIR2DL2 have an additional identical partial deletion 
in exon 7, a characteristic of these genes, only. KIR2DS1-5 differ from the other type I KIR2D 
genes only in the length of the coding sequences for the cytoplasmic tail in exon 9. Finally, 
the KIR2DP1 pseudogene structure shows a shorter exon 4 sequence due to a single base 
pair deletion. Type II KIR2D genes (KIR2DL4, KIR2DL5A and KIR2DL5B) have a translated 
exon 3 and a deletion of exon 4 sequence. Within the Type II KIR2D genes, KIR2DL4 is further 
differentiated from KIR2DL5A/B and from all other KIR genes, on the base of the length of its 
exon 1 sequence. In KIR2DL4, exon 1 was found to be longer by six nucleotides displaying a 
different initiation codon, interestingly in better agreement with the 'Kozak transcription 
initiation consensus sequence' than those present in the other KIR genes. KIR3D genes are 
characterized by nine exons and include the structurally related KIR3DL1, KIR3DS1, KIR3DL2 
and KIR3DL3 genes, where the KIR3DL2 locus has the longest genomic nucleotide sequence 
among all KIR genes (16,256 bp). Within the KIR3D group the genes differ in the length of 
exon 9, so that the cytoplasmic tail encoded sequences vary in length from 23 to 116 amino 
acid residues in KIR3DS1 or in KIR2DL4, respectively. Moreover, KIR3DS1 differs from 
KIR3DL1 or KIR3DL2 loci for the presence of a short exon 8 sequence, while KIR3DL3 is 
lacking exon 6. Finally, KIR3DP1 shares a high degree of sequence identity to KIR3DL3 
sequences, but it lacks sequences from exon 6 to exon 9, and occasionally also exon 2. 
2.1.1 KIR haplotypes 
The assortment of KIR genotypes may vary significantly in different subjects due to 
duplication or deletion of gene loci that have occurred during evolution. This has lead to 
two major groups of haplotypes, “A” or “B”, based on the relative KIR gene content. 
Members of haplotype B are characterized by a higher number of genes coding for 
activating receptors than members of the haplotype A group. Immunogenetic analyses of 
different ethnic populations show significant differences in terms of the distribution of 
group A and B haplotypes. The linkage disequilibrium analyses of the centromeric and 
telomeric regions clearly indicate the evolutionary histories of these regions, which may 
have undergone different gene assortment and may also have been inherited separately 
during evolution. Thus, the complexity of haplotypes is such that the genomic region 
belonging to the KIR complex is structurally organized having as centromeric boundaries 
the gene KIR3DL3 and at the telomeric ends the KIR3DL2 locus (Figure 3). In addition it is 
possible to define separate partial haplotypes since a centromeric portion distinct from the 
telomeric one is structurally separated by the two framework genes KIR3DP1 and KIR2DL4 
(Figure 3). Based on this classification, members of the haplotype “A” group needs to 
display both centromeric (CenA) and telomeric (TelA) genotype organization A/A (Uhrberg 
et al., 1997). We have also to consider that KIR gene inheritance is the result of distinct 









Panel A: Inhibitory KIR named on the bottom and the relative HLA-ligand recognized by the same 
receptors (shown on the top). D0, D1 and D2 Ig-like domain structures are shown. Cell membrane is 
shown as an open rectangle. Small black-filled parallelograms represent ITIM in the cytoplasmic tail of 
the receptors. 
Panel B: Activating KIR named on the bottom and the relative HLA-ligand recognized by the same 
receptors (shown on the top). D0, D1 and D2 Ig-like domain structures are shown. Cell membrane is 
shown as an open rectangle. Small black-filled parallelogram represent ITIM in the cytoplasmic tail of 
the KIR2DL4. Small black-filled ovals represent ITAM in the cytoplasmic tail of the associated chains. 
These signal transducing molecules are associated with the receptors through a polar interaction, inside 
the hydrophobic tranmembrane environment, involving either lysine (K) or arginine (R) present in the 
cytoplasmic tail of triggering KIR with an aspartic acid residue (D) in the cytoplasmic tail of the 
signalling transducing molecules. 
I80>T80: indicates the affinity of interaction with KIR3DL1 
Fig. 2. Structural representation of either inhibitory (A) or activating (B) KIR. 
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in exon 7, a characteristic of these genes, only. KIR2DS1-5 differ from the other type I KIR2D 
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pair deletion. Type II KIR2D genes (KIR2DL4, KIR2DL5A and KIR2DL5B) have a translated 
exon 3 and a deletion of exon 4 sequence. Within the Type II KIR2D genes, KIR2DL4 is further 
differentiated from KIR2DL5A/B and from all other KIR genes, on the base of the length of its 
exon 1 sequence. In KIR2DL4, exon 1 was found to be longer by six nucleotides displaying a 
different initiation codon, interestingly in better agreement with the 'Kozak transcription 
initiation consensus sequence' than those present in the other KIR genes. KIR3D genes are 
characterized by nine exons and include the structurally related KIR3DL1, KIR3DS1, KIR3DL2 
and KIR3DL3 genes, where the KIR3DL2 locus has the longest genomic nucleotide sequence 
among all KIR genes (16,256 bp). Within the KIR3D group the genes differ in the length of 
exon 9, so that the cytoplasmic tail encoded sequences vary in length from 23 to 116 amino 
acid residues in KIR3DS1 or in KIR2DL4, respectively. Moreover, KIR3DS1 differs from 
KIR3DL1 or KIR3DL2 loci for the presence of a short exon 8 sequence, while KIR3DL3 is 
lacking exon 6. Finally, KIR3DP1 shares a high degree of sequence identity to KIR3DL3 
sequences, but it lacks sequences from exon 6 to exon 9, and occasionally also exon 2. 
2.1.1 KIR haplotypes 
The assortment of KIR genotypes may vary significantly in different subjects due to 
duplication or deletion of gene loci that have occurred during evolution. This has lead to 
two major groups of haplotypes, “A” or “B”, based on the relative KIR gene content. 
Members of haplotype B are characterized by a higher number of genes coding for 
activating receptors than members of the haplotype A group. Immunogenetic analyses of 
different ethnic populations show significant differences in terms of the distribution of 
group A and B haplotypes. The linkage disequilibrium analyses of the centromeric and 
telomeric regions clearly indicate the evolutionary histories of these regions, which may 
have undergone different gene assortment and may also have been inherited separately 
during evolution. Thus, the complexity of haplotypes is such that the genomic region 
belonging to the KIR complex is structurally organized having as centromeric boundaries 
the gene KIR3DL3 and at the telomeric ends the KIR3DL2 locus (Figure 3). In addition it is 
possible to define separate partial haplotypes since a centromeric portion distinct from the 
telomeric one is structurally separated by the two framework genes KIR3DP1 and KIR2DL4 
(Figure 3). Based on this classification, members of the haplotype “A” group needs to 
display both centromeric (CenA) and telomeric (TelA) genotype organization A/A (Uhrberg 
et al., 1997). We have also to consider that KIR gene inheritance is the result of distinct 





Tel A/A combinations, i.e., both parents having CenA and TelA, and both parents passing 
both sets to their offspring who then has CenAA/TelAA (Cooley et al., 2010). Thus in this 
situation KIR2DL3, KIR2DP1, KIR2DL1 loci are typically present in the centromeric portion 
while a single activating gene (KIR2DS4) could be present in its telomeric region together 
with KIR3DL1 (Figure 3). All other haplotypes are described as members of the B haplotype, 
which is the more variable in terms of genotype, having at least one of the following genes: 
KIR2DL5A/B, KIR2DL2, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1. 
Interestingly, KIR3DL1 and KIR3DS1 segregate as alleles of the same gene locus, the former 
associated with TelA haplotype, while the latter with TelB group of genes; in addition, the 
unexpressed KIR2DL5B variant is usually present together with KIR2DS3 or more rarely 
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2DL4
 
The framework 3DL3, 3DP1, 2DL4 and 3DL2 gene loci are drawn on the line representing 
chromosome19q13.42 region oriented from centromer (left) to telomer (right). Inhibitory receptors 
(shown gray boxes), activating ones (unfilled boxes) and pseudogenes (boxed with thicker line) are 
indicated. The genomic organizations of centromeric and telomeric regions are boxed with continuous 
line trait. The genes defining A haplotype are drawn on top, while the ones typical for B haplotype on 
the bottom. Boxes represented with dotted lines indicate gene regions frequently deleted, in detail 
KIR2DL5B is more frequently, but no exclusively associated with KIR2DS3 and on the opposite the gene 
telomeric to KIR2DL5A is KIR2DS5 and rarely KIR2DS3. The KIR3DP1 may be also present as KIR3DP1 
ex2. Centromeric and/or telomeric haplotye B need to have at least one of the genes indiacted with *. 
The four ways arrow indicate possible combination of centromeric and telomeric regions to determine 
CenAA-TelAA, CenAA-TelAB, CenAA-TelBB, CenAB-TelAA, CenAB-TelAB, CenAB-TelBB, CenBB-
TelAA, CenBB-TelAB, CenBB-TelBB. 
Fig. 3. Simplified genomic organization defining the KIR haplotypes 
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KIR Aliases Ligand Function 
2DL1 CD158a, cl-42, 47.11,nkat1, p58.1 
HLA-C2Lys80 (Biassoni et al., 1995; 
Colonna et al., 1995; Wagtmann et al., 
1995 ; Winter  Long, 1997) 
Inhibition 
2DS1 CD158h, EB6Actl, EB6Actll HLA-C2Lys80 (weak) (Biassoni et al., 1997) Activation 
2DL2 CD158b1, cl-43, nkat6 
HLA-C1Asn80, HLA-B*73, -B*46, some 
HLA-C2 (Biassoni et al., 1995; Moesta et 
al., 2008) 
Inhibition 
2DL3 CD158b2, cl-6, nkat2, nkat2a, nkat2b, p58 
HLA-C1Asn80, HLA-B*73, -B*46 (Moesta 
et al.,2008; Winter et al., 1998) Inhibition 
2DS2 CD158j, 183Actl, cl-49, nkat5 HLA-C1
Asn80 (weak) (Stewart et al., 
2005) Activation 






2DS3 nkat7 Unknown Activation 
2DS4 CD158i, cl-39, KKA3, nkat8 Various HLA-C1 and HLA-C2 alleles, HLA-A*11(Graef et al., 2009) Activation 
2DS5 CD158g, nkat9 Unknown Activation 
3DL1 CD158e1, cl-2, cl-11, AMB11, nkat3, NKB1, NKB1B 
HLA-Bw4 (I80>T80) except HLA-B*13:01/02 
(Foley et al., 2008)  
HLA-A*23,-*24,-*32 (Stern et al., 2008; 
Thananchai et al., 2007) 
HLA-A*25 (Foley et al., 2008 : but not by 
Stern et al., 2008) 
Inhibition 
3DS1 CD158e2, nkat10 HLA-Bw4 ?  Activation 
3DL2 CD158k, cl-5, nkat4, nkat4a, nkat4b HLA-A*3,-*11 (weak) (Pende et al., 1996; Hansasuta et al., 2004) Inhibition 
3DL3 CD158z, KIR3DL7, KIR44, KIRC1 Unknown Inhibition 
I80>T80: indicates the affinity of interaction with KIR3DL1 
Definition of KIR-mismatch in the case of HSCT 
- ligand-ligand model: incompatibility between the donor KIR ligand and recipient KIR ligand is 
based on the “missing-self“ hypothesis. Thus a ligand-ligand mismatch is possible if the donor has 
a ligand that is absent in the recipient (Ruggeri et al., 2002). 
- missing ligand model: the above ligands-ligand paradigm is complicated by the fact that not all 
the individual genomes contain the complete set of KIR genes. Thus, you have to take in 
consideration that incompatibility between the donor KIR and recipient KIR ligand (receptor-
ligand mismatch) is true if the donor has an inhibitory receptor for which the cognate ligand is 
absent in the recipient (Leung et al., 2004; Hsu et al., 2005). Thus to avoid this problem a KIR 
genotypic and phenotypic analysis is required. 
- receptor-receptor model: it is known as KIR-haplotype incompatibility between the donor KIR and 
recipient KIR and it is valid if the donor has a receptor that is absent in the recipient (Gagne et al., 
2002; McQueen et al., 2007) 
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The framework 3DL3, 3DP1, 2DL4 and 3DL2 gene loci are drawn on the line representing 
chromosome19q13.42 region oriented from centromer (left) to telomer (right). Inhibitory receptors 
(shown gray boxes), activating ones (unfilled boxes) and pseudogenes (boxed with thicker line) are 
indicated. The genomic organizations of centromeric and telomeric regions are boxed with continuous 
line trait. The genes defining A haplotype are drawn on top, while the ones typical for B haplotype on 
the bottom. Boxes represented with dotted lines indicate gene regions frequently deleted, in detail 
KIR2DL5B is more frequently, but no exclusively associated with KIR2DS3 and on the opposite the gene 
telomeric to KIR2DL5A is KIR2DS5 and rarely KIR2DS3. The KIR3DP1 may be also present as KIR3DP1 
ex2. Centromeric and/or telomeric haplotye B need to have at least one of the genes indiacted with *. 
The four ways arrow indicate possible combination of centromeric and telomeric regions to determine 
CenAA-TelAA, CenAA-TelAB, CenAA-TelBB, CenAB-TelAA, CenAB-TelAB, CenAB-TelBB, CenBB-
TelAA, CenBB-TelAB, CenBB-TelBB. 
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KIR Aliases Ligand Function 
2DL1 CD158a, cl-42, 47.11,nkat1, p58.1 
HLA-C2Lys80 (Biassoni et al., 1995; 
Colonna et al., 1995; Wagtmann et al., 
1995 ; Winter  Long, 1997) 
Inhibition 
2DS1 CD158h, EB6Actl, EB6Actll HLA-C2Lys80 (weak) (Biassoni et al., 1997) Activation 
2DL2 CD158b1, cl-43, nkat6 
HLA-C1Asn80, HLA-B*73, -B*46, some 
HLA-C2 (Biassoni et al., 1995; Moesta et 
al., 2008) 
Inhibition 
2DL3 CD158b2, cl-6, nkat2, nkat2a, nkat2b, p58 
HLA-C1Asn80, HLA-B*73, -B*46 (Moesta 
et al.,2008; Winter et al., 1998) Inhibition 
2DS2 CD158j, 183Actl, cl-49, nkat5 HLA-C1
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2DS3 nkat7 Unknown Activation 
2DS4 CD158i, cl-39, KKA3, nkat8 Various HLA-C1 and HLA-C2 alleles, HLA-A*11(Graef et al., 2009) Activation 
2DS5 CD158g, nkat9 Unknown Activation 
3DL1 CD158e1, cl-2, cl-11, AMB11, nkat3, NKB1, NKB1B 
HLA-Bw4 (I80>T80) except HLA-B*13:01/02 
(Foley et al., 2008)  
HLA-A*23,-*24,-*32 (Stern et al., 2008; 
Thananchai et al., 2007) 
HLA-A*25 (Foley et al., 2008 : but not by 
Stern et al., 2008) 
Inhibition 
3DS1 CD158e2, nkat10 HLA-Bw4 ?  Activation 
3DL2 CD158k, cl-5, nkat4, nkat4a, nkat4b HLA-A*3,-*11 (weak) (Pende et al., 1996; Hansasuta et al., 2004) Inhibition 
3DL3 CD158z, KIR3DL7, KIR44, KIRC1 Unknown Inhibition 
I80>T80: indicates the affinity of interaction with KIR3DL1 
Definition of KIR-mismatch in the case of HSCT 
- ligand-ligand model: incompatibility between the donor KIR ligand and recipient KIR ligand is 
based on the “missing-self“ hypothesis. Thus a ligand-ligand mismatch is possible if the donor has 
a ligand that is absent in the recipient (Ruggeri et al., 2002). 
- missing ligand model: the above ligands-ligand paradigm is complicated by the fact that not all 
the individual genomes contain the complete set of KIR genes. Thus, you have to take in 
consideration that incompatibility between the donor KIR and recipient KIR ligand (receptor-
ligand mismatch) is true if the donor has an inhibitory receptor for which the cognate ligand is 
absent in the recipient (Leung et al., 2004; Hsu et al., 2005). Thus to avoid this problem a KIR 
genotypic and phenotypic analysis is required. 
- receptor-receptor model: it is known as KIR-haplotype incompatibility between the donor KIR and 
recipient KIR and it is valid if the donor has a receptor that is absent in the recipient (Gagne et al., 
2002; McQueen et al., 2007) 





group A the haplotype diversity is primarily associated at the allelic polymorphism, while 
the group B haplotypes have greater diversity in gene content exhibiting only a moderate 
allelic polymorphism. In particular an analysis based on the genotype of only the four 
KIR2DL1, 2DL3, 3DL1 and 3DL2 loci showed at least 22 different haplotype A members 
with only 0.24% of unrelated individuals sharing an identical genotype (Shilling et al., 
2002).The different B haplotypes may have mixed “B/x” genotypes (CenAA/TelAB, 
CenAB/TelAA, CenAA/TelBB, CenAB/TelAB, CenBB/TelAA, CenAB/TelBB, or 
CenBB/TelAB), which display all genes typical of group B plus at least an additional KIR 
group A gene, or may have a pure B/B genotype, without any A genes, CenBB/TelBB 
(Figure 3) (Cooley et al., 2010; Gourraud et al., 2010; Hsu et al., 2002; Middleton & Gonzelez, 
2010; Pyo et al., 2010). 
2.2 Ligand(s) of the Killer immunoglobulin-like receptors 
On human NK cells, the KIR family of receptors participates in the complex regulation of 
NK cell responses through recognition of specific human leukocyte antigen (HLA) class I 
molecules on target cells. Both the KIR receptor and its cognate HLA ligand must be 
expressed in order to regulate NK cell activity. In fact each KIR interacts directly with 
distinct groups of expressed HLA alleles and the NK-mediated responses are governed by 
the avidity of interaction with HLA class I 1-helix around amino acid residue-80 (Figure 2). 
Thus, this 1-helix region is directly responsible for defining the different NK 
alloreactivities. In particular, inhibitory KIR2DL1, KIR2DL2 and KIR2DL3 receptors, and to 
a lesser extent the activating KIR2DS1 and probably KIR2DS2 are able to discriminate 
between two essentially non-overlapping groups of HLA-C alleles (Table 1). KIR2DL1 and 
KIR2DS1 (weaker) are specific for HLA-C alleles belonging to C2-group sharing V76, N77 and 
K80 residues (essentially the majority of HLA-Cw2, 4, 5, 6 and some other alleles) (Figure 2A) 
(Table 1). In contrast, KIR2DL2 and to a lesser extent KIR2DL3 recognize HLA-C alleles (C1-
group) characterized by V76, S77 and N80 amino acids (mainly defined by HLA-Cw1, 3, 7, 8 
and some other alleles). Additionally, some rare or geographically localized HLA-B 
allotypes (B73 and B46, respectively) containing a functional C1 epitope, originated by 
recombination events and sharing amino acids 66–77 with HLA-Cw3 alleles, and therefore 
interact with KIR2DL2 and KIR2DL3 (Biassoni et al., 1995; Abi-Rached et al., 2010) (Figure 
2A). In addition, both KIR2DL2 and KIR2DL3 have also been described in having weak 
alloreactivity against some C2 allotypes (Moesta et al, 2008; Pende et al, 2009), probably due 
to allelic differences within the C2 subgroup (Figure 2A) (Table 1) (Moesta et al., 2008). 
Intriguingly, NK cell biology evolution drove to dominance in the recognition of HLA-C 
loci, where in humans at least 3 inhibitory and 2 activating receptors are able to sense the 
dimorphisms covering all known HLA-C alleles. It is known that MHC-C evolved only 
recently in humans and great apes (at least in orangutans), and not before. Apparently, the 
KIR and C1 loci evolved before the KIR-C2 since in Orangutans neither MHC-C2 alleles nor 
C2-specific KIRs could be detected (Older Aguilar et al., 2010). KIR3DL1 loci encode specific 
receptors for HLA-B alleles that share the public epitope Bw4 corresponding to amino acids 
77-83 on the HLA class I 1-helix with the exception of HLA-B*13:01 and HLA-B*13:02 
(Foley et al., 2008), and for some HLA-A alleles characterized by Bw4-supertypic specificity 
like A23, A24, , and A32 (Stern et al., 2008; Thananchai et al., 2007). An additional paper 
suggested that also HLA-A*25 alleles may be recognized by KIR3DL1 (Foley et al., 2008) 
although these data have not been confirmed by others (Stern et al., 2008). 
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KIR3DL1 has been described to strongly interact with target cells expressing homozygous Bw4 
alleles sharing Isoleucine-80, and weakly with homozygous Bw4 Threonine 80 (Figure 2A) 
(Table 1). KIR3DL2 has been reported to be specific for HLA-A3 and -A11 allotypes, but with a 
limited ability to inhibit NK-mediated lysis (Döhhring et al., 1996; Pende et al., 1996) (Figure 
2A) (Table 1). 
Among activating KIR receptors, the direct HLA binding was demonstrated only for KIR2DS1, 
where the weaker avidity of interaction was been found to be dependent on the dimorphism 
of amino acid residue 70 (Biassoni et al., 1997) (Figure 2B). In contrast, evidence that KIR3DS1 
may be associated with HLA-B recognition has been hypothesized, since it was found to be 
responsible for the delay of AIDS progression, but direct binding could not be demonstrated 
(Martin et al., 2002a; Gillespie et al., 2007). Recently a single KIR3DS1 allele (KIR3DS1*014), 
selected on the basis of critical D1-domain residues associated with Bw4-specificity (Figure 2B) 
(Norman et al., 2007), and carrying glycine-138 instead than tryptophan, was found to have 
direct HLA-Bw4 binding capability (O’Connor et al., 2011). The non-synonymous mutations in 
the extracytoplasmic domain linked with HLA-specific interaction are typical on activating 
KIR molecules (Biassoni et al., 1997; O’Connor et al, 2011), and also experimental shuffling of 
2DS2 residue 45 from tyrosine to phenylalanine typical of 2DL2 receptor were found to 
enhance the affinity of the KIR2DS2 for HLA-C1 ligand (Winter et al., 1998). These 
observations may be the results of evolution followed by selection pressure, since activating 
KIR may have evolved from ancestral inhibitory receptors (Abi-Rached & Parham, 2005). 
Further, it is likely that the triggering ones have evolved to decrease the affinity of HLA-
recognition probably to avoid autoimmune phenomena, but with time, they acquired the 
potential to recognize HLA class I molecules presenting peptides of viral origin (Khakoo et al., 
2000; Vilches  Parham, 2002; Abi-Rached  Parham, 2005). Class I MHC tend to present 
peptides of ~9 amino acids in length in their binding groove bounded by the 1- and 2-
helices. The amino acid residue at position 8 of the peptide in the MHC class I binding groove 
may be governing KIR/HLA class I-interactions. Interestingly, this amino acid in position 8 is 
localized near the residue 80 amino acid of the 1-helix. In particular, the KIR2DL/HLA-C and 
KIR3DL1/HLA-Bw4 interactions are affected by the presence of P8-residues either bearing 
strong negative or positive charges (Malnati et al., 1995; Peruzzi et al., 1996; Rajagopalan & 
Long, 1997). The relevance of pathogen derived-peptide is known to be associated with the 
positive association of both KIR3DS1 and Bw4 gene loci in HIV-infected subjects thus 
suggesting a possible role for HIV-associated peptides and by the fact that EBV infection is 
able to influence the KIR2DS1 HLA-C2 group interaction (Figure 2B) (Stewart et al., 2005). 
Pathogens present in the environment may have participated in the shaping of genetic loci of 
activating KIR thus explaining the hypothesis of recurrent acquisition and loss of activating 
KIR loci during evolution. In addition, the role of peptide in the KIR-mediated HLA class I 
recognition is known, since KIR3DL2 have a strong dependence from EBV-derived peptides 
presented by HLA-A3 and A11 alleles, and by that the presentation of particular self-peptide 
via HLA-Bw4 alleles were found to be protective from NK cell mediated lysis (Hansasuta et 
al., 1997; Malnati et al., 1995). Finally, KIR2DL4 binds to the non classical MHC class I HLA-G 
molecules (Ponte et al., 1999; Rajagopalan & Long EO, 1999), while KIR2DS4, probably 
originated from a gene conversion event with KIR3DL2 sequences, binds specifically to 
subsets of HLA-C1 and HLA-C2 group of alleles, and to HLA-A11 (Figure 2B) (Table 1) (Graef 
et al., 2009). Different analyses have demonstrated that KIR and their ligands may influence 





group A the haplotype diversity is primarily associated at the allelic polymorphism, while 
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molecules on target cells. Both the KIR receptor and its cognate HLA ligand must be 
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KIR3DL1 has been described to strongly interact with target cells expressing homozygous Bw4 
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reliable molecular typing, to determine the assortment of KIR genes together with HLA class I 
genes, is imperative. This is necessary to define the KIR-ligand associations in order to 
determine possible interactions associated either in the positive or negative responses to 
several diseases and pathologic states. 
3. Molecular typing techniques 
Accurate typing methods to discriminate HLA class I alleles and KIR genotypes is of great 
interest to establish the associations of KIR/HLA, and their activation or inhibition 
potentials. Due to the extraordinary polymorphism of the Human Leukocyte Antigen 
complex, it is recognized that serological HLA typing techniques are inadequate for this 
task. The correct assignment of HLA class I alleles relies on molecular typing techniques 
(Harville, 2009). The introduction of Polymerase chain reaction (PCR) has allowed the 
development of more advanced techniques for molecular typing of HLA alleles. Additional 
methods dedicated in the HLA typing of group of alleles relevant in the NK-mediated 
function have been published using either RT-PCR or pyrosequencing on genomic DNA 
(Shilling et al., 2002; Ugolotti et al., 2011). At present for the identification of KIR genotype 
there is a tendency to use methods familiar to laboratories, such as the sequence-specific 
primers (SSP-PCR) and sequence-specific oligonucleotide probes (SSOP). In fact, traditional 
KIR genotyping methods utilize SSP-PCR and requires that genomic DNA must be 
amplified using a collection of primers in separate reactions in order to define the various 
loci or alleles and to be detected by fragment lengths using gel electrophoresis. However, 
there are drawbacks to utilizing the SSP method for higher-throughput analysis of KIR loci 
in populations. Furthermore, the SSP method includes the problem of sample amplification 
failure, which could be due to either general PCR failure, or an as of yet undefined variant 
sequence. The first problem could be partially overcome using different primer 
combinations to amplify the same KIR locus, and if the same primer set is able to amplify 
different KIR loci (Martin & Carrington, 2008; Kulkarni et al., 2010). Unfortunately, the 
inability to detect variant KIR alleles due to primer mismatch is without a practical solution. 
Accordingly, amplification failure could result in erroneous KIR genotyping results. An 
alternative KIR genotyping assay uses sequence-specific oligonucleotide probes (SSOP) 
developed for locus-specific resolution of 14 KIR gene loci. The SSOP assay requires a 
smaller quantity of genomic DNA than SSP techniques. Although generally more efficient 
than SSP methods, genotyping analysis by SSOP assays is still cumbersome and may have 
similar pitfalls in the detection of previously unreported variants (Middleton & Gonzeles, 
2010). Some groups use sequencing for the KIR allele determination, whereas others have 
used mass spectrometry, or real-time reverse transcription-polymerase chain reaction, 
which not only could prove useful for allele determination but also for determining copy 
number of either gene or allele (Cooley et al., 2009; Du et al., 2008; Norman et al., 2007). 
Recently, the possibility to discriminate the KIR alleles by the technique of high-resolution 
melting (HRM) has been reported (Gonzales et al., 2009). 
More recently, KIR haplotypes have been completely sequenced using Next Generation 
Sequencer (NGS), different patents using NGS have been filed (De Re et al., 2011), and some 
of sequenced haplotypes are present on the EBI database (http://www.ebi.ac.uk/ipd/kir/ 
sequenced_haplotypes.html). Further, commercial kits are available for KIR typing in the 
clinical setting. 
 
Killer Immunoglobulin-Like Receptors and Their Ligands 
 
103 
4. KIR/HLA class I genotypes and their implication in disease progression 
As noted, an accurate typing system to discriminate groups of HLA class I alleles of a 
subject together with the analysis of KIR genotypes is of great interest to establish the 
association KIR/HLA, and their possible involvement in different pathologic or disease 
states. Another issue is to accurately define the sub-population of effector cells responsible 
for the immune responses. In this regard, an important issue is that KIR receptors are not 
only expressed by NK cells, but also by a subpopulation of CD8+ T lymphocytes. In this 
context, the role of this latter subpopulation may mask, or may actually be, the principal 
subject in any association between pathologic states and KIR/HLA interactions. 
4.1 Human immunodeficiency virus (HIV) 
HIV was the first viral infection for which an association between specific KIR and HLA 
class I ligands was observed. In detail, it has been reported that specific combinations 
between the activating receptor KIR3DS1 and HLA-Bw4 alleles, characterized by isoleucine 
at position 80 (HLA-Bw4I80), have a protective effect against AIDS progression (Martin et al., 
2002a). In fact, the interaction between HLA-Bw4I80 alleles and the activating receptor 
KIR3DS1 could be associated with enhanced NK cell reactivity that improves antiviral 
immune responsiveness. Moreover, this combination was found to confer protection against 
the onset of opportunistic infection during AIDS (Qi et al., 2006). Additionally, others found 
that KIR3DL1 alleles are correlated with the outcome of HIV infection in combination with 
HLA-B57, also an HLA-Bw4I80 allele. It has been found to be more protective than the 
KIR3DS1/HLA-Bw4I80 interaction (Martin et al., 2002a). It has to be stressed that the most 
protective KIR allele was KIR3DL1*004, which is not expressed on the cell surface, thus 
suggesting that absence of inhibition, or the better the enhanced KIR/HLA triggering 
potential, play roles in the immune-response against HIV (Rajagopalan et al., 2006). These 
data may not be in contrast though, since KIR3DS1 and KIR3DL1 are allelic form of the 
same gene present in haplotype B or A, respectively, thus representing different aspects of a 
complex system of interactions. 
As expected, since the KIR complex has a multiloci ligand system, in some subject not only 
HLA-B alleles, but also HLA-C ligands appear to play roles in the control of HIV infection. 
A higher expression of HLA-C has also been associated with a slower AIDS progression 
(Fellay et al., 2007; Jennes et al., 2006; Thomas et al., 2009). While the HLA-C*07 alleles (C1-
group), which are generally less expressed probably due to a mutation in the –35 residue 
(C>T), are associated with the most rapid progression of disease. Whereas alleles expressed 
at high levels (characterized by the –35 “C” allele), are associated with slower progression 
(Fellay et al., 2007; Thomas et al., 2009). These data may suggest the existence in these 
subjects of activating KIR(s) with C1-group specificity. Recently, a correlation of NK cell 
responses against HIV1-derived peptides has been associated with the presence of 
activating KIR(s) characterized by such C1-group specificity (Tiemessen et al., 2011). 
4.2 Hepatitis C virus (HCV) 
KIR/HLA combinations, suggesting a weak inhibitory potential, or better suggesting a 
triggering interaction, are been also found to be relevant in the viral clearance in hepatitis C 
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chronic diseases such as cirrhosis and hepatocellular carcinoma in 85% of infected subjects 
due to non-efficient immune-responsiveness. Among the high number of patients with 
chronic infection, 17% develop complications such as cirrhosis, and 2% due the most serious 
progression of disease like hepatocellular carcinoma. The factor leading to these different 
outcomes are not clear yet, although the route of infection, size of inoculums, and the viral 
genotype may play major roles. Interestingly, it is known that a particular MHC 
polymorphism is associated with the spontaneous clearance, or a self-limited HCV infection. 
Thus, subjects characterized by weaker KIR-mediated inhibitory interaction 
(KIR2DL3/HLA-C1 group) would be protective. Probably, it is because this inhibition could 
be more easily overridden by activating receptors, which generate a more efficient viral 
clearance than a stronger inhibitory interaction such as that triggered from KIR2DL2/HLA-
C1 group or KIR2DL1/HLA-C2 group. In detail, analyses on more than 1000 subjects 
revealed that 350 recovered spontaneously without treatment for HCV infection. The more 
common characteristics among them were the homozygous inheritance of the KIR2DL3 
locus and of its relative HLA-C1 group ligand (Khakoo et al., 2004). When a KIR does not 
efficiently suppress immune cells, the cells can be more easily activated to eliminate 
infected cells. Another retrospective study was performed in 151 donor-recipient pairs, 
evaluating the KIR/HLA genotypes and the relapse of HCV disease, and its progression 
after liver transplantation. Liver biopsies were obtained from the recipients 1, 3, 5, 7 and 
10 years post-transplant to determine when hepatitis relapsed, the degree of fibrosis, and 
the progression to cirrhosis (Espadas de Arias et al., 2009). They found that hepatitis was 
more at risk to recur when the KIR/HLA-C interacting ligands are “staggered” between 
donor and recipient. In addition, the presence of KIR2DL3 in the recipient was related to 
the progression of liver fibrosis. In general, a simple model of genetic protection has not 
been found in all patient populations. KIR2DL3 is found in the “A” group of haplotypes, 
as it is true for KIR2DS4. Consistent with this, KIR2DS4 has also been associated with 
protection against chronic HCV infection. Similarly, the B group of haplotypes marked 
with KIR2DL5, but without the presence of both KIR2DL3 and KIR2DS4, have been found 
to be associated with a poor response to treatment for HCV (Carneiro et al., 2010). Finally, 
the KIR2DL3/HLA-C1 group interaction was not found to be protective in a cohort of 
HIV/HCV co-infected individuals, implying that the HIV viral infection might modulate 
the protective effect of KIR3DL3. 
4.3 Hepatitis B virus (HBV) 
The same rationale of weak inhibition by the homozygous KIR2DL3 and HLA-C1/C1 
group genotype has been also indicated in the protection from hepatitis B (HBV) viral 
infection, while the presence of KIR2DL1 in combination with HLA-C2 group ligand 
(stronger interaction), conferred the susceptibility to chronic hepatitis B (Gao et al., 2010). 
Chronic hepatitis B (CHB) is an inflammatory disease of the liver caused in 10% of people 
who become infected with hepatitis B virus (HBV). Many of those with chronic infection 
may be asymptomatic, thus increasing the risk of viral transmission. Chronic infection 
with hepatitis B may increase the chance of permanent damage to the liver, including 
cirrhosis and liver cancer. Chronic hepatitis B (CHB) affects more than 350 million persons 
in the world. Another study, has also investigated on the KIR gene polymorphisms in a 
large cohort of 150 chronic hepatitis B patients, 251 subjects with resolution of infection, 
and 412 healthy controls. These authors found a correlation between KIR2DS2 and 
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KIR2DS3 as HBV susceptible genes able to induce a persistent weak inflammatory 
reaction that results in continuous injury of live tissues, and thus to chronic hepatitis; 
whereas, KIR2DS1, KIR3DS1, and KIR2DL5 may act as protective genes that facilitate the 
clearance of HBV (Zhi-ming et al., 2007). 
4.4 Human Cytomegalovirus (HCMV) 
Human Cytomegalovirus (HCMV) is the cause of latent infections in the majority of 
infected individuals. In infected immuno-compromised subjects, this virus may reactivate 
causing life-threatening infection. Again, activating KIR genes are thought to be 
important for the control of CMV reactivation after haematopoietic stem cell 
transplantation (HSCT), and KIR2DS2 together with KIR2DS4, or a total of at least 5 loci 
coding for activating KIR present, could be associated with reduced CMV infection after 
transplantation (Zaia et al., 2009). 
4.5 Human papilloma virus (HPV) 
Activating KIR genes are associated with recurrent respiratory papillomatosis (RRP), a rare 
disease caused by human papilloma virus (HPV). In this context, activating KIR3DS1 and 
KIR2DS1 receptors have been found to be involved in the triggering of an effective early 
immune response against HPV-infected targets to establish resistance to RRP development 
(Bonagura et al., 2010). 
4.6 Herpes simplex virus (HSV) 
In the case of infections sustained by herpes simplex virus (HSV) it has been found that both 
KIR2DL2 and KIR2DS2 genes could be associated in all asymptomatic cases (Estefania et al., 
2007). However, at present it was impossible to determine whether the inefficient responses 
to HSV could be associated to one of the gene loci coding for the activating or the inhibitory 
receptor. The uncertainty is because these genes are in tight linkage disequilibrium since 
they are expressed as different adjacent loci of the B-haplotypes. 
4.7 Psoriasis 
There is a strong genetic basis associated with the development of the chronic inflammatory 
condition of the skin known as psoriasis. The MHC class I region that includes HLA-A, -B, -
C, and -E genes has been found associated with psoriasis (Bowcock & Krueger, 2005; Nair et 
al., 2000). Among them, HLA-Cw6 appears to be one of the loci most associated with 
psoriasis (Nair et al., 2006; Tiilikainen et al., 1980). At least 3 additional loci, an allele with a 
HLA-Bw4 epitope (Feng et al. 2009), HLA-E alleles representing the ligand for type II 
heterodimeric receptors (NKG2A/CD94, and NKG2C/CD94), and stress-induced MICA 
molecules, representing the ligand for the NKG2D triggering receptor (Cerwenka & Lanier, 
2003; Cheng et al., 2000) may be involved in disease. Data about which KIR may be involved 
in psoriasis are still unresolved, since some researchers have found KIR2DS1 associated in 
the development of disease (Holm et al., 2005; Luszczek et al., 2005; Suzuki et al., 2004), 
while others could not find any association (Chang et al., 2006; Williams et al., 2005). The 
findings about a possible association between KIR2DS1 and psoriasis is intriguing, since this 
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HLA-Bw4 epitope (Feng et al. 2009), HLA-E alleles representing the ligand for type II 
heterodimeric receptors (NKG2A/CD94, and NKG2C/CD94), and stress-induced MICA 
molecules, representing the ligand for the NKG2D triggering receptor (Cerwenka & Lanier, 
2003; Cheng et al., 2000) may be involved in disease. Data about which KIR may be involved 
in psoriasis are still unresolved, since some researchers have found KIR2DS1 associated in 
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attractive, although a consensus on the biological significance of this association is still 
without an unanimous consensus. Another study pointed out the KIR2DL5 locus as the 
locus associated with the development of psoriasis (Suzuki et al., 2004). KIR2DS1 and 
KIR2DS2 have been found to be associated with psoriatic arthritis (PsA) (Williams et al., 
2005), but without the expression of their associated HLA-C ligands (Martin et al., 2002b), or 
conversely, in presence of their ligands (Nelson et al., 2004). Altogether, the variability of the 
data published on psoriasis and PsA, indicate the absence of consensus, either because the 
numbers of patients analyzed were too low, or because the data on KIR/HLA association 
could be epiphenomenon and not the real cause of disease. 
4.8 Inflammatory bowel disease (IBD) 
In chronic inflammatory diseases of the gastrointestinal tract (IBD), Crohn’s disease (CD) 
and ulcerative colitis (UC), the frequency of KIR2DL1 and KIR2DL3 is lower in patients than 
in healthy donors. It is of note that, the KIR2DL1/HLA-C2 group interaction is less frequent 
in IBD patients than with controls (Zhang et al., 2008). Therefore, the data suggest that poor 
inhibition through the KIR/HLA interaction contribute to the genetic susceptibility of IBD, 
and may be the direct cause of the chronic inflammation. 
4.9 Use of NK cell activity in hematopoietic stem cell transplantion (HSCT) 
NK cells have been used in adoptive immunotherapy as alloreactive natural killer (NK) cells 
for treatment of hematologic malignancies, in particular the myeloid leukemias. The 
knowledge acquired have made possible the use of NK cell alloreactivity (donor-versus-
recipient) for eradication of leukemia cells using KIR/HLA haplotype-mismatched 
transplants ('haploidentical') or haploidentical hematopoietic stem cell transplantation 
(haplo-HSCT) (Pende et al., 2009; Velardi, 2008). This immunotherapy is based on the 
selection of donor NK cell expressing appropriate KIR repertoire (Table 1). The selection of 
KIR mismatches in HLA-matched donors by KIR genotyping is fundamental in the clinical 
treatment approach to define a donor selection strategy for improving transplant outcomes 
(Table 1) (Leung, 2011; van der Meer et al., 2008). 
4.10 Reproduction 
The interaction between NK cells and uterine trophoblasts is an active process for blood 
vessel enlargement, and in remodelling during placentation, in order to have a more 
efficient blood supply to the fetus during pregnancy. Defective invasion of uterine 
trophoblasts is one cause of abnormal placental development, which may occur in 
disorders such as pre-eclampsia. In this pathological condition there is incomplete 
enlargement of blood vessels, which is often associated with high blood pressure, ending 
up in poor fetal growth, or in recurrent miscarriages. Much evidence indicates that 
interactions between fetal trophoblasts and maternal uterine NK cells are important in 
human placentation, with abnormal interaction resutling in increased risk for developing 
pre-eclampsia. This situation arises in a mother displaying homozygosity for KIR 
haplotype A (essentially absence of activating KIRs) and presence of HLA-C2 group 
alleles in the fetal tissues (Hiby et al., 2004). These data suggest that strong KIR inhibitory 
signals may be associated with a reduction of vessel enlargement, resulting in poor 
implantation, and increasing the risk of recurrent spontaneous abortions. More 
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interestingly, also the HLA-C typing of the father was found to be crucial in miscarriages, 
where an increased frequency of HLA-C2 group alleles in both the mother and the father, 
associated with the lack of KIR2DS1 in the mother, seems to increase the risk of abortion. 
These data are the first evidence of a male factor that increases the risk in spontaneous 
abortions (Hiby et al., 2008). Others have found that mothers with recurrent miscarriages 
showed an increase of KIR2DS1 frequency, together with a decrease of HLA-C2 group 
alleles, in comparison with mothers without recurrent spontaneous abortions, while the 
expression of KIR2DL1, the inhibitory receptor for HLA-C2 group, was unchanged (Wang 
et al., 2007). In addition, trophoblast cells express on their cell surface the non-classical 
MHC class I, HLA-G, while decidual NK cells express the HLA-G-specific KIR2DL4 
receptor. Thus, the HLA-G-specific KIR2DL4 receptors could play an important role in 
pregnancy outcome though the interaction between decidual NK cells and trophoblasts. 
Indeed several studies showed that higher cell surface expression of KIR2DL4 is 
associated with successful pregnancy (Yan et al., 2007). These data are not in conflict with 
the idea that activating KIR likely support placentation, since KIR2DL4 is known to have 
triggering potential. While KIR/HLA interactions, including maternal and paternal HLA 
and KIR alleles, between NK cells and trophoblasts are involved in preservation or loss of 
prenancies, they do not represent the only set of factors. For example, women who are 
missing KIR2DL4 have had successful pregnancy outcomes (Nowak et al., 2011). 
5. Conclusion 
Killer Ig-like receptors (KIR) expressed by NK cells and by some CD8+ T lymphocytes are 
known to have important roles in normal immune protection, and certain pathological 
conditions, such as cancer, infectious diseases, loss of pregnancy, and autoimmunity. NK 
cells and some CD8+ T lymphocytes, which express KIR, also express multiple other 
receptors on their cell surface able to modulate/regulate their function and thus influence 
host immune-responses through a complex matrix of intra-cytoplasmic signals. All the 
knowledges gathered in the last 15 years about the structure of KIR, their function, as well 
as defining their ligand specificity, although still not completed, have made some clinical 
applications possible. It is currently possible via specific HLA matching and KIR 
mismatching to use NK cells to kill tumor cells. It can be envisioned that via knowledge of 
KIR associations with specific pathogen-infected cells, directed NK cell therapy, activation 
and inhibition, can be utilized to result in erradication of the virus, rather than chronic 
infection. All of these approaches are based on the correct KIR genotyping, performed 
together with the determination of the HLA class I allele. And, is ultimately based on the 
specific residues determining the KIR specificity, and interaction with HLA. Since NK cells 
and a subpopulation of CD8+ T lymphocytes express KIR, efforts continue to require 
addressing which is the correct cell population associated with the process under 
investigation. In addition, due to differential KIR levels of expression and haplotypic 
expression, studies must consider the presence, an increase, or a decrease of expression of 
certain KIR locus in the analyzed population versus the control population for valid 
assessment of the obtained results. At the current time, published information is lacking on 
the relative expression levels of KIR in different populations of people. In conclusion, an 
accurate evaluation of KIR/HLA interaction, taking in consideration the complexity of the 
KIR and HLA gene systems, together with a sufficient number of subjects analyzed is 
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1. Introduction 
Genes of the major histocompatibility complex (MHC) offer several assets that make them 
unique candidates for studies of adaptation in natural populations (Potts & Wakeland, 1990; 
Hedrick, 1994). The primary role of the MHC is to recognize foreign proteins, present them 
to specialist immune cells and initiate an immune response (Klein & Figueroa, 1986). The 
MHC gene family includes highly polymorphic genes encoding a set of transmembrane 
glycoproteins that are critical to the generation of immune responses (Kennedy et al., 2002). 
In general, foreign proteins enter cells either by infection or by phagocytosis into antigen-
presenting cells such as macrophages. These foreign proteins are broken down into small 
peptides and loaded onto specific MHC molecules. The MHC molecule comprises an 
immunoglobulin stalk, which anchors the molecule to the cell surface, and a basket receptor 
called antigen-recognizing sites (ARS) located in peptide binding region (PBR). A subset of 
these protein/MHC complexes are then transported to the cell surface and presented for 
interrogation by the circulating T-cell population. A complex cascade of immune responses 
is triggered when the T cell binds to the presented peptide. Two major groups of MHC 
genes can be distinguished. MHC class I genes play an essential role in the immune defense 
against intracellular pathogens by binding peptides mainly derived from viral proteins and 
cancer-infected cells. They are expressed on the surface of all nucleated somatic cells. In 
contrast, MHC class II genes are predominantly involved in monitoring the extracellular 
environment by presenting peptides mainly derived from parasites (e.g. bacteria, 
nematodes, cestodes) to the T-cells. They are primarily expressed on antigen-presenting cells 
of the immune system, such as B cells and macrophages. Although ARS do show a degree of 
specificity, a single MHC molecule can bind multiple peptides that have common amino 
acids at particular anchor positions (Altuvia & Margalit, 2004). Genes within the MHC 
involved in antigen presentation constitute the most polymorphic loci known in vertebrates 
(Hedrick, 1994). The polymorphism of the MHC-molecules is associated with the diversity 
of the T-lymphocyte receptors that in turn determine the disease and parasite resistance of 
an organism and thus may affect the long-term survival rate of populations (Hedrick et al., 
1999; Paterson et al., 1998). The ARS show high levels of polymorphism not only in the 
number of alleles but also in the sequence variation among alleles (Hughes & Yeager, 1998). 
The general view is that balancing selection is the determinant role in shaping patterns of 
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The general view is that balancing selection is the determinant role in shaping patterns of 





Balancing selection refers to forms of natural selection in which no single allele is absolutely 
most fit (Hughes & Yeager, 1998, Meyer & Thomson, 2001). It is in contrast to directional 
selection that favors a few alleles. Balancing selection results not only in the maintenance of 
large numbers of alleles in populations, but also in greatly enhanced persistence of allelic 
diversity over extremely long time periods relative to neutral genetic variation (Paterson, 
1998). It results in an observation termed 'trans-species evolution of polymorphism (Klein & 
Figueroa, 1986), which some alleles from a species are more similar to the alleles of different 
species than each other, rather than the species-specific pattern. 
Genetic and antigenic diversity of the MHC could be important in a host’s ability to 
accommodate rapidly evolving infectious agents that periodically afflict natural populations 
(Klein & Sato, 1998). Exactly how much MHC diversity is required to ensure long-term 
population viability remains a fundamental question in conservation genetics. A lack of 
variation at the MHC may increase the susceptibility of an isolated population to infectious 
disease epidemics, with potentially catastrophic consequences (Bowen et al., 2002). For 
example, a link between MHC diversity and an effective response to both pathogenic and 
toxicogenic challenges was proposed (Acevedo-Whitehouse et al., 2003). Therefore, 
understanding the polymorphism of these genes, and their products, is vital for studying 
infectious disease ecology at the population level. This is particularly important in marine 
species whose chemical and microbial environment is increasingly influenced by 
anthropogenic encroachment, which increases marine species’ risk of exposure to novel 
pathogens (Harvell et al., 1999). However, not all MHC genes show high diversity. The most 
diverse and extensively studied MHC genes are the DQB and DRB genes. Diversity of DQB 
or DRB genes has been characterized in many mammalian species such as primates 
(Bontrop et al., 1999), bank vole (Axtner & Sommer, 2004), domestic mammals (Schook & 
Lamont, 1996, Yuhki & O'Brien, 1997, Mikko et al., 1999, Wagner et al., 1999), and marine 
mammals (Murray et al., 1999, Bowen et al., 2002, 2004, Baker et al., 2006, Hayashi et al., 
2006, Yang et al., 2007, Xu et al., 2007). After these studies on non-model free-ranging 
species were carried out, intriguing questions were raised about whether and how selection 
operates on the MHC of natural populations characterized by distinct pathogens and 
demographic and environmental conditions (Bernatchez & Landry, 2003; Sommer, 2005). 
It was suggested that the pathogen environment of marine mammals may provide a 
diminished selective pressure for maintaining MHC polymorphism (Murray et al., 1995; 
Murray & White, 1998; Slade, 1992), due to the relatively low prevalence of infectious 
disease in the marine environment. For example, Murray et al. (1995) found that the genetic 
variability at the MHC DQB loci of the beluga (Delphinapterus leucas) was much lower than 
those of primates. There are several other hypotheses that have been put forward to explain 
the reduction of MHC diversity in marine mammals, such as population bottlenecks and 
random drift acting in small populations (Murray & White, 1998; Slade, 1992). In order to 
discriminate among the hypotheses, it would be most informative to assess MHC variation 
in delphinids with large populations and no evidence of historic population bottlenecks.  
Seventy to fifty five million year ago (Mya), in the warm shallow waters of the Tethy Sea, 
mammals related to ungulates are thought have begun one of the most successful 
recolonizations of the marine environment (Arnason & Gullberg, 1996; Bajpai & Gingerich, 
1998; Thewissen & Williams, 2002). It is possible that earliest cetaceans were faced with a 
new range of pathogens associated with the marine environment. The study of the evolution 
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of the MHC in cetaceans presents an exciting opportunity to observe the response of the 
MHC to the new pressures of the marine environment. We reviewed the relationship 
between alleles in different cetacean species to evaluate whether certain allele sequences 
were shared by different cetaceans inhabiting similar or different environments. In addition, 
phylogenetic analyses revealed that the sequence divergence in several species might reflect 
different selective pressures between pathogens in oceanic and coastal waters. The 
information gained from sequence analysis is the essential foundation to analyze variation 
of MHC genes and study infectious disease ecology.  
2. Sequence variation of MHC class II genes in cetaceans  
The studies of MHC variation in cetaceans were directed at investigating variation of DQB 
gene exon 2 locus, which has been shown to be highly polymorphic in many terrestrial 
carnivores and domestic animals (Schook & Lamont, 1996; Wagner et al., 1999; Yuhki & 
O'Brien, 1997). MHC class II gene investigation in cetacean species presumed that 
immunogenetic diversity is generated by polymorphism at one or two specific loci (Murray 
et al., 1999), a reasonable assumption based on established knowledge in terrestrial species 
(Mikko et al., 1999; Wagner et al., 1999). In most studies, the sequence analysis of amplified 
172 bp fragments showed that there are no more than two alleles revealed in each 
individuals. One single DQB locus has been reported in other toothed whales (Hayashi et 
al., 2003; Hayashi et al., 2006; Murray et al., 1995). However, duplicate DQB genes were 
described in the baleen whales (Baker et al., 2006), baiji (Lipotes vexillifer) (Yang et al., 2005), 
and finless porpoise (Neophocaena phocaenoides) (Xu et al., 2007, 2009). It was proposed that 
bearing multiple DQB genes is consistent with the retention of an ancestral condition shared 
with the ruminants, and it has been lost in the more derived cetaceans such as the true 
dolphins (Baker et al., 2006). However, this suggestion is not supported by the finless 
porpoise, which is also supposed to be a derived species.  
MHC variation has been examined in some species of cetaceans and revealed different 
results. Earlier studies demonstrated low level of MHC genetic diversity in fin whales 
(Balaenoptera physalus) and sei whales (Balaenoptera borealis) (Trowsdale et al., 1989). 
However, Nigenda-Morales et al. (2007) reported the PBR of the DQB locus in  fin whales 
from Gulf of California has experienced strong positive selection. Sequence analysis of 
beluga whales MHC-II loci (including DQB and DRB) revealed low but measurable 
polymorphism (Murray et al., 1995; Murray & White, 1998). Recent sequencing analysis of 
cetacean populations revealed considerable sequence variation in some species of the baleen 
whales and toothed whales (Baker et al., 2006; Hayashi et al., 2003; Xu et al., 2007, 2008, 2009; 
Vassilakos et al., 2009; Yang et al., 2005; Yang et al., 2007, 2008, 2010; Heimeier et al., 2009). 
These studies also found evidence of positive selection, as showed by high levels of 
nonsynonymous substitutions at ARS. For example, the amount of variation of DQB in 
common bottlenose dolphins (Tursiops truncatus) (Yang et al., 2008) is significantly higher (6 
alleles and 21 nucleotide substitutions in 172 bp found in 42 dolphins) than that in beluga 
(only 5 alleles and 11 nucleotide substitutions in 172 bp found in 233 beluga) (Murray et al., 
1995). Xu et al. (2007) reported that finless porpoises seem to retain considerable MHC 
genetic variation (14 DQB alleles in 195 porpoises) despite population decline in recent 
years. Moreover, the finding in humpback whales (23 DQB alleles from 30 individuals) 
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1995). Xu et al. (2007) reported that finless porpoises seem to retain considerable MHC 
genetic variation (14 DQB alleles in 195 porpoises) despite population decline in recent 
years. Moreover, the finding in humpback whales (23 DQB alleles from 30 individuals) 





for animals with large body size and long generation time. These findings not only suggest a 
positive selection pressure on the cetacean DQB locus but also argue against a reduction in 
the marine environment selection pressure. Similar arguments were made in the studies on 
beluga DRB1 locus (Murray & White, 1998), North Atlantic right whale (Eubalaena glacialis) 
DQB locus (Murray, 1997), Baiji DQB locus (Yang et al., 2005), and finless porpoise DQB 
locus (Hayashi et al., 2006). Besides, no deviation from Hardy-Weinberg expectations (i.e. no 
excess of heterozygotes) was observed in beluga and common bottlenose dolphins, 
suggesting that the effect of balancing selection for short time periods might be weak and 
masked by other microevolutionary forces (e.g. gene flow, mutation, drift, and non-random 
mating). Similar conclusions were reached by Boyce et al. (1997) from bighorn sheep (Ovis 
canadensis), Huang and Yu (2003) from the Southeast Asian house mouse (Mus musculus 
castaneus) in Taiwan, and Miller et al. (2004) from New Zealand robins (Petroica australis). 
Nonetheless, there are other possible explanations, such as spatiotemporal variation of 
selection and demographic processes acting on small populations (reviewed by Piertney & 
Oliver, 2006). Hayashi et al. (2006) also found evidence for both balancing selection overall, 
and genetic drift in small, local populations for the DQB locus in the finless porpoise. 
The sequence information raises important questions regarding immunologic diversity in 
cetaceans. While those studies present valuable information, variation at 1 part of a gene, or 
1 gene, is not an appropriate measure of variation for the entire MHC (Murray & White, 
1998). It is possible that low diversity at the MHC has been observed only because short 
fragments (usually less than 200 bp) were amplified and the functionality of the alleles was 
not taken into account (e.g., Sommer, 2003, Amills et al., 2004), which might lead to a 
misinterpretation of the results (Axtner & Sommer, 2007), with the possible consequence 
that a severe population bottleneck is inferred (Baker et al., 2006). Besides, the MHC 
variation in one locus cannot definitely represent the ability of pathogen defense of a species 
because MHC polymorphism in marine mammals arises from several loci. For example, a 
moderate to high degree of polymorphism is only found in DRB genes, not in DQB gene, in 
beluga and California sea lion (Zalophus californianus) (Bowen et al., 2004; Murray and 
White, 1998), and the situation reverses in humpback whale (Megaptera novaeangliae) (Baker 
et al., 2006). Therefore, characterization of full-length expressed sequences of MHC genes is 
very important for making valid evolutionary inferences on non-model species like 
cetaceans. To date, there is only one published article characterizing the full-length DQB and 
DRB gene sequences in cetaceans (Yang et al., 2007), which were from the RACE cDNA 
products of T. truncatus and T. aduncus. The nucleotide and deduced amino acid sequences 
of the 780- (DQB-primer derived) and 801-bp (DRB-primer derived) products were typical 
of transcripts from mammalian class II genes. The result revealed the presence of 1 DQB 
locus and 2 DRB loci in Tursiops. The high proportions of non-synonymous nucleotide 
substitutions in the putative peptide-binding regions of Tutr-DQB, Tuad-DRB, and Tutr-DRB 
suggest positive selection pressure on these gene loci (Hughes & Yeager, 1998) and imply 
functional roles for these molecules in pathogen-specific immune responses. In DRB of T. 
aduncus, for example, the majority of 44 variable sites were in exon 2 (38/44), with the 
remainder being distributed in exons 1 (1/44), 3 (4/44), and 4 (1/44).  The deduced amino 
acid sequences indicated that the substitutions clearly tended to be clustered around the 
ARS.  The divergence of non-synonymous substitutions was significant at the codons of the 
ARS (p < 0.005).  The polymorphic Tuad-DRβ amino acid residues (n = 25) were located in 
the leader peptide (1/25), the β1 domain (21/25), the β2 domain (2/25), and the 
transmembrane domain (1/25).  
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The correlations between MHC alleles and disease resistance (e.g. malaria, hepatitis B, 
leprosy, tuberculosis) and disease-susceptibility (cancer, parasite infestation) have been 
reported (reviewed by Sommer, 2005). Human pathologies have also been correlated to 
specific amino acid replacement and motif changes in ARS among different populations 
(reviewed by Vassilakos et al., 2009). There are striking differences in the prevalences of 
some disease-resistance alleles in different human population. MHC associations also show 
some geographic variation. It seems likely that the same evolutionary selection pressures 
that have given rise to polymorphisms in genes involved in resisting infectious pathogens 
have contributed to marked allele frequency differences at the same loci. Gene-environment 
interactions are likely to introduce another layer of complexity. In marine mammals, for 
example, MHC genotypes of California sea lions were associated with urogenital cancer 
(Bowen et al., 2005). One of the DQB allele in T. truncatus was found being assocaited with 
strandings although only marginally significant (Yang et al., 2008). In addition, only five 
individuals carried this allele were fresh enough for pathological examination in that study 
so that the subsequent statistical analysis of lesions could not be done. Therefore, further 
studies are needed to identify genes of major to moderate effect in a single population with 
large sample size and then determine whether a similar effect is found elsewhere, and we 
may elucidate the potential mechanisms underlying the association between MHC alleles 
and cetacean strandings. 
3. Phylogenetic analyses of MHC class II genes in cetaceans  
Recent molecular and morphological studies have suggested that the order Cetacea may be 
more closely related to even-toed ungulates than to other orders of ungulates (Arnason et 
al., 2000; Boisserie et al., 2005; Kumar & Hedges, 1998; Murphy et al., 2001). In addition, 
cetaceans and hippopotamuses (Hippopotamus amphibius) form a monophyletic group deeply 
nested within Cetartiodactyla while camels and pigs are basal to this order (Boisserie et al., 
2005; Gatesy 1997; Gatesy et al., 1996; Nikaido et al., 1999). The molecular clock estimate for 
the divergence of the artiodactyls and cetaceans is about 60 Mya (Arnason and Gullberg 
1996). It is believed that early cetaceans initially lived in freshwater habitats as terrestrial 
quadrupeds and were partly dependent on freshwater at some stages of their life before 
they gradually adapted to the marine environment and became fully aquatic marine 
mammals in the end (Thewissen & Williams, 2002). The adaptation of immune response in 
cetaceans is supposed to be critical to cetaceans in their move from land to water, which is 
an enormous shift in habitat environment. Since major qualitative differences in 
microorganisms and infectious diseases are believed to exist between marine and terrestrial 
environments (McCallum et al., 2004), the immune genes of primitive cetaceans are 
supposed to be adapted for defending against distinct pathogens in aquatic environment. 
Several empirical studies showed that heterogeneity in selection pressure directly correlates 
with MHC gene diversity (Bernatchez & Landry, 2003; Charbonnel & Pemberton, 2005; 
Wegner et al., 2003).  
Both class I and class II MHC gene families have been shown to evolve according to the 
birth-and-death process (Nei et al., 1997). The MHC class II loci of mammals have 
homologous relationships and slower rate of birth-and-death evolution than that of class I 
loci (Takahashi et al., 2000). Takahashi et al. (2000) used long nucleotide sequences (573 bp) 
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the time of origin and evolutionary relationships of these loci. Their result showed the 
definite grouping of sequences from different genes. However, only three species from 
Cetartiodactyla (pig, cattle, and sheep) were studied while the evolutionary relationships of 
MHC genes among Cetartiodactyla remain unresolved. We may know how and when the 
habitat shift, accompanied by the change of foreign antigens, affected the history of co-
evolution between MHC genes and pathogens when cetaceans moved from land to water by 
interpreting the phylogenetic relationship and divergence time estimates of MHC class II 
genes in cetaceans and their close-related terrestrial species. Yang et al. (2010) constructed 
phylogenetic trees and estimate the divergence times of clades using cDNA sequences (616 
bp) of DQB and DRB genes that encode the extracellular domain (including PBR), 
connecting peptide, transmembrane, and part of the cytoplasmic tail from cetaceans 
(bottlenose dolphins; T. truncatus and T. aduncus), hippo and other ungulates, together with 
other MHC class II -chain genes from fish, frog, chicken, and other mammals. It showed 
that the phylogenetic relationships in the respective cetartiodactyl group in DQB and DRB 
clades in this study do not correspond to that in the previously accepted species tree. It is 
striking to observe that cetaceans (bottlenose dolphins) and artiodactyls (pig, hippo, and 
ruminants) form two distinct clades in both DQB and DRB phylogenies, rather than being of 
the same clade with hippo and dolphin as the closest relatives. The authors presumed that 
the sequences of cetaceans and artiodactyls are paralogous in DQB and DRB genes, 
respectively. Paralogous genes separated by gene duplication events, which has been 
proposed to be a major force in MHC evolution, while the orthologous genes separated by 
speciation events. (Klein et al., 1998). The gene duplication has been observed in the genetic 
organization of MHC genes in many mammals. In bovine MHC class II genes, for example, 
two DQB genes and nine DRB genes were detected, with eight of the DRB genes being likely 
pseudogenes (Ellis & Ballingall, 1999). Since natural selective pressures of infectious diseases 
between terrestrial and aquatic (especially marine) environments are different (McCallum et 
al., 2004), the pathogen-driven evolution (Meyer & Thomson, 2001) was supposed to be very 
likely the driving force of birth-and-death process in the MHC genes for the cetaceans and 
their terrestrial relatives leading to the paralogy (Yang et al., 2010). Besides, if the MHC 
genes of cetaceans did evolve in a different direction from their terrestrial relatives, it is 
important to know when cetaceans entered into the water and how their MHC genes 
evolved. For estimating the divergence time of MHC genes of cetartiodactyls, Bayesian 
inference (BI) tree with birth-death clock model provided better estimates of divergence 
time of MHC genes than neighbor-joining (NJ) tree using Kimura 2-parameter model with 
linearized tree method (Yang et al., 2010). The result suggested that cetaceans (T. truncatus 
and T. aduncus) diverged from artiodactyls (pig, hippo, and ruminants) about 60 Mya or 
slightly earlier, which is comparable with the first appearances of fossil cetaceans around 
53.5 Mya, artiodactyls at 55 Mya, and other molecular estimate of divergence time of 
cetacean/artiodactyl at 60 Mya (Arnason & Gullberg, 1996; Arnason et al., 2000, 2004; 
Theodor, 2004). However, only two close-related species of true dolphins were included in 
this study, and therefore the full-length sequences from other early divergence of cetaceans 
(such as baleen whales and river dolphins) are needed for confirming the hypothesis. 
Furthermore, several other mammal groups have also made the evolutionary transition 
from land to sea, such as pinnipeds, sea otters, polar bears and sirenians. Studying MHC 
genes of these marine mammals and their terrestrial relatives will provide us further insight 
into the evolution of MHC genes.  
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Some MHC alleles from a species are more similar to the alleles of different species than 
each other, rather than the species-specific pattern. This scenario has been referred to as 
trans-species evolution (Klein, 1987), which is one of the characteristics of the MHC genes 
and has been identified in a wide range of taxa including primates, salmonids, ungulates, 
pinnipeds, rodents, geckos, and warblers (reviewed by Piertney & Oliver, 2006). In 
cetaceans, most of the phylogenetic analyses of PBR sequences of DQB and DRB loci also 
show trans-specific pattern (Baker et al., 2006; Hayashi et al., 2003; Xu et al., 2009; Yang et 
al., 2008; Heimeier et al., 2009). Involving in 28 species of cetaceans, Xu et al. (2009) shows 
no or weak support for clades of same family or species in the phylogenetic relationship 
among DQB alleles. For example, no monophyletic groups for two cetacean suborders 
(Mysticeti and Odontoceti) were found. In addition, some alleles were more closely related 
with those from other species even from other families rather than with intraspecific alleles. 
It raised question about whether such pattern of apparent transspecific sharing of alleles is 
due to common lineages or convergence of independent lineages (Yeager & Hughes, 1999). 
Coalescent and neutral theories predict that two species will share a proportion of alleles at 
any given locus immediately following divergence from their ancestral form. Over time, 
from a phylogenetic perspective one should see a gradual progression from polyphyly, 
through paraphyly, to monophyly. However, balancing selection, which acts on MHC 
genes, retains alleles among species for considerably longer periods of time and increases 
the time over which there is incomplete lineage sorting and delaying the time to monophyly 
(Piertney and Oliver, 2006). If the trans-species evolutionary pattern in cetaceans described 
in previous studies is due to common lineage, the sharing of similar alleles by a common 
ancestry between cetacean families would require their preservation for a considerably long 
time, such as Delphinidae (dolphins) / Monodontidae (beluga) separating at least 15 Mya 
(Arnason et al., 2004), or Delphinidae/Lipotidae (baiji) 25 Mya (Nikaido et al., 2001). The 
result in Yang et al. (2010) supported this assumption. The authors estimated the divergence 
time of two close-related dolphin species (Tursiops truncatus and T. aduncus) in DQB and 
DRB genes (>20 Mya) is much earlier than the separation date of these two species. The 
earliest fossils identifiable as Tursiops dated to only 4-7 Mya (Barnes 1990), as well as the 
emergence of oldest delphinid which is possible 11 Mya of latest Miocene (Barnes 1977). The 
authors postulated these allelic lineages of Tursiops MHC genes may emerge by gene 
duplication during the period of early radiation of small toothed whales (from late 
Oligocene to early Miocene, 22 Mya (Arnason et al., 2004). Since MHC alleles could be 
persisted over extremely long time period by balancing selection (Bernatchez and Landry 
2003), these lineages were maintained for a long evolutionary period through speciation 
events of cetaceans and cause the observed scenario of trans-species evolutionary pattern. 
Apart from trans-species evolution, several studies on phylogenetic analyses of PBR 
sequences of DQB and DRB loci showed other interesting evolutaionay patterns. The first is 
the homoplasy of PBR in DQB and DRB genes (Baker et al., 2006; Yang et al., 2010). The DQB 
and DRB genes are thought to have arisen early in the placental mammals and evolved 
independently such that sequences of each gene can be recognized as orthologous across 
lineages (e.g., Ellis 1999; Groenen et al., 1990). Thus, sequences from either gene of different 
mammals should group together with their orthologs in phylogenetic reconstruction, 
exclusive of sequences from paralogous loci. Although this pattern was observed when the 
longer or full length of the fragment was used (Baker et al., 2006; Yang et al., 2010), it was 
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longer or full length of the fragment was used (Baker et al., 2006; Yang et al., 2010), it was 





sequences of Tursiops are sistergroups within the clade containing all other DRB sequences 
of mammals (Yang et al., 2010), and cetacean DQB sequences grouped with some cetacean 
DRB sequences and appeared most closely related to the primate and ungulate DQB (Baker 
et al., 2006). A similar pattern of DQB/DRB convergence is reported in the canids (Seddon & 
Ellegren, 2002). The best explanation is convergent evolution (Yeager & Hughes, 1999), and 
small-scale conversion of the DRB by DQB alleles seems most consistent with the available 
evidence and is the most potentially responsible for convergence (Baker et al., 2006). 
Second, Xu et al. (2008) reported that the DQB exon 2 of the baiji revealed striking similarity 
with those of the finless porpoise. Especially, some identical alleles were shared by both 
species at the DQB locus. The scenario of total identity amongst MHC alleles from different 
species have been reported, but most of which are restricted to congeneric species and rarely 
from above genus level (reviewed by Xu et al., 2008). The two species are highly divergent 
with each other, with the baiji included in Lipotidae of the superfamily Lipotoidea and the 
finless porpoise in Phocoenidae of the superfamily Delphinoidea, respectively. It is difficult 
to explain the identity and high similarity between distantly related species using trans-
species evolution. Unlike trans-species evolution, the identity and similarity that are shared 
in the case of convergent evolution are not the result of evolution from a common ancestor, 
but typically explained as the result of common adaptive solutions to similarly 
environmental pressures. It is known that baiji and finless porpoise are sympatric in the 
Yangtze River and facing similar selection pressure from the similar freshwater 
environment, shaping the same motifs or alleles in both species in order to adapt to the 
similar pressures (Xu et al., 2008). Further studies are needed to clarify the convergent 
evolution with more MHC loci or other molecular data. 
The third is adaptive differentiation. Yang et al. (2007) reported that the phylogenetic 
analyses of the full-length region and exon 2 of DQB and DRB showed no mixture but a 
clear division between T. truncatus (from Taiwan and Japan) and T. aduncus (from Taiwan 
and Indonesia). This is an intriguing result compared to the general trans-specific pattern of 
evolution observed for cetacean MHC loci. The species-specific clustering of DQB or DRB 
loci has been described in a few species (South African antelope by van der Walt et al. 2001, 
cotton rats by Pfau et al. 1999). Compared with T. truncatus which generally appears in 
deep, offshore waters, T. aduncus inhabits shallow, tropical, coastal waters and its body size 
is smaller than T. truncatus (Zhou & Qian, 1985). Because shallow waters along the coast are 
influenced by terrestrial runoff, the diversity and abundance of pathogens in the coastal 
waters likely differ from those in oceanic areas (Hayashi et al., 2006). Moreover, Wang et al. 
(1994) showed the parasites, Phyllobothrium, Monorhygma, and Crassicauda, are found 
only in the offshore form of T. truncatus, whereas Braunina is found in the coastal 
population in the western North Atlantic. Since T. truncatus and T. aduncus have different 
diets, microflora, and distributions (Wang et al., 1999, Wang 2003), thus it is reasonable to 
assume that different selective pressures from pathogens exist in oceanic (T. truncatus) and 
coastal (T. aduncus) waters. The most likely explanation is that species-specific alleles may 
have adaptive value for certain species and can be discriminately selected. When the 
selective advantage of MHC alleles differs among environments that vary in the diversity 
and abundance of pathogens, pathogen-driven directional selection could act differentially 
among individuals from distinct populations (Bernatchez and Landry 2003). This would 
have resulted in sequence divergence of exon 2 in bottlenose dolphins as observed in the 
study (Yang et al., 2007). The findings in Vassilakos et al. (2009) provided further support of 
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this hypothesis. They showed coastal and offshore samples of Tursiops from various sources 
exhibited significantly different profiles of PBR (Coastal: Western North Atlantic coastal T. 
truncatus and T. aduncus off South Africa; offshore: T. truncatus from the Mediterranean Sea, 
Eastern North Atlantic, Western North Atlantic pelagic, and the eastern North Pacific off 
southern California). Similar functional analysis has been used in human studies (reviewed 
by Vassilakos et al., 2009). We do not know how similar the pathogen environments are for 
coastal T. truncatus and T. aduncus. Although the possible pathogen-specific interactions are 
not known, it suggested the directional selection in local, differentiated populations because 
the pattern of differences and similarities is consistent with this interpretation (Vassilakos et 
al., 2009). Since extant cetacean fauna consists of more than 80 species and live in varied 
habitats, such as ocean, estuary, polar regions, and river, it is interesting to elucidate the 
evolution of cetacean MHC genes by obtaining more sequences and loci from a variety of 
cetacean species.  
4. Conclusion 
Over the past two decades cetacean MHC immunogenetics has developed from a genetic 
diversity study to a diverse field exploiting new methodologies to identify the evidence of 
pathogen-host coevolution. The previous studeis set out to achieve two major goals: (1) to 
assess levels of MHC variation in cetaceans to elucidate the role of selection in the evolution 
of cetacean MHC loci; (2) to characterize PBR and full-length MHC class II DQB and DRB 
genes in cetaceans and shed light on the evolution of cetacean MHC genes by performing 
the phylogenetic analyses. Although the information provides aspects for discussing the 
relationship between emergence of cetaceans and evolutionary pattern of MHC genes, the 
key questions remain the same. What MHC polymorphisms affect differential susceptibility 
to infectious diseases in cetaceans? What extent has selection by particular pathogens or 
enviroment given rise to observed polymorphism in MHC genes? Can the identification of 
certain allele related to specific environment or population identify loci that  are targets for 
conservation interventions? For these highly mobile marine species, the expectation would 
be for random-mating across broad geographic ranges, but various studies have shown 
restricted gene flow over a range of hundreds or even tens of kilometers (Natoli et al. 2005). 
We could expect, and cannot excluded, the differentiation by drift at MHC loci. However, 
the stronger indications from previous studies reflect both the long-term unifying effects of 
balancing selection, and local, differentiated populations that suggest directional selection. 
As emerging infectious diseases in the marine environment are becoming more widely 
recognized (Harvell et al., 1999), investigations into the genetics of host susceptibility are 
becoming increasingly important. It appears that most new diseases are not caused by new 
microorganisms, but rather by known agents infecting new or previously unrecognized 
hosts. Disease outbreaks are favored by the undermining of host resistance (Harvell et al., 
1999), by a shift in balance in the microevolution between pathogens and host, or by the 
introduction of a novel pathogen into an immunogenetically naive host (Paterson 1998). The 
rise of catastrophic disease epidemics in marine organisms brings into question the balance 
between pathogen virulence and host resistance in these systems (Harvell et al., 1999). In 
fact, recent study in marine mammals proposes a link between MHC polymorphism and an 
effective response to both pathogentic and toxicogenic challenge (Acevedo-Whitehouse et 
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encroachment, the risk of exposure to novel pathogens of marine species is increased 
(Harvell et al., 1999), especially for coastal species such as T. aduncus. Yang et al. (2010) 
clearly show that MHC gene sequences of T. aduncus and T. truncatus diverged at least 20 
Mya that may enable them to bear different assignment for pathogen defense, indicating 
that T. aduncus might be able to survive under the pathogen pressure in coastal waters. The 
species’ near-shore distribution makes it vulnerable to environmental degradation, direct 
exploitation, and fishery conflicts (Hammond et al., 2008). Still of concern is the potential 
transmission of novel pathogens into populations of T. aduncus not equipped with the 
specific immunogenetic repertoire necessary for an effective immune response. Dolphin 
health and population status reflect the effects of natural and anthropogenic stressors on the 
species (Wells et al., 2004). Monitoring the health of T. aduncus could serve as not only 
sentinels of the health and status of lower trophic levels in the marine system, but also 
indicators and warning of impacts on human as more humans inhabit coastal regions. 
Furthermore, previous studies indicate that cetacean MHC genes have been adapted to 
different marine environments. Their ability to defend against terrestrial pathogens needs 
investigation and close monitor, especially in these times there are potential risks of 
epidemics for cetaceans when they have more occasions for encountering terrestrial 
pathogens through human exploitation of marine environments or, directly, keeping 
cetaceans in captivity.  
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1. Introduction 
Originally recognized for their role in triggering T cell responses that caused the rejection of 
transplanted tissue, it is now known that MHC-encoded molecules are involved in immune-
surveillance and antigen presentation to T lymphocytes. These MHC molecules act as 
“signposts” that displays fragmented pieces of an antigen (viral proteins in virus-infected 
cells or mutated proteins in tumor cells) on the host cell surface. Because viruses can infect 
virtually all nucleated cells, class I molecules are constitutively expressed on almost all 
nucleated cells. The association of antigenic peptides and MHC molecules is a saturable 
interaction and once formed, persist for a sufficiently long time to be recognized by the few 
T cells specific for the antigen as they circulate through. The outcome of TC cells-mediated 
killing of the virus-infected cells is usually via apoptosis.  
2. Antigen processing and presentation 
The cellular pathways of antigen processing are designed to generate peptides that have 
structural characteristics required for associating with MHC molecules and to place these 
peptides in the same cellular location as the appropriate MHC molecules with the available 
peptide-binding cleft. Peptide binding to MHC molecules is essential for stable assembly 
and surface expression of the MHC molecules. 
Class I MHC-associated peptides may be the products of viruses or other intracellular 
microbes that infect cells or protein antigens produced by mutated oncogenes in tumour 
cells (Rammensee 1995). They are produced by proteolytic degradation of cytosolic proteins 
in the proteasome, a large multiprotein enzyme complex found in the cytoplasm (Tanaka 
and Kasahara 1998). Two catalytic subunits of the proteasome, called low molecular weight 
protein 2 (LMP-2) and LMP-7 are encoded by genes in the MHC locus (York and Rock 1996). 
Peptides generated in the cytosol are translocated into the endoplasmic reticulum (ER) by 
specialized transport associated with antigen processing (TAP) proteins encoded by the 
TAP1 and TAP2 genes, also in the MHC gene complex. They mediate active ATP-dependent 
ferrying of peptides from the cytosol into the ER lumen (Spiliotis et al. 2000; Momburg et al. 
2001).  
Class I α chains and β2-microglobulin are synthesized in the ER and remain attached to the 
TAP complex by an ER chaperone protein linker called tapasin until they are loaded with 
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“signposts” that displays fragmented pieces of an antigen (viral proteins in virus-infected 
cells or mutated proteins in tumor cells) on the host cell surface. Because viruses can infect 
virtually all nucleated cells, class I molecules are constitutively expressed on almost all 
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interaction and once formed, persist for a sufficiently long time to be recognized by the few 
T cells specific for the antigen as they circulate through. The outcome of TC cells-mediated 
killing of the virus-infected cells is usually via apoptosis.  
2. Antigen processing and presentation 
The cellular pathways of antigen processing are designed to generate peptides that have 
structural characteristics required for associating with MHC molecules and to place these 
peptides in the same cellular location as the appropriate MHC molecules with the available 
peptide-binding cleft. Peptide binding to MHC molecules is essential for stable assembly 
and surface expression of the MHC molecules. 
Class I MHC-associated peptides may be the products of viruses or other intracellular 
microbes that infect cells or protein antigens produced by mutated oncogenes in tumour 
cells (Rammensee 1995). They are produced by proteolytic degradation of cytosolic proteins 
in the proteasome, a large multiprotein enzyme complex found in the cytoplasm (Tanaka 
and Kasahara 1998). Two catalytic subunits of the proteasome, called low molecular weight 
protein 2 (LMP-2) and LMP-7 are encoded by genes in the MHC locus (York and Rock 1996). 
Peptides generated in the cytosol are translocated into the endoplasmic reticulum (ER) by 
specialized transport associated with antigen processing (TAP) proteins encoded by the 
TAP1 and TAP2 genes, also in the MHC gene complex. They mediate active ATP-dependent 
ferrying of peptides from the cytosol into the ER lumen (Spiliotis et al. 2000; Momburg et al. 
2001).  
Class I α chains and β2-microglobulin are synthesized in the ER and remain attached to the 
TAP complex by an ER chaperone protein linker called tapasin until they are loaded with 
high-affinity peptides (Momburg and Tan 2002). These components collectively form the 
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peptide-loading complex. The class I molecules, once loaded, exit the ER at unique exit sites, 
transit through the Golgi apparatus, and reach the cell surface to display their bound 
peptides for recognition by specific CD8+ TC cells. TC cell-mediated killing is usually via 
apoptosis, mediated mainly by granule exocytosis, which releases granzymes and perforin.  
MHC molecules that fail to obtain high affinity peptides are either subjected to immediate 
degradation or short term expression at the cell surface followed by endocytosis and 
degradation (Spiliotis et al. 2000).  
Antigen presentation via MHC class I is regulated by interferon (IFN)-γ which increases 
expression of the class I molecules, transporter proteins (TAP1 and TAP2) and 
immunoproteasome subunits (LMP2 and LMP7) via transcriptional regulation (Momburg et 
al. 2001). The induction of TAP by IFN-γ is more rapid than that of MHC class I molecules, 
which is consistent with the view that the constitutive level of TAP expression is insufficient 
to support inducible increases of MHC class I (Lobigs et al. 2003). 
3. Immune evasion strategies of MHC class I antigen presentation by viruses 
The ability of the MHC class I molecules to sample intracellular milieu and present antigens 
to TC cells poses great threat to viruses. To freely replicate in infected cells, viruses have 
evolved numerous strategies that target key stages of the MHC class I antigen presentation 
pathway, with the goal of preventing the presentation of viral peptides to TC cells. In order 
to circumvent this problem, many viruses have evolved strategies to interfere with the 
antigen presentation pathway. If a virus could inhibit the MHC presentation pathway, that 
virus would become invisible to TC cells and would be able to replicate.  
Since the first descriptions of adenovirus protein binding to MHC Class I molecules over 20 
years ago, there have been many reports of virus counter-attack strategies aimed at the 
cellular immune response. The main aim of immune-evasion strategies by viruses is to 
decrease the cell surface expression of the MHC molecules. Numerous viral proteins have been 
found to inhibit components of the MHC class I assembly pathway. Several stages of the 
antigen presentation pathway have been identified as common target sites for these viral 
proteins. 
3.1 Viral interference with gene transcription 
Transcription of key players of the class I antigen presentation pathway is commonly 
targeted by many viruses such as human oncogenic adenovirus 12 (Ad12), human 
immunodeficiency virus 1 (HIV-1) and bovine papillomavirus (BPV) (Ambagala et al. 2005). 
Many viral genes which encode proteins that modulate host immune responses have been 
identified. The E1A viral protein of Ad12 inhibits transcription of nearly all components of 
the MHC class I pathway, including α-heavy chain, β2m, TAP1, TAP2, LMP2, LMP7 and 
tapasin (Friedman and Ricciardi 1988; Rotem-Yehudar et al. 1994). Similarly, the human 
cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) also inhibit gene 
transcription by disrupting the IFN-γ induced up-regulation of the expression of genes 
encoding many components of the MHC class I heavy complex (Miller et al. 1999). 
The E7 protein of oncogenic human papillomavirus (HPV) type-18 has been shown to 
downregulate the TAP1 gene transcription by repressing its promoter activity. The E1A 
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protein of adenovirus (Ad) type-12 also has similar inhibitory activity on the TAP1 gene 
transcription (Abele and Tampé 2006). Although both DNA viruses belong to different virus 
classes, the resemblance in structure and functions of the two proteins may be mediating the 
effects. 
The human immunodeficient virus type 1 (HIV-1) Tat gene encodes a protein that 
transactivates transcription of the viral long terminal repeat of HIV-1. It is essential for HIV- 
gene expression, replication and infectivity. The Tat protein is also able to repress several 
cellular gene promoters including the heavy chain of the class I molecule and the β2m genes 
of the MHC class I (Carroll et al. 1998; Cohen et al. 1999). Bovine papillomavirus E5 and E7 
proteins also inhibit transcription of class I heavy chain (Ashrafi et al. 2006).   
3.2 Viral interference with peptide generation    
The central cytoplasmic processing unit for the generation of peptides for the MHC class I 
antigen presentation pathway is the proteasome. The degradation of viral proteins into short 
peptides in the proteasome is a highly complex process and proteolysis is regulated in an 
ATP-dependent manner. The proteasome recognizes and unfolds ubiquitylated proteins 
through its 19S subunit and target deubiquitylated forms of these substrates to the 20S 
proteolytic subunit. 
Several viruses interfere with the generation of high affinity peptides to be loaded onto and 
expressed by the MHC class I complex. These include Epstein-Barr virus 1 (EBV), Kaposi’s 
sarcoma herpesvirus (KSHV), murine leukemia virus (MuLV) and again, HIV-1 Tat protein. 
The EBV genome encodes EBV nuclear antigen 1 (EBNA-1) protein that contains long 
repeats of glycine and alanine residues that are resistant to proteasomal processing 
(Dantuma 2002).  It was shown that these repeats may interfere with the recognition and 
unfolding functions of the 19S subunit, rather than inhibiting ubiquitylation or proteolytic 
activity.  
KSHV encodes a protein known as latency-associated nuclear antigen 1 (LANA1) which 
resembles the inhibitory properties of EBNA1. However, the repetitive acidic sequence is 
rich in glutamine, glutamic acid and aspartic acid residues; differing from that of EBNA1. 
As LANA1 and EBNA1 have no sequence homology, one possible explanation may be that 
the two have similar structural features with related inhibitory properties. Nonetheless, 
because the mechanism of antigen processing by the proteasome is the least well-
characterized event in the MHC class I presentation pathway, it may be that the inhibition is 
occurring at a step in the proteasomal degradation that is yet to be identified (Hansen and 
Bouvier 2009). 
The Tat regulatory protein produced by HIV-1 very early after infection that is capable of 
repressing gene transcription, also has a role in inhibiting the generation of peptides. This 
protein competes with the IFN-γ inducible 11S regulator for binding to the 20S proteasome. 
Binding of Tat to the 20S proteasome inhibits the peptidase and proteotytic activity of 20S 
proteasome (Gavioli et al. 2004). The MuLV, an oncogenic retrovirus, takes advantage of the 
peptide cleavage specificity of the proteasome in order to prevent the generation of specific 
immunodominant epitopes and this is achieve only via a single amino acid change in a 
target protein of MuLV (Beekman et al. 2000).  
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peptide-loading complex. The class I molecules, once loaded, exit the ER at unique exit sites, 
transit through the Golgi apparatus, and reach the cell surface to display their bound 
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years ago, there have been many reports of virus counter-attack strategies aimed at the 
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Many viral genes which encode proteins that modulate host immune responses have been 
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tapasin (Friedman and Ricciardi 1988; Rotem-Yehudar et al. 1994). Similarly, the human 
cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) also inhibit gene 
transcription by disrupting the IFN-γ induced up-regulation of the expression of genes 
encoding many components of the MHC class I heavy complex (Miller et al. 1999). 
The E7 protein of oncogenic human papillomavirus (HPV) type-18 has been shown to 
downregulate the TAP1 gene transcription by repressing its promoter activity. The E1A 
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protein of adenovirus (Ad) type-12 also has similar inhibitory activity on the TAP1 gene 
transcription (Abele and Tampé 2006). Although both DNA viruses belong to different virus 
classes, the resemblance in structure and functions of the two proteins may be mediating the 
effects. 
The human immunodeficient virus type 1 (HIV-1) Tat gene encodes a protein that 
transactivates transcription of the viral long terminal repeat of HIV-1. It is essential for HIV- 
gene expression, replication and infectivity. The Tat protein is also able to repress several 
cellular gene promoters including the heavy chain of the class I molecule and the β2m genes 
of the MHC class I (Carroll et al. 1998; Cohen et al. 1999). Bovine papillomavirus E5 and E7 
proteins also inhibit transcription of class I heavy chain (Ashrafi et al. 2006).   
3.2 Viral interference with peptide generation    
The central cytoplasmic processing unit for the generation of peptides for the MHC class I 
antigen presentation pathway is the proteasome. The degradation of viral proteins into short 
peptides in the proteasome is a highly complex process and proteolysis is regulated in an 
ATP-dependent manner. The proteasome recognizes and unfolds ubiquitylated proteins 
through its 19S subunit and target deubiquitylated forms of these substrates to the 20S 
proteolytic subunit. 
Several viruses interfere with the generation of high affinity peptides to be loaded onto and 
expressed by the MHC class I complex. These include Epstein-Barr virus 1 (EBV), Kaposi’s 
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The EBV genome encodes EBV nuclear antigen 1 (EBNA-1) protein that contains long 
repeats of glycine and alanine residues that are resistant to proteasomal processing 
(Dantuma 2002).  It was shown that these repeats may interfere with the recognition and 
unfolding functions of the 19S subunit, rather than inhibiting ubiquitylation or proteolytic 
activity.  
KSHV encodes a protein known as latency-associated nuclear antigen 1 (LANA1) which 
resembles the inhibitory properties of EBNA1. However, the repetitive acidic sequence is 
rich in glutamine, glutamic acid and aspartic acid residues; differing from that of EBNA1. 
As LANA1 and EBNA1 have no sequence homology, one possible explanation may be that 
the two have similar structural features with related inhibitory properties. Nonetheless, 
because the mechanism of antigen processing by the proteasome is the least well-
characterized event in the MHC class I presentation pathway, it may be that the inhibition is 
occurring at a step in the proteasomal degradation that is yet to be identified (Hansen and 
Bouvier 2009). 
The Tat regulatory protein produced by HIV-1 very early after infection that is capable of 
repressing gene transcription, also has a role in inhibiting the generation of peptides. This 
protein competes with the IFN-γ inducible 11S regulator for binding to the 20S proteasome. 
Binding of Tat to the 20S proteasome inhibits the peptidase and proteotytic activity of 20S 
proteasome (Gavioli et al. 2004). The MuLV, an oncogenic retrovirus, takes advantage of the 
peptide cleavage specificity of the proteasome in order to prevent the generation of specific 
immunodominant epitopes and this is achieve only via a single amino acid change in a 
target protein of MuLV (Beekman et al. 2000).  
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3.3 Viral inhibition of peptide transport mechanisms 
The translocation of peptides into the ER by TAP represents a key stage in the assembly of 
the MHC class I molecule, since only peptide-loaded class I molecules can leave the ER for 
transport to the cell surface (Paulsson and Wang 2004). The TAP complex is composed of 
TAP1 and TAP2, each with an amino-terminal transmembrane domain and a carboxy-
terminal nucleotide-binding cytoplasmic domain. The two helices form a pore across the ER 
membrane through which antigenic peptides can be transported. Peptide transport by TAP 
consists of two basic steps: ATP-free binding of peptide to TAP and ATP-dependent 
translocation of peptide into the ER lumen (Abele and Tampé 2006). It is thought that 
binding of prptides to the cytoplasmic domains triggers a conformational change that 
stimulates ATP hydrolysis, thereby providing energy required for peptide translocation. 
However, the mechanism underlying this process is not completely understood. 
The human herpes simplex virus (HSV)-encoded protein, ICP47 (infected cell protein 47) 
inhibits the first step of peptide transport (Ambagala et al. 2005). By binding with high 
affinity to the cytoplasmic domain of human TAP, ICP47 inhibits peptide binding to and 
thereby ATP hydrolysis of TAP. In addition, evidence also suggests that ICP47 may act as a 
competitive inhibitor by binding with high affinity and induces a conformational change in 
TAP. This effect may be sufficient to cause destabilization and inactivation of TAP, thus 
turning off ATP hydrolysis and peptide translocation (Orr et al. 2005). ICP47 is highly 
species specific, since it inhibits with high affinity peptide binding to human TAP but not to 
TAP from mice, rabbit or guinea pigs. The region of TAP that interacts with ICP47 is, 
however, yet to be determined. 
Human cytomegalovirus (HCMV)-encoded protein, US6, also targets the TAP but through a 
mechanism that differs from that of ICP47. US6 is an ER-resident integral membrane protein 
that binds to the ER-luminal domain of TAP and inhibits ATP binding. Like ICP47, US6 
prevents peptide-stimulated ATP hydrolysis by inducing long range conformational 
rearrangements in TAP across the ER membrane (Hewitt et al. 2001). This subsequently 
inhibits peptide translocation and prevents MHC class I assembly. Unlike ICP47, however, 
interaction of US6 to TAP does not affect the peptide binding. 
Another recently identified protein by EBV, BNLF2a, was shown to prevent the binding of 
peptides and ATP to TAP (Horst et al. 2011). Another HIV-1 protein, Nef, blocks the TAP 
transport of peptides into the ER (Cohen et al. 1999; Williams et al. 2002b). Despite the 
different strategies used by ICP47, US6 and BNLF2a to block peptide transport, the common 
goal of these proteins is to block peptide-dependent, ATP-induced conformational changes 
in TAP, thereby exploiting the conformational flexibility of TAP, which is normally required 
for peptide translocation. This  will decrease the available peptide for binding to the MHC 
class I heavy chains that are waiting in the ER; thereby reducing the generation of 
completely assembled class I molecules. 
3.4 Inhibition of tapasin 
Tapasin is a transmembrane glycoprotein that is a crucial component of the peptide-loading 
complex. It has a key role in influencing the generation of peptide repertoire and expression 
of stable MHC class I molecules on the cell surface. Similar to TAP, tapasin is also targeted 
by a number of viral immunoevasins. Tapasin has a chaperone-like function that stabilizes 
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peptide transport, facilitates the removal of peptides weakly bound to MHC class I 
molecules and ensures high affinity peptide access to MHC class I molecules (Williams et al. 
2002a). Only those peptides that can form long-lived complexes with MHC class I molecules 
become part of the presented repertoire at the end of this so-called peptide-editing process. 
The mK3 protein of murine gammaherpesvirus-68 interacts with TAP without affecting 
peptide transport (Boname et al. 2004). The mK3 is located in the ER and Golgi and belongs 
to a large group of proteins named the K3 family that inhibits the surface expression of 
glycoproteins such as MHC class I, ICAM-1 and CD4. The mK3 binds via its C-terminal tail 
to tapasin and TAP, thereby positioning the N-terminal with ubiquitin ligase activity to the 
cytoplasmic tail of the MHC class I for subsequent ubiquitylation and proteosomal 
degradation.  
In addition, mK3 also induces the degradation of both TAP subunits and tapasin via direct 
interactions. In fact, the assembly complex proteins TAP and tapasin are absolutely required 
for mK3’s effect on MHC class I. The absence of TAP or tapasin, or MHC class I mutations 
abrogating interaction with TAP or tapasin, prevents mK3 from binding to MHC class I and 
down-regulating its surface expression (Lybarger et al. 2003). 
The E3/19K protein of the Adenovirus E3 is a transmembrane glycoprotein that inhibits the 
ability of tapasin to bridge TAP to MHC class I molecules by binding to TAP, without 
blocking peptide transport (Bennett et al. 1999). The association of E3/19K with TAP inhibits 
the formation of TAP-tapasin complex and this impairs the inclusion of TAP into the 
peptide-loading complex. This competitive inhibition of the bridging function of tapasin 
delays maturation of tapasin-dependent MHC class I molecule. Thus, the disturbance in the 
MHC-tapasin interaction ultimately prevents the assembly of MHC class I loading complex. 
HCMV also encodes another immediate early protein US3 that directly binds to and inhibits 
the action of tapasin (Park et al. 2004). The association of US3 with tapasin inhibits tapasin-
dependent peptide-loading, thereby preventing optimization of the peptide repertoire 
presented by the class I molecules. This subsequently leads to retention of the MHC class I 
molecules in the ER, although substantial amounts of the class I molecules can still reach the 
cell surface (Park et al. 2004). 
3.5 Viral interference with cell surface expression 
Down-regulation of the cell surface display of class I molecules is an important mechanism 
of immune evasion. Technically, once loaded with peptides, the class I MHC molecules 
leave the ER and translocate to the cell surface through the Golgi apparatus. Many viruses 
have the ability to interfere with these MHC class I trafficking processes (Ambagala et al. 
2005). 
In addition to inhibition of tapasin activity, the E3/19k adenovirus protein directly associate 
with the class I heavy chain and this blocks their transport out of the ER (Bennett et al. 1999). 
This association is mediated by the ER-luminal domains of both proteins and the retention 
effect is mediated by the cytoplasmic domains of E3/19k. Interaction between E3/19k and 
residue 56 of the MHC class I that appears to have crucial roles in modulating the 




3.3 Viral inhibition of peptide transport mechanisms 
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peptide transport, facilitates the removal of peptides weakly bound to MHC class I 
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MHC-tapasin interaction ultimately prevents the assembly of MHC class I loading complex. 
HCMV also encodes another immediate early protein US3 that directly binds to and inhibits 
the action of tapasin (Park et al. 2004). The association of US3 with tapasin inhibits tapasin-
dependent peptide-loading, thereby preventing optimization of the peptide repertoire 
presented by the class I molecules. This subsequently leads to retention of the MHC class I 
molecules in the ER, although substantial amounts of the class I molecules can still reach the 
cell surface (Park et al. 2004). 
3.5 Viral interference with cell surface expression 
Down-regulation of the cell surface display of class I molecules is an important mechanism 
of immune evasion. Technically, once loaded with peptides, the class I MHC molecules 
leave the ER and translocate to the cell surface through the Golgi apparatus. Many viruses 
have the ability to interfere with these MHC class I trafficking processes (Ambagala et al. 
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In addition to inhibition of tapasin activity, the E3/19k adenovirus protein directly associate 
with the class I heavy chain and this blocks their transport out of the ER (Bennett et al. 1999). 
This association is mediated by the ER-luminal domains of both proteins and the retention 
effect is mediated by the cytoplasmic domains of E3/19k. Interaction between E3/19k and 
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MHC class I chaperones are remarkably efficient in only allowing mature MHC molecules 
to exit the ER. The elimination of incompletely assembled or misfolded nascent 
glycoproteins, including MHC molecules, occurs by a process collectively called ER-
associated degradation (ERAD) (Vembar and Brodsky 2008). During ERAD, misassembled 
or misfolded proteins are recognized in the ER lumen and retrotranslocated to the 
cytoplasm, where they are degraded by the ubiquitin-proteasome machinery. 
The HCMV invests heavily in products able to interfere with the MHC class I. Apart from 
US3 and US6 that have abilities to inhibit TAP, there are also other unique short genes 
encoded by the virus: US2, US11, US8 and US10. The US2 and US11 are small membrane 
glycoproteins that target human MHC class I molecules for ERAD. US2 and US11 cause 
ejection of MHC class I heavy chain into the cytoplasm, which results in their proteasomal 
degradation. The US2 cytoplasmic domain appears to have major involvement in this 
process. Besides inhibiting TAP functions previously described, the US3 also possesses a 
novel, non-contagious ER retention sequence that binds to nascent MHC class I heavy 
chains in the ER and targets it to ERAD. This prevents its egress of the assembled class I 
molecules to the cell surface (Park et al. 2004).  
Another HCMV viral product, US8 binds MHC class I molecules in the ER and influence the 
MHC class I-restricted antigen presentation via a mechanism that is yet to be identified 
(Petersen et al. 2003). Lastly, the US10 also shares many features with US3. It associates with 
MHC class I heavy chain and delays the trafficking of peptide-loaded class I molecules out 
of the ER. 
The p12(I) protein of human T-cell leukemia virus type 1 (HTLV-1) also redirects MHC class 
I heavy chains into the cytosol. This protein is localized in the ER and/or Golgi 
compartments, bind to the heavy chain products of the class I molecules, thus preventing 
association of the heavy chain with β2m. This reroutes the MHC class I heavy chain into the 
cytosol for proteasomal degradation (Ambagala et al. 2005). 
The mK3 protein encoded by murine herpesvirus-68, that inhibits TAP and tapasin, also 
induces rapid turnover of MHC class I molecules by a mechanism not involving endocytosis. 
The mK3 protein has been demonstrated to assist the virus in the escape from T cells during 
latent phase of infection. It specifically ubiquitylates MHC class I heavy chains and targets 
them for ERAD. During infection, the expression of mK3 allows the virus to maintain a higher 
level of latency and reduces the number of antiviral TC cells. The mK3 associates with nascent 
MHC class I heavy chains only in the presence of TAP, its main binding partner. Subsequently, 
the complex awaits entry onto the peptide-loading complex and ubiquitylates the C-terminal 
tail of the heavy chain, thereby targeting for ERAD (Lybarger et al. 2003). 
Apart from downregulating the expression of MHC class I molecules, the HIV-1 Nef protein 
is also known to disrupt the trafficking of MHC class I molecules via two mechanisms. First, 
Nef uses the clathrin adaptor AP1 (adaptor protein 1) to divert the trafficking of MHC class I 
molecules directly from the Golgi network to an endocytic compartment before they reach 
the cell surface. This ultimately leads to degradation of the assembled class I molecules in 
the lysosomes (Lorenzo et al. 2001). MCMV m152gene product gp40 protein too may have 
similar effect on the trafficking of the class I molecules. The second mechanism of Nef-
mediated MHC class I down-regulation is enhancement of endocytosis of the class I 
molecules from the cell surface.  
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K3 and K5 proteins of KSHV inhibit the transport of class I molecules to the cell surface and 
induce rapid internalization of class I molecules from the cell surface via endocytosis (Cohen 
et al. 1999; Coscoy and Ganem 2000). Although the two proteins are predominantly located 
in the ER, K3 and K5 do not affect the assembly or transport of MHC class I molecules 
through the secretory pathway. Instead, they mediate ubiquitination of the cell surface 
MHC class I molecules by an unknown mechanism. Once ubiquitinated, internalized class I 
chains are then delivered to endolysosomal vesicles where they undergo degradation.  
4. Multiple targets versus multiple immunoevasin 
While some viruses encode a single immunoevasin to interfere with one or more steps of the 
MHC class I pathway, others encode multiple immunoevasins, targeting at different stages 
of the antigen presentation pathway. A good example of this is the US proteins of HCMV 
that can inhibit gene transcription, TAP and tapasin functions and also the surface 
expression of the MHC class I molecules. The HIV-1 also has three distinct proteins that 
target different site of inhibition, namely the Tat protein that inhibits peptide generation, the 
vpu protein interferes with the synthesis of class I while the Nef protein takes advantage of 
a cellular sorting pathway to pirate MHC class I molecules away from the cell surface. The 
likely reason for producing multiple immunoevasins is to overcome the resistance exerted 
by certain MHC class I alleles. Other reasons could be the cell and/or tissue specific 
adaptations of immunoevasins or that multiple immunoevasins, when expressed 
simultaneously, act synergistically to the benefit of the virus. 
Considering the fact that the virus genome size is somewhat restricted, it would be 
advantageous for a virus to encode a single protein that can interfere with more than one 
mechanism to counter-attack the MHC class I antigen presentation as methods of immune 
evasion. The E3/19K of adenovirus can cause direct retention of MHC class I in the ER, 
inhibits TAP and tapasin functions and also inhibits surface expression. The murine 
herpesvirus mK3 protein also has multiple actions at the peptide generation and TAP 
functions in addition to its interference of the surface expression step.  
5. Consequences of inhibition of MHC class I antigen presentation by viruses 
Inhibition of antigen processing and presentation blocks the assembly and expression of 
stable class I molecules and the display of viral peptides. As a result, cells infected with such 
viruses cannot be recognized or killed by CD8+ TC cells. Natural Killer (NK) cells may be a 
host adaptation to kill these infected cells because NK cells are activated by the absence of 
class I MHC molecules (Brutkiewicz and Welsh 1995). Viruses try to evade recognition by TC 
cells by inhibiting the class I MHC expression, but NK cells have evolved to respond 
specifically to the absence of class I MHC on virus-infected cells. Not surprisingly, there is 
emerging evidence that some viruses may produce proteins that act as ligands for NK 
inhibitory receptors and thus inhibiting NK cell activation. 
In many cases, the viral defense strategies against TC cells and NK cells are intertwined. The 
ability of NK cells to recognize and kill infected cells arises from its capacity to distinguish 
dangerous targets from healthy ‘self’ (Brutkiewicz and Welsh 1995; Biron et al. 1999). This is 
in turn dependent on the expression of both inhibitory and activating receptors. Inhibitory 
receptors on NK cells recognize class I molecules, which are constitutively expressed on 
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US3 and US6 that have abilities to inhibit TAP, there are also other unique short genes 
encoded by the virus: US2, US11, US8 and US10. The US2 and US11 are small membrane 
glycoproteins that target human MHC class I molecules for ERAD. US2 and US11 cause 
ejection of MHC class I heavy chain into the cytoplasm, which results in their proteasomal 
degradation. The US2 cytoplasmic domain appears to have major involvement in this 
process. Besides inhibiting TAP functions previously described, the US3 also possesses a 
novel, non-contagious ER retention sequence that binds to nascent MHC class I heavy 
chains in the ER and targets it to ERAD. This prevents its egress of the assembled class I 
molecules to the cell surface (Park et al. 2004).  
Another HCMV viral product, US8 binds MHC class I molecules in the ER and influence the 
MHC class I-restricted antigen presentation via a mechanism that is yet to be identified 
(Petersen et al. 2003). Lastly, the US10 also shares many features with US3. It associates with 
MHC class I heavy chain and delays the trafficking of peptide-loaded class I molecules out 
of the ER. 
The p12(I) protein of human T-cell leukemia virus type 1 (HTLV-1) also redirects MHC class 
I heavy chains into the cytosol. This protein is localized in the ER and/or Golgi 
compartments, bind to the heavy chain products of the class I molecules, thus preventing 
association of the heavy chain with β2m. This reroutes the MHC class I heavy chain into the 
cytosol for proteasomal degradation (Ambagala et al. 2005). 
The mK3 protein encoded by murine herpesvirus-68, that inhibits TAP and tapasin, also 
induces rapid turnover of MHC class I molecules by a mechanism not involving endocytosis. 
The mK3 protein has been demonstrated to assist the virus in the escape from T cells during 
latent phase of infection. It specifically ubiquitylates MHC class I heavy chains and targets 
them for ERAD. During infection, the expression of mK3 allows the virus to maintain a higher 
level of latency and reduces the number of antiviral TC cells. The mK3 associates with nascent 
MHC class I heavy chains only in the presence of TAP, its main binding partner. Subsequently, 
the complex awaits entry onto the peptide-loading complex and ubiquitylates the C-terminal 
tail of the heavy chain, thereby targeting for ERAD (Lybarger et al. 2003). 
Apart from downregulating the expression of MHC class I molecules, the HIV-1 Nef protein 
is also known to disrupt the trafficking of MHC class I molecules via two mechanisms. First, 
Nef uses the clathrin adaptor AP1 (adaptor protein 1) to divert the trafficking of MHC class I 
molecules directly from the Golgi network to an endocytic compartment before they reach 
the cell surface. This ultimately leads to degradation of the assembled class I molecules in 
the lysosomes (Lorenzo et al. 2001). MCMV m152gene product gp40 protein too may have 
similar effect on the trafficking of the class I molecules. The second mechanism of Nef-
mediated MHC class I down-regulation is enhancement of endocytosis of the class I 
molecules from the cell surface.  
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K3 and K5 proteins of KSHV inhibit the transport of class I molecules to the cell surface and 
induce rapid internalization of class I molecules from the cell surface via endocytosis (Cohen 
et al. 1999; Coscoy and Ganem 2000). Although the two proteins are predominantly located 
in the ER, K3 and K5 do not affect the assembly or transport of MHC class I molecules 
through the secretory pathway. Instead, they mediate ubiquitination of the cell surface 
MHC class I molecules by an unknown mechanism. Once ubiquitinated, internalized class I 
chains are then delivered to endolysosomal vesicles where they undergo degradation.  
4. Multiple targets versus multiple immunoevasin 
While some viruses encode a single immunoevasin to interfere with one or more steps of the 
MHC class I pathway, others encode multiple immunoevasins, targeting at different stages 
of the antigen presentation pathway. A good example of this is the US proteins of HCMV 
that can inhibit gene transcription, TAP and tapasin functions and also the surface 
expression of the MHC class I molecules. The HIV-1 also has three distinct proteins that 
target different site of inhibition, namely the Tat protein that inhibits peptide generation, the 
vpu protein interferes with the synthesis of class I while the Nef protein takes advantage of 
a cellular sorting pathway to pirate MHC class I molecules away from the cell surface. The 
likely reason for producing multiple immunoevasins is to overcome the resistance exerted 
by certain MHC class I alleles. Other reasons could be the cell and/or tissue specific 
adaptations of immunoevasins or that multiple immunoevasins, when expressed 
simultaneously, act synergistically to the benefit of the virus. 
Considering the fact that the virus genome size is somewhat restricted, it would be 
advantageous for a virus to encode a single protein that can interfere with more than one 
mechanism to counter-attack the MHC class I antigen presentation as methods of immune 
evasion. The E3/19K of adenovirus can cause direct retention of MHC class I in the ER, 
inhibits TAP and tapasin functions and also inhibits surface expression. The murine 
herpesvirus mK3 protein also has multiple actions at the peptide generation and TAP 
functions in addition to its interference of the surface expression step.  
5. Consequences of inhibition of MHC class I antigen presentation by viruses 
Inhibition of antigen processing and presentation blocks the assembly and expression of 
stable class I molecules and the display of viral peptides. As a result, cells infected with such 
viruses cannot be recognized or killed by CD8+ TC cells. Natural Killer (NK) cells may be a 
host adaptation to kill these infected cells because NK cells are activated by the absence of 
class I MHC molecules (Brutkiewicz and Welsh 1995). Viruses try to evade recognition by TC 
cells by inhibiting the class I MHC expression, but NK cells have evolved to respond 
specifically to the absence of class I MHC on virus-infected cells. Not surprisingly, there is 
emerging evidence that some viruses may produce proteins that act as ligands for NK 
inhibitory receptors and thus inhibiting NK cell activation. 
In many cases, the viral defense strategies against TC cells and NK cells are intertwined. The 
ability of NK cells to recognize and kill infected cells arises from its capacity to distinguish 
dangerous targets from healthy ‘self’ (Brutkiewicz and Welsh 1995; Biron et al. 1999). This is 
in turn dependent on the expression of both inhibitory and activating receptors. Inhibitory 
receptors on NK cells recognize class I molecules, which are constitutively expressed on 
 
Histocompatibility 140 
most healthy cells but are often not expressed by cells infected with virus. The activity of 
NK cells is down-regulated when inhibitory receptors interact with ‘self’ MHC class I 
(Lanier 1998). Activating receptors on NK cells recognize ligands present on both NK-
susceptible target cells and normal cells, but the influence of inhibitory pathways dominates 
when class I MHC is recognized.  
6. Regulation of MHC class I by flaviviruses 
In contrast to viruses that avoid the host immune response by down-regulating cell surface 
MHC complex expression, it is now recognized that Flaviviruses such as JEV, DV and WNV 
increase the cell surface expression of the MHC molecules (Lobigs et al. 2004; Lin et al. 2006; 
King et al. 2007; Othman et al. 2010). This peculiar phenomenon of the MHC class I immune 
modulation by Flaviviruses poses potential threats to both the replicating virus and host.  
Numerous experiments related to this have been conducted in various cell types and 
species. One particular experiment on mouse embryonic fibroblasts showed six- to ten-fold 
increase in the expression of H-2K and H-2D MHC antigens after infection with WNV, MVE 
and JEV (King 2003). Up-regulation of class I cell surface expression by WNV has also been 
demonstrated in human skin fibroblast cells, accounted for by both cytokine-dependent and 
cytokine-independent mechanisms (Arnold 2004; King et al. 2007). The exact mechanism of 
the up-regulation remains unclear but evidence of increased mRNAs for HLA-A, HLA-B, 
HLA-C, LMP-2 and TAP-1 have been observed, suggesting viral-induced transcription of 
genes involved in the MHC class I complex. 
An alternate mechanism for the up-regulation of MHC class I cell surface expression in 
flavivirus-infected cells, is via the TAP-dependent increase in peptide supply for assembly 
with MHC class I molecules (Momburg et al. 2001; Lobigs et al. 2003). Flavivirus-mediated 
peptide import into the ER lumen is time- and virus dose-dependent and takes place during 
the latent or early productive phase of virus replication (Momburg et al. 2001). Recombinant 
expression of flaviviral proteins in the absence of productive virus replication is unable to 
mimic this effect, establishing the importance of viral RNA replication in the induction of 
MHC class I expression, through both TAP-dependent and independent mechanisms 
(Hershkovitz et al. 2008). The involvement of NFκB, instead of interferons, has been 
demonstrated (Kesson and King 2001); yet no particular viral protein has been implicated in 
the mechanism of action of flaviviral-induced MHC class I surface expression. 
7. Consequences of MHC class I induction by flaviviruses to the human host 
Up-regulation of MHC class I expression by Flaviviruses has obvious potential 
disadvantage to the human host, that is increased susceptibility to attack by class I restricted 
cytotoxic T cells (Douglas and Kesson 1994; Lobigs et al. 2003). Increased cell surface 
expression of MHC class I molecules on infected cells would generally result in more efficient 
killing by TC cells, yet this phenomenon is not observed in flaviviral infections. It has been 
hypothesized that enhancement of MHC class I expression by flaviviruses enhances the 
avidity of the cytotoxic T cell-target interaction. Nevertheless, the mechanisms are yet unclear.  
With the additional up-regulation of co-stimulatory molecules induced by flaviviruses, the 
increase in avidity would be expected to recruit a wider range of low affinity T cells, which 
would otherwise be below the recognition threshold with normal expression of such surface 
 
Regulation of MHC Class I by Viruses 141 
molecules. This could therefore result in the generation of larger range of TC clones than is 
usual for antiviral responses, with accordingly varying affinities for MHC class I-virus 
peptide. This may divert the cytotoxic T cells system to infected cells in G0 of the cell cycle 
phase (that express high cell surface MHC concentrations) in preference to infected, most-
virus-productive cycling cells (with relatively low MHC) (King 2003; King and Kesson 2003). 
The latter produces more virus and does not up-regulate MHC and adhesion molecules to 
the same extent, hence resulting in higher viral propagation and poor viral clearance that 
become part of the viral survival strategy.  
Viral evasion from NK cell recognition involves the selective up-modulation of viral MHC 
class I homologues with structural similarity to endogenous host class I, mimicking ‘self’ 
antigens, that bind inhibitory receptors on NK cells (Orange et al. 2002). WNV- and 
Hepatitis C virus (HCV)-induced up-regulation of MHC class I cell surface expression has a 
pronounced effect on the susceptibility of target cells to NK cell lysis and may lead to 
insufficient induction of the adaptive immune response (Momburg et al. 2001; Herzer et al. 
2003). DV-infected cells expressing high levels of cell surface class I molecules are capable of 
evading lysis by NK cells through higher binding of MHC molecules to low-affinity 
inhibitory receptors of NK cells.  
Clearly, such immunopathological response would result in the destruction of uninfected 
tissues; in virus encephalitis, such damage would exacerbate the encephalitic syndrome (King 
2003). In the case of DV infection, T-cell responses seem to have both protective and 
pathogenic effects in mouse models. Cytotoxic CD8+ T cells that are cross-reactive among DV 
serotypes are thought to be immunopathological during secondary infections in humans, 
exacerbating DHF and causing liver damage through cytotoxic effects (An et al. 2004). 
8. Conclusions 
Viruses and their hosts have coevolved for millions of years. Viruses are obligate 
intracellular pathogens that enter permissive cells, hijack cellular metabolic pathways to 
generate progeny viruses that then leave the cells. At the same time, the human hosts have 
developed an intricate and fine-tuned adaptive immune system designed to combat these 
invaders. However, viruses have evolved a diverse array of strategies to evade the human’s 
immune responses and these strategies are as diverse as the viruses themselves. The down-
regulation of the MHC class I antigen presentation pathway is a strategy used by many 
viruses and this however, is counter-attacked by the presence of NK cells of the host.  
On the other hand, some viruses prefer to up-regulate the cell surface expression of the class 
I molecules. Although the opposite is expected, this strategy also appears to favour the virus 
and results in interference of both the TC cells-mediated cytolysis and the killing by NK 
cells. As the battle between viruses and human immune system continues, the discovery of 
novel immunoevasins and revelations of their modes of actions will continue to broaden the 
horizons of biology. 
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With the additional up-regulation of co-stimulatory molecules induced by flaviviruses, the 
increase in avidity would be expected to recruit a wider range of low affinity T cells, which 
would otherwise be below the recognition threshold with normal expression of such surface 
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molecules. This could therefore result in the generation of larger range of TC clones than is 
usual for antiviral responses, with accordingly varying affinities for MHC class I-virus 
peptide. This may divert the cytotoxic T cells system to infected cells in G0 of the cell cycle 
phase (that express high cell surface MHC concentrations) in preference to infected, most-
virus-productive cycling cells (with relatively low MHC) (King 2003; King and Kesson 2003). 
The latter produces more virus and does not up-regulate MHC and adhesion molecules to 
the same extent, hence resulting in higher viral propagation and poor viral clearance that 
become part of the viral survival strategy.  
Viral evasion from NK cell recognition involves the selective up-modulation of viral MHC 
class I homologues with structural similarity to endogenous host class I, mimicking ‘self’ 
antigens, that bind inhibitory receptors on NK cells (Orange et al. 2002). WNV- and 
Hepatitis C virus (HCV)-induced up-regulation of MHC class I cell surface expression has a 
pronounced effect on the susceptibility of target cells to NK cell lysis and may lead to 
insufficient induction of the adaptive immune response (Momburg et al. 2001; Herzer et al. 
2003). DV-infected cells expressing high levels of cell surface class I molecules are capable of 
evading lysis by NK cells through higher binding of MHC molecules to low-affinity 
inhibitory receptors of NK cells.  
Clearly, such immunopathological response would result in the destruction of uninfected 
tissues; in virus encephalitis, such damage would exacerbate the encephalitic syndrome (King 
2003). In the case of DV infection, T-cell responses seem to have both protective and 
pathogenic effects in mouse models. Cytotoxic CD8+ T cells that are cross-reactive among DV 
serotypes are thought to be immunopathological during secondary infections in humans, 
exacerbating DHF and causing liver damage through cytotoxic effects (An et al. 2004). 
8. Conclusions 
Viruses and their hosts have coevolved for millions of years. Viruses are obligate 
intracellular pathogens that enter permissive cells, hijack cellular metabolic pathways to 
generate progeny viruses that then leave the cells. At the same time, the human hosts have 
developed an intricate and fine-tuned adaptive immune system designed to combat these 
invaders. However, viruses have evolved a diverse array of strategies to evade the human’s 
immune responses and these strategies are as diverse as the viruses themselves. The down-
regulation of the MHC class I antigen presentation pathway is a strategy used by many 
viruses and this however, is counter-attacked by the presence of NK cells of the host.  
On the other hand, some viruses prefer to up-regulate the cell surface expression of the class 
I molecules. Although the opposite is expected, this strategy also appears to favour the virus 
and results in interference of both the TC cells-mediated cytolysis and the killing by NK 
cells. As the battle between viruses and human immune system continues, the discovery of 
novel immunoevasins and revelations of their modes of actions will continue to broaden the 
horizons of biology. 
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1. Introduction 
Immunological reactivity results from differences between the transplant host and donor 
for cell surface determinants known as histocompatibility antigens. Histocompatibility 
antigens that provoke the most severe transplant reactions are encoded by a series of 
genes that reside in a discrete chromosomal region termed the major histocompatibility 
complex (MHC) (Amos 1968). Genes of the human leukocyte antigen (HLA) system 
encode a complex array of histocompatibility molecules that play a central role in immune 
responsiveness and in determining the outcome of hematopoietic stem cell 
transplantation (HSCT) (Beatty, Anasetti et al. 1993; Petersdorf, Longton et al. 1995). The 
primary goal of histocompatibility testing for patients who are undergoing HSCT is the 
identification of a suitable HLA-matched donor to reduce the risk of post-transplant 
complications, which may result from HLA incompatibility. The extensive polymorphism 
of the HLA system, however, makes the selection of a comprehensively, optimally-
matched donor a challenging endeavor, particularly when donors outside of the patient’s 
immediate family are sought. If a suitable donor is not found, clinicians need to explore 
the possibility of permissive HLA mismatches. 
Haploidentical HSCT is curative treatment for patients lacking an HLA-compatible donor or 
cannot wait until a suitable donor can be found (Reisner, Kapoor et al. 1981; Buckley, Schiff 
et al. 1999). Haploidentical HSCT is usually employed with T-cell depletion or positive 
selection of CD34+ cells to avoid severe graft-versus-host disease (GVHD) (Aversa, Tabilio et 
al. 1994). However there are disadvantages, such as potential for graft failure, fatal 
opportunistic infections, and relapse of the treated malignancy. To deal with those 
problems, T-cell “replete” haploidentical HSCT have been performed by researchers in 
Japan (Ichinohe, Uchiyama et al. 2004). These are based on the hypothesis that long-term 
maternal microchimerism (MMc) is associated with acquired immunologic 
hyporesponsiveness to non-inherited maternal antigen (NIMA) (Andrassy, Kusaka et al. 
2003; Dutta, Molitor-Dart et al. 2009). T-cell replete HSCT, without GVHD, could be 
accomplished by using this phenomenon of feto-maternal tolerance. Unfortunately, graft 
rejection and hyperacute GVHD have been reported in HSCT from NIMA-mismatched 
siblings, despite detecting of MMc (Okumura, Yamaguchi et al. 2007). Therefore, 
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1. Introduction 
Immunological reactivity results from differences between the transplant host and donor 
for cell surface determinants known as histocompatibility antigens. Histocompatibility 
antigens that provoke the most severe transplant reactions are encoded by a series of 
genes that reside in a discrete chromosomal region termed the major histocompatibility 
complex (MHC) (Amos 1968). Genes of the human leukocyte antigen (HLA) system 
encode a complex array of histocompatibility molecules that play a central role in immune 
responsiveness and in determining the outcome of hematopoietic stem cell 
transplantation (HSCT) (Beatty, Anasetti et al. 1993; Petersdorf, Longton et al. 1995). The 
primary goal of histocompatibility testing for patients who are undergoing HSCT is the 
identification of a suitable HLA-matched donor to reduce the risk of post-transplant 
complications, which may result from HLA incompatibility. The extensive polymorphism 
of the HLA system, however, makes the selection of a comprehensively, optimally-
matched donor a challenging endeavor, particularly when donors outside of the patient’s 
immediate family are sought. If a suitable donor is not found, clinicians need to explore 
the possibility of permissive HLA mismatches. 
Haploidentical HSCT is curative treatment for patients lacking an HLA-compatible donor or 
cannot wait until a suitable donor can be found (Reisner, Kapoor et al. 1981; Buckley, Schiff 
et al. 1999). Haploidentical HSCT is usually employed with T-cell depletion or positive 
selection of CD34+ cells to avoid severe graft-versus-host disease (GVHD) (Aversa, Tabilio et 
al. 1994). However there are disadvantages, such as potential for graft failure, fatal 
opportunistic infections, and relapse of the treated malignancy. To deal with those 
problems, T-cell “replete” haploidentical HSCT have been performed by researchers in 
Japan (Ichinohe, Uchiyama et al. 2004). These are based on the hypothesis that long-term 
maternal microchimerism (MMc) is associated with acquired immunologic 
hyporesponsiveness to non-inherited maternal antigen (NIMA) (Andrassy, Kusaka et al. 
2003; Dutta, Molitor-Dart et al. 2009). T-cell replete HSCT, without GVHD, could be 
accomplished by using this phenomenon of feto-maternal tolerance. Unfortunately, graft 
rejection and hyperacute GVHD have been reported in HSCT from NIMA-mismatched 
siblings, despite detecting of MMc (Okumura, Yamaguchi et al. 2007). Therefore, 
                                                 





development of a predictable method for GVHD in NIMA-mismatched HSCT is needed. We 
have produced a novel prediction assay, using MLR-ELISPOT (mixed lymphocyte reaction; 
enzyme-linked immunospot) assay, for detecting reactivity to NIMA (Araki, Hirayama et al. 
2010). In this review, we discuss acute GVHD in T-cell depleted and T-cell replete HSCT, the 
role of major and minor histocompatibility in NIMA tolerance, and prediction of acute 
GVHD in T-cell replete HSCT via our model assay. 
2. Minor histocompatibility antigens in mouse and human  
Alloantigens can be divided into major histocompatibility complex (MHC) antigen and 
minor histocompatibility antigen (MiHA), the former responsible for eliciting the strongest 
immune responses to allogeneic tissues. The MHC is referred to as the H-2 complex in mice 
and as the HLA complex in humans. 
MHC identity of donor and host is not the sole factor determining immunological reactivity 
in HSCT. When transplantation is performed in an unrelated setting (MUD, matched-
unrelated donor), even if MHC antigens of donor are identical to recipient, considerable 
transplant reactions may occur because of differences at various minor histocompatibility 
loci. MiHAs are capable of eliciting cellular alloimmune responses in vitro and in vivo. They 
are peptides derived from polymorphic proteins. Their immunogenicity arises as a result of 
their presentation in the context of MHC class I or II, where they are recognized by 
alloreactive MHC-restricted T cells. The most important immune reactions elicited by in 
vivo alloreactivity to MiHA are graft rejection and GVHD. 
To date, human MiHAs have not been fully characterized. Some murine MiHAs have been 
compared with human counterparts though (see, HY antigens in Table 1). Immunological 
targeting of HY proteins results in a relatively high incidence of acute GVHD when male 
recipients receive HSCT from female donors (Stern, Passweg et al. 2006). While 
approximately one third of the known MiHAs are encoded in Y chromosome, many MiHAs 
are located on autosomal chromosomes (Table 1). Genetic linkage analysis has been used to 
define the genomic regions encoding the MiHAs (Akatsuka, Nishida et al. 2003; de Rijke, 
van Horssen-Zoetbrood et al. 2005). With these more recent advanced techniques, more 
human MiHAs epitopes have been identified (van Bergen, Kester et al. 2007; Kawase, 
Akatsuka et al. 2007; Tykodi, Fujii et al. 2008; Griffioen, van der Meijden et al. 2008; 
Spaapen, Lokhorst et al. 2008; Spaapen, de Kort et al. 2009; Kamei, Nannya et al. 2009; 
Stumpf, van der Meijden et al. 2009; Bleakley, Otterud et al. 2010; Van Bergen, Rutten et al. 
2010; Sellami, Kaabi et al. 2011). 
MiHA Species Chromosome Gene MHC restriction Tissue specificity References 
Y chromosome 
HY Mouse Y Smcy H-2Kk, H-2Db Ubiquitous (Markiewicz et al. 1998) 
HY Mouse Y Uty H-2Db Ubiquitous (Greenfield et al. 1996) 
HY Mouse Y Dby H-2Ab, H-2Ek Ubiquitous (Scott et al. 2000) 
SMCY Human Yq11 JARID1D HLA-A*02:01, B*07:02 Ubiquitous 
(Wang et al. 
1995) 
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MiHA Species Chromosome Gene MHC restriction Tissue specificity References 
UTY Human Yq11 UTY HLA-B8, B60 Ubiquitous (Vogt et al. 2000) 
DBY Human Yq11 DDX3Y HLA-B*27:05, DRB1*15:01, DQ5 Hematopoietic (Zorn et al. 2004) 
DFFRY Human Yq11.2 USP9Y HLA-A*01:01 Ubiquitous (Pierce et al. 1999) 
RPS4Y Human Yp11.3 RPS4Y1 HLA-B*52:01, DRB3*03:01 Ubiquitous 
(Spierings et al. 
2003) 
TMSB4Y Human Yq11.221 TMSB4Y HLA-A*33:03 Ubiquitous (Torikai et al. 2004) 
Autosomal chromosome 
H3 Mouse 2 Zfp106 H-2Db Ubiquitous (Zuberi et al. 1998) 
H4 Mouse 7 Emp3 H-2Kb Ubiquitous (Luedtke et al. 2003) 
H7 Mouse 9 D9Mit182 H-2Db Ubiquitous (Perreault et al. 1996) 
H13 Mouse 2 47c1 cDNA H-2D
b Ubiquitous (Mendoza et al. 1997) 
H28 Mouse 3 NS1178 H-2Kb Ubiquitous (Malarkannan et al. 2000) 
H46 Mouse 7 Il4i1 H-2Ab Hematopoietic (Sahara et al. 2003) 
H47 Mouse 7 H47 H-2Db Ubiquitous (Mendoza et al. 2001) 
H60 Mouse 10 Rae1 H-2Kb Hematopoietic (Choi et al. 2001) 
HA-1 Human 19p13.3 HMHA1 HLA-A*02:01, A*02:06, B60 Hematopoietic
(Mommaas et al. 
2002) 
HA-2 Human 7p13-p11.2 MYO1G HLA-A*02:01 Hematopoietic (den Haan et al. 1995) 
HA-3 Human 15q24-q25 AKAP13 HLA-A*01:01 Ubiquitous (Spierings et al. 2003) 
HA-8 Human 9p24.2 KIAA0020 HLA-A*02:01 Ubiquitous (Brickner et al. 2001) 
HB-1 Human 5q31.3 HMHB1 HLA-B*44:02, B*44:03 B-cell 
(Dolstra et al. 
1999) 
ACC-1, 2 Human 15q24.3 BCL2A1 HLA-A*24:02, B*44:03 Hematopoietic
(Akatsuka et al. 
2003) 
UGT2B17 Human 4q13 UGT2B17 HLA-A*02:06, A*29:02, B*44:03 Ubiquitous 
(Murata et al. 
2003) 
LRH-1 Human 17p13.3 P2RX5 HLA-B*07:02 Hematopoietic (de Rijke et al. 2005) 
CTSH Human 15q25.1 CTSH HLA-A*31:01, A*33:03 Ubiquitous 
(Torikai et al. 
2006) 
LB-
ECGF1-1H Human 2q13.33 ECGF1 HLA-B*07:02 Hematopoietic
(Slager et al. 
2006) 
PANE1 Human 22q13.2 CENPM HLA-A*03:01 Hematopoietic (Brickner et al. 2006) 
SP110 Human 2q37.1 SP110 HLA-A*03:01 Hematopoietic (Warren et al. 2006) 
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3. Acute GVHD in T-cell depleted or replete haploidentical transplantation 
Haploidentical HSCT has made progress over the past 30 years and has become a feasible 
option for patients without an HLA-identical sibling donor. This is especially true for 
reconstitution of immunity in infants with severe combined immunodeficiency, where use 
of rigorously T-cell depleted marrow has been quite successful (Buckley, Schiff et al. 
1999). In early trials of haploidentical HSCT, ex vivo T-cell depletion method of 
haploidentical bone marrow cells was an effective method reported by Reisner et al 
(Reisner, Kapoor et al. 1981). This procedure without immunosuppressive prophylaxis 
allowed durable engraftment rate about 75% with acceptable incidence of acute GVHD 
(36%) in patients with severe combined immunodeficiency (Buckley, Schiff et al. 1999). 
However, its application to haploidentical HSCT for leukemia was less encouraging due 
to the high incidence of graft failure (30%) and infectious complications (80%) (O'Reilly, 
Keever et al. 1987). In a trial from the University of Perugia, the use of T-cell depletion in 
combination with a high dose of stem cells overcame graft rejection as well as acute 
GVHD (Aversa, Tabilio et al. 1994). Improved positive selection of CD34+ cells was 
accomplished by depletion of B cells, in addition to T cells, which resulted in a lower 
incidence of EBV-associated lymphoproliferative disease (LPD) (Aversa, Terenzi et al. 
2005). Another method using ex vivo T-cell depletion of bone marrow cells with anti-T-
cell monoclonal antibodies, followed by treatment with cyclosporine and ATG, was 
encouraging for the use of haploidentical marrow (Henslee-Downey, Abhyankar et al. 
1997). Over 95% durable engraftment and low incidence of acute GVHD (13%) were 
obtained, and accompanied with an acceptable relapse rate (31%) (Mehta, Singhal et al. 
2004). Although these various depletion techniques achieved benefit, to truly achieve 
more acceptable results, further improvement is necessary to address the high rate of 
malignancy relapses, acute and chronic GVHD, and otherwise, treatment-related 
morbidity and mortality. 
As an alternative to ex vivo T-cell depletion, in vivo T-cell depletion methods have been 
undertaken for improving relapse rates and treatment-related mortality. Lu et al. from 
Peking University described the transplantation of combination of G-CSF-primed bone 
marrow and peripheral blood with intensive immunosuppression using ATG (Lu, Dong et 
al. 2006). Although the cumulative incidence of grade II to IV acute GVHD was 
comparatively high, 40%, two-year incidences of relapses and treatment-related mortality 
were low, 22% and 18%, respectively. More recently, Huang et al., in the same group 
reported encouraging clinical outcomes in 250 patients with haploidentical HSCT. The 3-
year of leukemia free survival in standard and high-risk AML was 70.7% and 55.9%, 
respectively, and 59.7% and 24.8% for ALL (Huang, Liu et al. 2009). In another approach, 
Rizzieri et al. reported that alemtuzumab was used for in vivo depletion of both recipient 
and donor T-cells, in order to allow for more reliable engraftment and decreased GVHD 
(Rizzieri, Koh et al. 2007). 
Sibling-related NIMA-mismatched transplantation, as an approach to T-cell replete 
haploidentical HSCT, was introduced as an alternative to ex vivo or in vivo T-cell depleted 
haploidentical HSCT. Van Rood et al. first showed that the incidence of acute GVHD was 
lower in patients who received T-cell replete grafts from an NIMA-mismatched sibling than 
those from non-inherited paternal antigen (NIPA) -mismatched sibling (van Rood, Loberiza 
et al. 2002). This indicated that the presence of immunological hyporesponsiveness against 
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NIMA in haploidentical transplantation could be important for prevention of GVHD and 
other immunologic comorbidities. Ichinohe et al. also showed that T-cell replete 
haploidentical HSCT from NIMA-mismatched family donor was feasible in selected patients 
with poor-risk hematologic malignancies using standard GVHD prophylaxis (Ichinohe, 
Maruya et al. 2002). However, 10% of patients still experienced severe acute GVHD, and 
there was not a useful method to predict acute GVHD in these patients. Thus, both T-cell 
depleted and T-cell replete haploidentical HSCT have benefits and drawbacks (Table 2). The 
problems of T-cell depleted HSCT were relatively high rate of graft failure, delayed immune 
reconstitution resulting in infections, and relapse of malignancies (Henslee-Downey, 
Abhyankar et al. 1997; Guinan, Boussiotis et al. 1999; Mehta, Singhal et al. 2004; Lu, Dong et 
al. 2006; Huang, Liu et al. 2009). On the other hand, the problems of T-cell replete 
haploidentical HSCT were relatively high rates of acute GVHD and treatment-related 
mortality (Ichinohe, Maruya et al. 2002; van Rood, Loberiza et al. 2002; Kanda, Ichinohe et 
al. 2009). Therefore, if an effective method to predict GVHD is available, T-cell replete 
haploidentical HSCT may be feasible with relative safety; lower risk of GVHD, lower risk of 
infections, and lower risk of malignancy relapse. 
 
Type of 




failure TRM Relapse DFS 
T-cell depleted 
(Ex vivo) 0-33 BM + 5-8 % 3-5 % 17-47 % 11-25 % 35-38 % 
(In vivo) 16-25 BM ± PB + 13-46 % 0-13 % 22-51 % 18-31 % 18-64 % 
T-cell replete 
(NIMA/ 
Mother) 15-28 BM or PB -* 41-58 % 0-20 % 18-57 % 6-25 % 30-81 % 
(NIPA/ 
Father) 17-20 BM -* 55-63 % 13-29 % 36-45 % Unknown 24-44 % 
*More than 90% of patients were not used. 
Abbreviations: ATG, anti-thymocyte globulin; TRM, treatment-related mortality; DFS, disease-free 
survival; BM, bone marrow; PB, peripheral blood. 
Table 2. Frequency of acute GVHD in T-cell depleted and T-cell replete HSCT 
4. Tolerance to non-inherited maternal antigen in murine studies 
Maternal cells and fetal cells, most notably lymphocytes, are known to reciprocally traffic 
across the placenta during fetal development (Hall, Lingenfelter et al. 1995; Lo, Lo et al. 
1996), and can result in life-long MMc in the offspring (Maloney, Smith et al. 1999). Prenatal 
exposure to NIMA affects the neonate’s developing immune system, producing some 
tolerization to the non-inherited MHC components. There have been several previously 
reported investigations of NIMA (Burlingham, Grailer et al. 1998; Andrassy, Kusaka et al. 
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A-Left, C57BL/6 (B6) males (H-2b/b) were mated with (B6 x DBA/2) F1 female (H-2b/d), thus exposing 
the H-2b/b offspring in utero and via breast feeding to NIMAd antigens. Right, (B6 x DBA/2) F1 males 
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background, in other words, their MiHA (i.e. H-4, H-13, H-60, etc) are matched, and H-2 antigens are 
mismatched in both class I and II. B-II-Left, C3H males (H-2k) were mated with CB (BALB/c x B6) F1 
females (H-2d/b), thus exposing the H-2d/k type offspring to NIMA b antigens and MiHA (NIMAH-
2b+MiHA), and H-2b/k type offspring to NIMAH-2d+MiHA. Right, CB F1 males (H-2d/b) were mated with C3H 
females (H-2k), creating the controls; both H-2d/k and H-2b/k type offspring that had not been exposed to 
H-2b+MiHA and H-2d+MiHA, respectively. C, Breeding pattern were summarized in terms of major 
and minor histocompatibility Ags to NIMA. 
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In addition, maternal cells and MHC/HLA proteins are ingested by the baby during 
nursing, possibly stimulating oral tolerance (Verhasselt, Milcent et al. 2008; Aoyama, 
Koyama et al. 2009). The clinical benefits of developmentally acquired tolerance to NIMA 
were first noted by Owen et al. more than 50 years ago (Owen, Wood et al. 1954). Since then, 
tolerogenic effects of NIMA have been documented at both T- and B-cell levels in a variety 
of clinical settings (Claas, Gijbels et al. 1988; van Rood and Claas 1990; Burlingham, Grailer 
et al. 1998). Presence of feto-maternal tolerance was anticipated due to the presence of MMc 
(Andrassy, Kusaka et al. 2003), and the concept has been used in clinical studies (Ichinohe, 
Uchiyama et al. 2004). On the basis of this hypothesis, several transplantation centers in 
Japan have performed clinical trials to test the feasibility of HLA-haploidentical HSCT from 
a NIMA mismatched relative, without using either T-cell depletion or intensive post-
transplant immunosuppression (Ichinohe, Uchiyama et al. 2004; Kanda, Ichinohe et al. 2009). 
Persistent MMc is associated with antigen-specific suppression of the associated T-cell 
responses (van Rood, Loberiza et al. 2002). With the help of highly sensitive polymerase 
chain reaction (PCR)-based techniques, long-term MMc can be detected from the peripheral 
blood, or various tissues including liver, skin, and thyroid gland (Ichinohe, Maruya et al. 
2002). Several investigators have suggested the association of long-term MMc with the 
development of tolerance to NIMA (Kodera, Nishida et al. 2005). Thus, successful NIMA-
mismatched haploidentical HSCT have been performed confirming long-term MMc as an 
indication of tolerance induction, in agreement with the correlation between MMc and 
tolerance in mice, which has been described recently (Dutta, Molitor-Dart et al. 2009). 
However, in some individuals unsuccessful NIMA-mismatched haploidentical HSCT have 
occurred, when the concept of MMc would have predicted otherwise. 
The relevance of MiHA in tolerance to NIMA has not been reported. In both MHC-identical 
and MHC-haploidentical transplants, MiHA alloreactivities may be induced (Verdijk, 
Kloosterman et al. 2004). Therefore, maintaining the focus on the tolerance-induction of 
NIMA to MHC may have greater clinically relevance. In accord with this, we have shown 
differences in the NIMA tolerogenic effect in different individuals, divided into high 
responder (HR) or low responder (LR) categories, depending on the magnitude of the MLR 
of donor against recipient NIMA (Araki, Hirayama et al. 2010). The magnitude of the 
responses was associated with the extent of regulatory T cells (Treg) and Foxp3 expression 
in MHC-mismatched, MiHA-matched HSCT (Figure 2). This, with other reports, describe 
that Treg mediate tolerance to NIMA (Aluvihare, Kallikourdis et al. 2004; Matsuoka, 
Ichinohe et al. 2006). Survival rates and GVHD clinical scores of NIMA-exposed LR mice 
were significantly better than those of NIMA-exposed HR mice (Figure 3). Moreover, the 
level of MMc was correlated with the tolerogenic effect of the NIMA (Araki, Hirayama  
et al. 2010). 
The mouse MiHA loci confers a wide range of immunogenicity, ranging from weakly to 
strongly immunogenic (Roopenian, Choi et al. 2002). Several studies have provided evidence 
that GVHD could be caused by only a limited number of mouse MiHA as described above 
(Choi, Yoshimura et al. 2001; Yang, Jaramillo et al. 2003; Eden, Christianson et al. 1999). The 
specific MiHA immunodominance was manifested on genetically varied backgrounds among 
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and MHC-haploidentical transplants, MiHA alloreactivities may be induced (Verdijk, 
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The mouse MiHA loci confers a wide range of immunogenicity, ranging from weakly to 
strongly immunogenic (Roopenian, Choi et al. 2002). Several studies have provided evidence 
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We have shown a difference of proliferative response to NIMA in NIMA-exposed and NIMA-non-exposed 
mice. The mice were classified into two groups by MLR, based on their reactivity to NIMA; the high 
responder (HR ≥ mean+1SD in NIMA-nonexposed) or the low responder (LR < mean+1SD) group (Araki, 
Hirayama et al. 2010). Upper, The percentage of CD4+CD25+ cells in CD4+ cell population was analyzed by 
flow cytometry. Lower, The relative expression of Foxp3 compared with GAPDH is presented as the mean 
+ SE. Samples were obtained 21 days after GVHD induction from recipients injected with cells from 
NIMA-exposed LR, HR, and NIMA-nonexposed mice (n=5 in each group). *p<0.05. 
Fig. 2. Regulatory T cells and Foxp3 expression correlated with reactivity to MHC. 
Malarkannan, Horng et al. 2000). Previously, there has been no report distinguishing the 
reactivities of MHC and MiHA from the tolerogenic effect of NIMA. We have proposed to 
classify the murine models of NIMA based on major and minor histocompatibility antigens 
to NIMA (Hirayama and Azuma 2011) (Figure 1C). In our study, all B10 congenic mice were 
used as the former NIMA model, “major only” (Figure 1B-I), and those MiHA had matched 
entirely in this system (Araki, Hirayama et al. 2010). On the other hand, the previous model 
(Andrassy, Kusaka et al. 2003; Matsuoka, Ichinohe et al. 2006) (Figure 1A) and the latter our 
model, “major + minor” (Figure 1B-II) were mismatched at both H-2 and MiHA. Therefore, 
we need to consider an influence of both major and minor histocompatibility when NIMA 
tolerance is evaluated (Hirayama and Azuma 2011) (Figure 1C). 
 




A, The survival of sublethally irradiated recipient B10 female mice injected with vehicle (□, n = 14), cells 
from NIMA-exposed LR mice (H-2d/k, NIMAb) (○, n = 30), HR mice (NIMAb) (△, n = 33), NIMA-
nonexposed mice (H-2d/k, NIMAnone) (●, n = 39), and allogeneic B10.D2 mice (■, n =14). B, The GVHD 
clinical score was determined in recipients injected with cells from NIMA-exposed LR mice (○, n = 48), 
HR mice (△, n = 45), allogeneic mice (●, n = 47), and vehicle (□, n = 12). The degree of clinical GVHD 
was assessed by the scoring system that incorporates five clinical parameters: weight loss, posture, 
activity, fur texture, and skin integrity, grading from 0 to 2 for each parameter. A clinical index was 
subsequently generated by summation of the five criteria scores (maximum index=10). Data are 
expressed as the means + SE of individual animals. **p<0.01, *p<0.05. 
Fig. 3. Two distinct reactivities to H-2 in NIMA-exposed mice resulted in differences in 
GVHD induction. 
 
A, ELISPOT assay combining with MLR (MLR-ELISPOT) is a sensitive functional assay to detect 
alloreactivity for both major and minor histocompatibility antigens in mice. B, The IFN-γ-producing 
ability before GVHD induction was presented by MLR-ELISPOT. Peripheral blood mononuclear cells 
from NIMA-exposed LR mice (H-2d/k, NIMAb, n=8), HR mice (n=7), and nonexposed mice (n=6) were 
stimulated with B10 mice peripheral blood mononuclear cells. Data are expressed as the means + SE of 
individual animals. *p<0.05. 
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5. Reactivity to mismatched histocompatibility antgens; Tolerogenic or 
immunogenic? 
The mechanisms by which NIMA drive the immune system toward tolerance or rejection of 
the allograft are still unclear. Although mismatch at MiHA can provoke severe immune 
responses against host cells upon transplantation (Goulmy, Schipper et al. 1996), the role of 
MiHA in the NIMA effects has not been described. Recently, naturally acquired tolerance 
and sensitization to MiHA have been reported (van Halteren, Jankowska-Gan et al. 2009). 
The presence of MiHA-specific Treg was shown in healthy adult women and men. In 
addition, it remains to be studied whether or not particular microchimeric cell types are 
associated with either a sensitized or a tolerized MiHA effect. Our study showed the 
difference of individual reactivities toward MHC, not MiHA, was critically influenced by 
the amount of MMc expression (Araki, Hirayama et al. 2010). The relationship between 
tolerogenic effect and MMc are consistent with a report of Dutta et al. They described the 
correlation between MMc and NIMA-specific Treg capable of suppressing both delayed 
type hypersensitivity and lymphoproliferative responses of effector T cells in a conventional 
NIMA mouse model (van Rood and Claas 1990; Andrassy, Kusaka et al. 2003). Opiela et al. 
described that transient exposure to low levels of NIMA alloantigens in early life may lead 
to long-term priming for both cytotoxic and helper T cell functions (Opiela, Levy et al. 2008). 
On the other hand, Aoyama et al. showed that both oral and in utero exposures to NIMA are 
required for the maximum induction of tolerance (Aoyama, Koyama et al. 2009). In any case, 
the mechanism underlying the development of tolerance versus priming to NIMA 
alloantigens remains to be clarified. 
6. Prediction of acute GVHD in mismatched HSCT 
Prediction of acute GVHD by in vitro assays prior to transplantation have not be very 
successful until now. In vitro detection of the frequencies of cytotoxic T-lymphocyte 
precursors (CTLp) and helper T-lymphocyte precursors (HTLp), in conjunction with MLR 
have been used as a method to detect individual reactivity to NIMA (Falkenburg, van 
Luxemburg-Heijs et al. 1996; Moretta, Locatelli et al. 1999; Tsafrir, Brautbar et al. 2000). 
Moretta et al. described that the frequency of NIMA-specific CTLp in cord blood samples 
were measured in order to better define the phenomenon of NIMA tolerance (Moretta, 
Locatelli et al. 1999). NIMA-reactive cord blood cells are detectable, but they were unable to 
detect differences between CTLp frequencies towards NIMA or NIPA. Falkenburg et al. 
investigated whether NIMA tolerance could allow transplantation over certain HLA 
barriers. Both CTLp and HTLp frequencies against NIPA were not statistically different than 
those directed against NIMA (Falkenburg, van Luxemburg-Heijs et al. 1996). Indeed, 
Kircher et al. showed that CTLp and HTLp frequencies were not predictive for the risk of 
acute GVHD in patients received allogeneic HSCT (Kircher, Niederwieser et al. 2004). 
Established test systems are therefore not available for the prediction of alloreactions and 
outcome after HSCT. Originally, it was predicted that CTLp reflects alloreactivity of class I 
mismatch, and HTLp reflect alloreactivity of class II mismatch. Levitsky et al. reported an 
evaluation of allogeneic reaction that used Treg (Levitsky, Miller et al. 2009). They generated 
carboxy-fluorescein diacetate succinimidyl ester-labeled CD4+CD25high FOXP3+ cells in 
MLR, which they called “Treg MLR”. These cells had varying HLA disparities and varying 
reactivities to cell components. However, this method reflects only a difference related to 
MHC class II. Thus, the above-mentioned methods can detect MHC class I or class II 
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separately, but it is difficult to detect them simultaneously. Recently, we reported a novel 
method, MLR-ELISPOT, to overcome these difficulties, as shown in Table 3. 
Assay Target antigen References 
Frequency of CTLp MHC class I (Hadley et al. 1990; Falkenburg et al. 1996; Moretta et al. 1999) 
Frequency of HTLp MHC class II (Falkenburg et al. 1996; Kircher et al. 2004) 
MLR, modified MLR MHC class II (Tsafrir, Brautbar et al. 2000) 
Treg MLR MHC class II (Levitsky, Miller et al. 2009) 
MLR-ELISPOT for IFN-γ MHC class I and II (MiHA) (Araki, Hirayama et al. 2010) 
Table 3. Detection assay to allogeneic antigen 
Alloreactivity of NIMA-exposed mice and NIMA-nonexposed mice were evaluated by MLR, 
and we found quite wider range of reactivity in the former compared with the latter. This 
helps to indicate that feto-maternal interaction acts on both tolerance (low responder) and 
sensitization (high responder) (Molitor-Dart, Andrassy et al. 2008; van Halteren, Jankowska-
Gan et al. 2009). The reports from Tsafrir et al. and Falkenburg et al. detected a reactivity to 
NIMA by MLR (Falkenburg, van Luxemburg-Heijs et al. 1996), and CTLp and HTLp 
(Tsafrir, Brautbar et al. 2000), respectively. Interestingly, when we scrutinized the figures in 
their articles, individual reactivities of NIMA-exposed group showed a wider range than the 
control group, and those reactivities seem to be divided into low and high reactions, 
although they did not discuss these observations. This was further indication that reactivity 
to NIMA could be detected in vitro, and the condition of feto-maternal interaction promoted 
either tolerance (low-responder) or sensitization (high-responder). 
Several investigators have reported that evaluations of reactivity to NIMA can be assessed, 
but the clinical relevance remains unknown. Presence of feto-maternal tolerance was 
anticipated due to MMc (Andrassy, Kusaka et al. 2003), and this concept has been used in 
clinical studies (Ichinohe, Maruya et al. 2002). Functional importance of MMc in humans has 
been further studied (Carter, Cerundolo et al. 1999; Cho, Choi et al. 2006). The majority of 
assays used to detect donor-derived cells in a recipient’s blood exploit sex-mismatch 
between donor and recipient or the polymorphism of the HLA-DR region of the MHC, 
determined with sequence specific primer PCR (SSP-PCR). SSP-PCR is commonly used for 
HLA typing the extent of match between donors and recipients prior to transplantation, but 
may not work well for detection of MMc. The sensitivity of detection of this technique can 
range from 0.5% to 0.01%, more than adequate for routine HLA-typing, but MMc levels may 
be from 0.01% to 0.001%, well below the sensitivity of the assay. Therefore, the sensitivity of 
SSP-PCR for HLA-DR alleles has been increased by the introduction of a nested priming of 
exon 2 SSP-PCR approached. Most of NIMA-mismatched haploidentical HSCT in Japan 
require positive MMc of the donor by using the nested SSP-PCR (Ichinohe, Maruya et al. 
2002; Carter, Cerundolo et al. 1999). 
Although detection of MMc was clinically used for an indication of probable tolerance to 
NIMA, severe acute cases of GVHD developed (Okumura, Yamaguchi et al. 2007; Kanda, 
Ichinohe et al. 2009). Studies indicate that NIMA allografts do better than NIPA allografts in 
vivo (Burlingham, Grailer et al. 1998), and in vitro T-cell responses to NIMA are 
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MLR, which they called “Treg MLR”. These cells had varying HLA disparities and varying 
reactivities to cell components. However, this method reflects only a difference related to 
MHC class II. Thus, the above-mentioned methods can detect MHC class I or class II 
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separately, but it is difficult to detect them simultaneously. Recently, we reported a novel 
method, MLR-ELISPOT, to overcome these difficulties, as shown in Table 3. 
Assay Target antigen References 
Frequency of CTLp MHC class I (Hadley et al. 1990; Falkenburg et al. 1996; Moretta et al. 1999) 
Frequency of HTLp MHC class II (Falkenburg et al. 1996; Kircher et al. 2004) 
MLR, modified MLR MHC class II (Tsafrir, Brautbar et al. 2000) 
Treg MLR MHC class II (Levitsky, Miller et al. 2009) 
MLR-ELISPOT for IFN-γ MHC class I and II (MiHA) (Araki, Hirayama et al. 2010) 
Table 3. Detection assay to allogeneic antigen 
Alloreactivity of NIMA-exposed mice and NIMA-nonexposed mice were evaluated by MLR, 
and we found quite wider range of reactivity in the former compared with the latter. This 
helps to indicate that feto-maternal interaction acts on both tolerance (low responder) and 
sensitization (high responder) (Molitor-Dart, Andrassy et al. 2008; van Halteren, Jankowska-
Gan et al. 2009). The reports from Tsafrir et al. and Falkenburg et al. detected a reactivity to 
NIMA by MLR (Falkenburg, van Luxemburg-Heijs et al. 1996), and CTLp and HTLp 
(Tsafrir, Brautbar et al. 2000), respectively. Interestingly, when we scrutinized the figures in 
their articles, individual reactivities of NIMA-exposed group showed a wider range than the 
control group, and those reactivities seem to be divided into low and high reactions, 
although they did not discuss these observations. This was further indication that reactivity 
to NIMA could be detected in vitro, and the condition of feto-maternal interaction promoted 
either tolerance (low-responder) or sensitization (high-responder). 
Several investigators have reported that evaluations of reactivity to NIMA can be assessed, 
but the clinical relevance remains unknown. Presence of feto-maternal tolerance was 
anticipated due to MMc (Andrassy, Kusaka et al. 2003), and this concept has been used in 
clinical studies (Ichinohe, Maruya et al. 2002). Functional importance of MMc in humans has 
been further studied (Carter, Cerundolo et al. 1999; Cho, Choi et al. 2006). The majority of 
assays used to detect donor-derived cells in a recipient’s blood exploit sex-mismatch 
between donor and recipient or the polymorphism of the HLA-DR region of the MHC, 
determined with sequence specific primer PCR (SSP-PCR). SSP-PCR is commonly used for 
HLA typing the extent of match between donors and recipients prior to transplantation, but 
may not work well for detection of MMc. The sensitivity of detection of this technique can 
range from 0.5% to 0.01%, more than adequate for routine HLA-typing, but MMc levels may 
be from 0.01% to 0.001%, well below the sensitivity of the assay. Therefore, the sensitivity of 
SSP-PCR for HLA-DR alleles has been increased by the introduction of a nested priming of 
exon 2 SSP-PCR approached. Most of NIMA-mismatched haploidentical HSCT in Japan 
require positive MMc of the donor by using the nested SSP-PCR (Ichinohe, Maruya et al. 
2002; Carter, Cerundolo et al. 1999). 
Although detection of MMc was clinically used for an indication of probable tolerance to 
NIMA, severe acute cases of GVHD developed (Okumura, Yamaguchi et al. 2007; Kanda, 
Ichinohe et al. 2009). Studies indicate that NIMA allografts do better than NIPA allografts in 
vivo (Burlingham, Grailer et al. 1998), and in vitro T-cell responses to NIMA are 





Kusaka et al. 2003). Tsafrir et al. demonstrated this NIMA effect using umbilical cord blood 
mononuclear cells by a MLR assay (Tsafrir, Brautbar et al. 2000), but Hadley et al. could not 
detect the NIMA effect using peripheral blood mononuclear cells from healthy individuals 
(Hadley, Phelan et al. 1990). Thus, there is not a useful method to predict a tolerogenic effect 
for NIMA, although these studies may suggest that newborns are more tolerogenic to NIMA 
than older individuals. Recently, we demonstrated that the level of cells producing IFN-γ, 
but not IL-4 and IL-10, were significantly lower in NIMA-exposed group than NIMA-
nonexposed group by using an MLR-ELISPOT assay in a murine model (Araki, Hirayama et 
al. 2010) (Figure 4). This assay should be easily applicable to humans, and is a versatile 
method to detect reactivities to MHC class I as well as class II. And, it may also detect 
reactivity to MiHA (Table 3). In other words, this assay might be useful to predict the total 
immunological reaction of donor T cells to recipient in mismatched HSCT. 
7. Conclusions 
The risk of acute GVHD might be influenced by various genetic factors HLA, MiHA, or 
others (Hsu, Chida et al. 2002; Lin, Storer et al. 2003). NIMA-mismatched haploidentical 
HSCT has been improving with sustained engraftment, lower early treatment-related 
mortality, and acceptable rates of GVHD. However, it has been difficult to predict severe 
GVHD prior to transplantation. Our recent report has addressed the issue (Araki, Hirayama 
et al. 2010; Hirayama and Azuma 2011). NIMA effects directed toward MHC antigen were 
divided into high (immunogenic) and low (tolerogenic) reactivities. Our results in mice 
demonstrated that there was an unevenness in the acquisition and maintenance of MMc in 
the offspring. Further differential inheritance of MiHA did not influence our results, i.e., the 
variability amongst offspring was not due to solely to differences in MiHA gene inheritance. 
The variability seemed intrinsic to chance events in mammalian reproduction; i.e. allogeneic 
pregnancy and nursing itself (Aoyama, Koyama et al. 2009; Dutta, Molitor-Dart et al. 2009). 
To date, T-cell replete haploidentical transplantation is performed only in the presence of 
detected MMc in the recipient, although individual reactivity of donor to the receipient has 
not been evaluated. Could the pairing result in a low-responder/tolergenic or high-
responder/immunogenic situation? Therefore, our recent study is clinically relevant. T-cell 
replete NIMA-mismatched haploidentical transplantation could be performed more safely 
by using our assay to evaluate IFN-γ-producing cells of donor against NIMA as a way to 
further reduce graft failure, prevent transplant mortality, and prevent severe GVHD. 
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The immune system of higher organisms has the unique capability of mounting a specific 
and adaptive response against invading pathogens. Specific in the sense that immune cells 
recognize molecular features from foreign pathogens, and adaptive in the sense that upon re-
encounter of the foreign pathogen the immune system respond faster and more efficiently, 
which is the basic principle used in vaccination. In addition, the immune system has 
evolved the innate capability of recognizing common, slow mutating features on pathogens 
by using several different pattern recognition receptors. These defense mechanisms are 
important, but just like any other organisms pathogens also mutate to adapt to selection 
pressures thereby escaping immune surveillance. Likewise, the immune system of higher 
organisms is not a static system, but rather a dynamic ever-changing defense system 
continuously evolving over millions of years to constantly battle pathogens trying to 
overcome immune defense barriers and take over the host protein translation machinery. 
Furthermore, the immune system needs to be in balance with its host, but sometimes the 
line between functional immunity and auto-reactivity becomes hard to draw. Importantly, it 
is now a firmly established concept that the immune system eradicates host cells undergoing 
malignant transformation to prevent tumor formation. With these functions in mind, it is 
reasonable to claim the adaptive immune system as highly essential in the protection of 
pathogenic infections and malignant cells. The adaptive immune system contains a variety 
of T cells; two major groups are the CD4+ T cells that interact with MHC class II (MHC-II) 
cell surface receptors, and CD8+ T cells, also termed cytotoxic T cells (CTLs) that interact with 
MHC class I (MHC-I) cell surface receptors. The CTLs kill malignant host cells or host cells 
infected with foreign pathogens. This chapter focuses on the immunology concerning CTLs 
and MHC-I. Specifically, we focus on the multi-step, intracellular maturation of MHC-I. 
CTLs continuously re-circulate throughout our body and secondary lymphoid organs to 
scan our cells for peptides presented on MHC-I. These peptides are derived from the 
interior of the cell, and presented on MHC-I outside the cell on its membrane surface. Each 
MHC-I receptor binds and presents one small endogenous or foreign peptide, which is 
derived from within the cell, (Roder, Geironson et al. 2008) and the entire ligand-receptor 
complex is termed a peptide-MHC-I complex (pMHC-I). Essentially, through their T cell 
receptor (TcR) the CTLs may recognize a particular pMHC-I on the cell surface of the 
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both the TcR and the pMHC-I, and occurs normally only when a foreign peptide is bound in 
the pMHC-I. This is the exact purpose of MHC-I defense system: use peptides to report any 
intracellular abnormalities such as infections or malignant states, and make the CTLs kill 
these cells. In the secondary lymphoid organs naïve CTLs encounter the pMHC-I complexes 
presented by professional APCs, cells with unique co-stimulatory capability able to prime 
naïve T cells. Upon recognition of a pMHC-I complex the CTLs become active dividing cells 
able to kill infected cells outside the lymphoid organs (Santana and Esquivel-Guadarrama 
2006). An important characteristic of CTL activity is that it is pMHC-I restricted, giving that 
it only recognizes the peptide antigen in the context of a certain MHC-I molecule. Also, the 
pMHC-I is only recognized if it reaches and remains on the cell surface of the APC. If the 
pMHC-I disintegrates along the maturation and transport to, or while staying at, the cell 
surface it will never be available for CTL scrutiny. These criteria impose serious 
requirements to the intricate MHC-I maturation processes inside the cell as we shall describe 
in this chapter. 
2. The mature MHC-I binds only certain peptides in its binding groove 
Before we delve deep into the MHC-I maturation in the cell, we first introduce the reader to 
the final product – the mature pMHC-I complex and some of its important properties. 
MHC-I molecules are found on most nucleated cells in the body. The MHC-I in humans is 
called human leukocyte antigen class I (HLA-I) and is grouped into A, B and C based on the 
genetic locus. Because the protein products, the allomorphs, of the alleles occupying the 
HLA-A, -B and -C loci are all co-dominantly expressed and chromosomes exist in pairs, one 
from the paternal and one from the maternal side, usually six different allomorphs are 
expressed in each human. To date (2011), over 5,000 different alleles and over 3,000 different 
allomorphs have been identified and sequence information is freely available from the HLA 
Informatics Group (http://www.anthonynolan.com/HIG/data.html). As seen in figure 1 
the final pMHC-I complex consists of a MHC-I heavy chain (HC) that is folded into three -
domains; the 1- and 2-domains are intertwined making up the membrane distal peptide 
binding groove, whereas the membrane proximal 3-domain has an Ig-like structure that 
supports binding of the MHC-I light chain, 2-microglobulin (2m). In addition, 2m 
stabilizes from below the anti-parallel -sheets and helices allowing these structural 
elements to create a large, but tight, peptide binding groove containing six peptide amino 
acid binding pockets. 
These pockets are very important in determining the peptide binding specificity of any 
particular MHC-I allomorph. The MHC-I residues in each binding pocket determine, which 
peptide residues are compatible enough to bind in the pocket, and thus determine the 
requirement for particular residues at particular positions in the binding peptide. This is the 
MHC-I peptide binding specificity, and it turns out that only a few residue positions in the 
peptide are the major determinants of peptide binding specificity. Thus, only a small 
fraction of the entire peptide universe will be allowed to bind to any particular MHC-I 
allomorph, and it is this knowledge that is one important key to allow us to design peptide-
based vaccines that are highly specific, cheap and easy to disseminate. In this respect, it is 
important to understand MHC-I maturation and the underlying criteria. 
 




Fig. 1. The MHC-I protein structure allows short peptides to bind tightly in the peptide 
binding groove spanning the MHC-I 1/2-domains. A) Schematic structure of MHC-I, 
which consists of a HC with 3 -domains (light blue) and 2m (dark blue). In the peptide 
binding groove (at the top) the MHC-I has bound a peptide (yellow). B)  The protein crystal 
structure of HLA-B*15:01. The HC is colored light grey and 2m is colored dark grey. The 
peptide binding groove is located at the top between two encapsulating -helices (red). The 
peptide (yellow) is seen from the C-terminal. The electron density of the Cys101-Cys164 
disulfide bond in the peptide binding groove is shown in the inset. C) Top down view of the 
MHC-I peptide binding groove. D) The electron density of the peptide (LEKARGSTY). 
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3. MHC-I matures and is loaded with peptide inside the cell 
The maturation of MHC-I and ultimate generation of pMHC-I complexes initially involves 
two different processes that later merge into one common maturation process. Firstly, the 
HC and 2m have to be produced separately and translocated into the endoplasmic 
reticulum (ER). At the same time, the peptide that will later bind to the MHC-I has to be 
produced and transported into the lumen of the ER. The entire MHC-I antigen processing 
machinery (APM) process is illustrated in figure 2 showing the accessory proteins and 
chaperones involved in the stepwise processes ultimately resulting in a fully mature pMHC-
I complex that is exported to and situated on the cell surface. 
Several APM components are involved in the MHC-I quality control cycle, and regulates the 
sequential maturation process of MHC-I (Paulsson and Wang 2004). The HC undergoes co-
translational glycosylation while being translocated into the ER lumen in a nascent unfolded 
state. Inside the ER the HC instantly interacts with BiP, the Hsp90 protein, and soon also 
with calnexin, a general ER lectin chaperone. Calnexin binds to newly synthesized proteins 
with mono-glycosylated N-linked glycans, and in line with this also to early folding stages 
of the N-glycosylated HC (Ware, Vassilakos et al. 1995). This initial chaperoning of the HC  
prevents it from collapse and aggregation, and also sets the HC in a conformation that 
allows mature 2m to bind the HC forming the MHC-I heterodimer. Calnexin interacts with 
ERp57, a member of the protein disulfide isomerase (PDI) family, and is thought to involve 
in the correct formation of disulfide bonds within the HC (Oliver, Roderick et al. 1999). 
These intramolecular disulfide bonds strengthen the structural integrity and stability of the 
final pMHC-I complex. The newly formed MHC-I heterodimer is inherently unstable, but 
might be partly stabilized by binding a suboptimal peptide that later dissociates from the 
MHC-I. During these maturation steps calnexin dissociates from MHC-I and is immediately 
replaced by calreticulin, its soluble homologue. 
At this stage the MHC-I might not be further matured due to the following reasons: 1) The 
MHC-I has acquired a peptide that induces final MHC-I maturation, 2) the particular MHC-I 
allomorph is inherently less prone to, or binds a peptide not inducing full maturation but 
inducing a structure not able to integrate into the peptide-loading complex (PLC), or 3), the 
MHC-I integration into the PLC is prohibited by viral interference (Roder, Geironson et al. 
2008). However, for most HLA-I allomorphs the majority of MHC-I molecules are integrated 
into the PLC through binding to tapasin, where the late-stage maturation of the pMHC-I 
complex takes place. Tapasin has been ascribed many functions besides integrating MHC-I 
into the PLC. One of the most important functions, but also difficult to study, is to edit – and 
thereby optimize – the peptide loaded onto the MHC-I in the PLC with the purpose of 
generating stable pMHC-I complexes. In the PLC, which at least consists of the transporter 
associated with antigen processing (TAP), tapasin, calreticulin and ERp57, the MHC-I finally 
matures into a stable pMHC-I complex. ERp57 has proven important in the PLC, because it 
forms a disulfide conjugate with tapasin (Peaper, Wearsch et al. 2005). The tapasin-ERp57 
disulfide conjugate has been suggested to significantly boost the efficiency, whereby tapasin 
edits the MHC-I bound peptide repertoire (Wearsch and Cresswell 2007). 
So far, we have discussed the production and initial folding of the MHC-I. The generation 
and supply of peptides is equally important in the maturation of the final pMHC-I complex, 
and it all starts in the cytosol. Here, proteins are produced by the ribosome, but sometimes 
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the production fails, resulting in defective ribosomal products (DRiPs). The DRiPs are 
targeted for degradation by the cytosolic proteasome, and it is from this cleavage process that 
peptides are generated. It has been proposed that a large fraction of the MHC-I binding 
peptides derive from DRiPs (Yewdell, Anton et al. 1996). Other cytosolic proteases, such as 
TPPII, may assist in trimming the proteasome processed peptides.  
 
Fig. 2. An array of APM components present in the ER and the cytosol is involved in the 
sequential maturation and peptide loading of MHC-I. Early folding stages of MHC-I are 
promoted by BiP and then calnexin, which recruits ERp57. Subsequently, the MHC-I HC 
associates with 2m, and calnexin is replaced by calreticulin. Most of the MHC-I molecules 
are recruited into the PLC, which consists of ERp57, calreticulin, tapasin and TAP, where the 
folding of the mature MHC-I conformation as well as peptide loading is facilitated. Peptides 
are generated in the cytosol by the proteasome and trimmed in the ER to MHC-I optimal 
lengths by ERAP1. MHC-I molecules loaded with optimal peptides become stable and can 
exit the ER and be transported via the Golgi network to the cell surface, possibly, between 
ER and Golgi, through transport in COP-II vesicles. Loading of an optimal peptide can also 
occur before recruitment into PLC. The stable pMHC-I complex can the exit the ER through 
alternative ER exit sites for transport to the cell surface. Sub-optimally loaded MHC-I 
molecules can escape the ER but are the recycled in COP-I vesicles recruited by tapasin, 
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An essential part of the PLC is the heterodimeric TAP, which is composed of the TAP1 and 
TAP2 subunits, both containing an N-terminal transmembrane domain and a C-terminal 
cytosolic nucleotide-binding domain. Situated in the ER membrane TAP actively 
translocates the cytosolic peptides into the ER in a multistep process, which begins with 
association of peptides, usually 8-16 amino acid long with TAP (van Endert, Tampe et al. 
1994). Peptide binding to TAP is followed by an isomerization of the TAP complex that 
triggers an ATP-dependent peptide translocation across the ER membrane (Neefjes, 
Momburg et al. 1993). Many of the peptides that are transported by TAP into the ER lumen 
are still too long to bind firmly in the MHC-I peptide binding groove. These peptides are 
then further trimmed by the ER aminopeptidases ERAP1 and ERAP2 at the extended N-
terminus to 8-10 amino acids, which is the appropriate length for association with MHC-I 
(York, Chang et al. 2002; Tanioka, Hattori et al. 2003).  
We define an optimal MHC-I binding peptide as a peptide binding to MHC-I resulting in a 
stable pMHC-I complex. Thus, as a general rule, an optimal peptide has to bind firmly in the 
MHC-I peptide binding pockets. When a stable pMHC-I is formed, it is released from the 
PLC and transported to the cell surface. This underscores the importance of PLC-mediated 
pMHC-I quality control. pMHC-I complexes that consists only of suboptimal peptides are 
(per definition) unstable, and are not released from the PLC. This ensures the release of only 
stable pMHC-I complexes to the cell surface, which is vital for the subsequent CTL scrutiny. 
The pMHC-I transportation to the cell surface has been suggested to start with packaging of 
the pMHC-I complexes in COPII vesicles, which then migrate to the Golgi apparatus, and 
then further on to the cell surface (Paquet, Cohen-Doyle et al. 2004). The following sections 
discuss the MHC-I maturation, and peptide supply in much more detail. 
4. The MHC-I maturation is facilitated by multi-protein complexes in the ER 
In this section we go through the details of the HC production and folding in the ER 
involving APM components such as calnexin, calreticulin, ERp57 and tapasin. The 
chaperone BiP, known to interact cotranslationally with the nascent HC before other 
chaperones will not be further discussed. The following interactions of HC with each APM 
component are discussed in the maturation sequence as it is thought to occur. 
4.1 Calnexin and calreticulin shape the initial MHC-I heterodimer 
Both calnexin and its soluble homologue calreticulin are part of the general ER protein 
folding machinery, and bind to mono-glucosylated proteins. Despite overlapping substrate 
specificities, they also have distinct preferences, which can be explained by: 1) the positions 
and numbers of the glycosylation sites on the target protein (High, Lecomte et al. 2000), and 
2) the membrane anchoring of calnexin versus the soluble calreticulin. The latter was shown 
to be a major determinant, since an experiment with soluble calnexin demonstrated that the 
glycoprotein association pattern for soluble calnexin resembles the pattern for calreticulin 
(Danilczyk, Cohen-Doyle et al. 2000). Similarly, calreticulin expressed with an ER membrane 
anchor binds to a set of glycoproteins resembling those proteins normally bound to calnexin 
(Wada, Imai et al. 1995).  
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4.1.1 Calnexin and calreticulin bind differently to MHC-I around the glycosylation site 
As alluded to in the previous section, the location of the glycosylation sequon in the MHC-I 
determines its binding to calnexin and calreticulin, which would then be reflected in the 
sequential maturation of MHC-I. Human MHC-I HCs have a single N-linked glycosylation 
site at Asn86, whereas mouse HC possess glycosylation sequons at additional sites (Maloy 
1987). To support this notion, experiments have shown that introduction of a second 
glycosylation site in the human HC at the same position as in mouse HC, resulted in a 
maturation process that more resembled the mouse HCs with respect to calnexin and 
calreticulin association (Zhang and Salter 1998). In the human, the HC glycosylation sequon 
is located close to the ER membrane during translocation into the ER, calnexin first gains 
access to this site. Calnexin induces 2m binding to the HC, which brings the glycosylation 
sequon away from the membrane allowing the soluble calreticulin to replace calnexin 
(Solheim, Carreno et al. 1997).  
In the 2m deficient human cell line Daudi, there is little or no association of MHC-I HC 
with calreticulin, suggesting that calreticulin only binds the MHC-I heterodimer, but not the 
single HC (Solheim, Harris et al. 1997; Tector, Zhang et al. 1997). In mice the situation is 
somewhat different, because calnexin not only binds to free HC but also to the HC 
heterodimer (Nossner and Parham 1995). Furthermore, it was shown that calnexin is 
associated with assembled mouse MHC-I even after peptide loading and dissociation from 
the PLC (Suh, Mitchell et al. 1996). Mouse HCs are able to bind to TAP also in the 2m 
deficient mouse cell line S3, and calnexin is present in this complex. Interestingly, also the 
fully folded human HLA-B*27 heterodimer has been shown to bind calnexin in human cells 
when using sensitive experimental systems, this is however outside the PLC (Carreno, 
Solheim et al. 1995). This shows, that the calnexin and calreticulin binding to MHC-I is not 
only species specific but also HC allomorph specific. 
4.1.2 Glycosylation and the calnexin/calreticulin cycle 
During the folding process, the MHC-I go through several rounds of dynamic binding, 
release and re-binding of calnexin/calreticulin in what is referred to the glycoprotein 
quality-control cycle (Helenius and Aebi 2004). The cycle is part of the general protein 
folding machinery in the ER, and is here illustrated in figure 3 in the context of MHC-I 
maturation. When bound calnexin or calreticulin is released from the HC, its glycosyl 
moiety becomes available for de-glucosylation by glucosidase II. Subsequently, the MHC-I 
folding status is evaluated by the soluble enzyme UDP-glucose glycosyl transferase 
(UGGT). If MHC-I is incorrectly folded the HC will be re-glycosylated and re-enter the 
glycoprotein quality control cycle (Helenius and Aebi 2004).  
During translation and the BiP assisted folding the Asn86 of the MHC-I HC is N-glycosylated 
resulting in attachment of a Glc3Man9GlcNAc2 oligosaccharide moiety (Kornfeld and Kornfeld 
1985). The two outer glucose residues are then removed by glycosidase I and II leaving the 
MHC-I HC mono-glucosylated (Glc1Man9GlcNAc2) at this step in the maturation process 
(Elbein 1991). This enables subsequent interaction of HC with the lectin chaperones, calnexin 
and calreticulin (Hebert, Foellmer et al. 1995; Ware, Vassilakos et al. 1995). 
Both calnexin and calreticulin bind mono-glucosylated substrates (Hammond, Braakman  
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Fig. 3. The glycoprotein quality control cycle. Following the cotranslational glycosylation of 
MHC-I during translocation into the ER, glucosidase I and II remove the two outer glucoses 
immediately. When calnexin/calreticulin releases MHC-I the third glucose is removed and 
the folding status is evaluated by UDP-glucose glycosyl transferase. Incorrectly folded 
proteins will be re-glycosylated and re-enter the glycoprotein quality cycle whereas terminally 
misfolded proteins are degraded in the ER associated degradation (ERAD) pathway. 
non-glucosylated proteins (Ihara, Cohen-Doyle et al. 1999; Saito, Ihara et al. 1999). As the 
newly synthesized MHC-I HC enters the ER via the translocon it is subjected to N-linked 
glycosylation of the sequon Asn-X-Ser/Thr (Bause, Muller et al. 1983). The glycosylation 
adds three glucose residues to the protein. The presence of a glycosylation site within the 
first 50 amino acids of a protein entering the ER through the translocon allows the 
interaction with calnexin and calreticulin to begin cotranslationally (Molinari and Helenius 
2000). Inhibition of glycosylation results in many cases in misfolded, aggregated and 
dysfunctional proteins (Hickman, Kulczycki et al. 1977; Konig, Ashwell et al. 1988; Williams 
and Enns 1991). After trimming by glucosidase I and glucosidase II, mono-glucosylated HC 
is generated (Parodi 2000). The mono-glucosylated HC will then bind to calnexin for 
oxidative folding (Nossner and Parham 1995). Sequentially, the immature HC will create a 
heterodimer with the stabilising polypeptide β2m. As this occurs, calnexin is replaced by 
calreticulin, which then recruits the immature heterodimer into the PLC where it can be 
loaded with high affinity peptides (Wearsch, Peaper et al. 2011).  
It has been shown that the glycosylation of the MHC-I molecules in the ER is highly 
regulated. Nearly all monoglycosylated HC found in human cells are incorporated into the 
PLC and if deglycosylation is inhibited, their interaction with the PLC is significantly 
prolonged (Radcliffe, Diedrich et al. 2002; Wearsch, Peaper et al. 2011). A study using in vitro 
methods showed that glucosidase II could only trim free monyglycosylated HC and not 
those that were bound to the PLC (Wearsch, Peaper et al. 2011). This indicates that the 
glucose residues of the monoglycosylated MHC-I molecule become accessible to the 
glucosidase II first after its release from the PLC. After the last glucose residues has been 
removed, the MHC-I molecule can no longer associate with the PLC as its recruitment is 
dependent on the interaction with calreticulin which only binds to monoglycosylated 
proteins (Wearsch, Peaper et al. 2011). However, it has been proposed that if a 
deglycosylated MHC-I molecule is loaded with suboptimal peptide it can be rescued back 
into the PLC via the soluble enzyme UDP-glucose glycoprotein glucosyltransferase 1 
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(UGT1) (Zhang, Wearsch et al. 2011). The UGT1 can selectively reglycosylate the 
suboptimally loaded/incorrectly folded MHC-I molecule, and after trimming by 
glucosidase I and glucosidase II the monoglycosylated MHC-I molecule can ones again 
enter the PLC, this what is called the calnexin/calreticulin cycle. After the MHC-I molecule 
has become correctly folded and loaded with an optimal peptide it will be deglycosylated 
and released from the calnexin/calreticulin cycle for transport from the ER to the cell 
surface for presentation (Radcliffe, Diedrich et al. 2002). The time spent in the calnexin-
calreticulin cycle can range from a few minutes to several hours, the more complex the 
folding of a protein, the more time it needs to spend. If a protein fails to reach mature 
conformation it is destined for ERAD (Klausner and Sitia 1990). Also for degradation tags 
the trimming of N-linked glycans has been shown to be of importance and calnexin has been 
implicated in the sequestering of proteins tagged for degradation (Liu, Choudhury et al. 
1997). 
4.1.3 Lack of calreticulin, but not calnexin, diminishes MHC-I quality control 
In normal human cells the PLC consist of calreticulin, tapasin, ERp57, TAP, maturing MHC-
I (Sadasivan, Lehner et al. 1996; Peaper, Wearsch et al. 2005). Ten years ago the hypothesis 
was that the abundant ERp57 found in the PLC was a consequence of its interaction with 
calreticulin or possibly calnexin (Oliver, Roderick et al. 1999). However, co-
immunoprecipitation from K42 cells (a calreticulin deficient embryonic mouse fibroblast cell 
line) showed complexes of calnexin together with ERp57, tapasin and HC suggesting an 
alternative PLC constellation lacking calreticulin (Gao, Adhikari et al. 2002). Co-
immunoprecipitation in lysates of K42 cells showed that ERp57 was associated with TAP, 
but that no calnexin could be detected in these precipitates, suggesting that neither calnexin 
nor calreticulin are essential for recruitment of ERp57 to the PLC (Suh, Mitchell et al. 1996; 
Gao, Adhikari et al. 2002). More recently it has been shown that ERp57 is directly disulfide 
conjugated to tapasin in the PLC (Peaper, Wearsch et al. 2005). 
Calnexin deficient mice are viable and they show no discernible effects on other systems, 
including the immune system, possible because calreticulin effectively replaces the calnexin 
function even at the earlier MHC-I HC maturation stages. In contrast, calreticulin deficiency 
negatively impacts both trafficking and localization of MHC-I molecules. In the absence of 
calreticulin the MHC-I molecules are not retained in the ER, and the transport of immature 
MHC-I to the cell surface is accelerated. In K42 cells, many MHC-I molecules would be 
loaded with suboptimal peptides, due to lack of calreticulin in the MHC-I quality control, 
and the pMHC-I complexes would fall apart either before or on the cell surface (Gao, 
Adhikari et al. 2002). It was shown that the peptide-receptive MHC-I molecules were not 
found in the cis-Golgi or ER as they would be in wild type cells; instead they were found in 
endosomes and lysosomes. Under these circumstances the suboptimally loaded MHC-I 
molecules are transported to the cell surface, where the pMHC-I complexes almost instantly 
disintegrate, and are readily endocytosed ultimately leading to a significant reduction in 
MHC-I mediated antigen presentation (Howe, Garstka et al. 2009). 
4.2 ERp57 oxidizes the MHC-I heavy chain and supports tapasin function 
ERp57 is a multifunctional protein belonging to the thioredoxin family of proteins (Khanal 






Fig. 3. The glycoprotein quality control cycle. Following the cotranslational glycosylation of 
MHC-I during translocation into the ER, glucosidase I and II remove the two outer glucoses 
immediately. When calnexin/calreticulin releases MHC-I the third glucose is removed and 
the folding status is evaluated by UDP-glucose glycosyl transferase. Incorrectly folded 
proteins will be re-glycosylated and re-enter the glycoprotein quality cycle whereas terminally 
misfolded proteins are degraded in the ER associated degradation (ERAD) pathway. 
non-glucosylated proteins (Ihara, Cohen-Doyle et al. 1999; Saito, Ihara et al. 1999). As the 
newly synthesized MHC-I HC enters the ER via the translocon it is subjected to N-linked 
glycosylation of the sequon Asn-X-Ser/Thr (Bause, Muller et al. 1983). The glycosylation 
adds three glucose residues to the protein. The presence of a glycosylation site within the 
first 50 amino acids of a protein entering the ER through the translocon allows the 
interaction with calnexin and calreticulin to begin cotranslationally (Molinari and Helenius 
2000). Inhibition of glycosylation results in many cases in misfolded, aggregated and 
dysfunctional proteins (Hickman, Kulczycki et al. 1977; Konig, Ashwell et al. 1988; Williams 
and Enns 1991). After trimming by glucosidase I and glucosidase II, mono-glucosylated HC 
is generated (Parodi 2000). The mono-glucosylated HC will then bind to calnexin for 
oxidative folding (Nossner and Parham 1995). Sequentially, the immature HC will create a 
heterodimer with the stabilising polypeptide β2m. As this occurs, calnexin is replaced by 
calreticulin, which then recruits the immature heterodimer into the PLC where it can be 
loaded with high affinity peptides (Wearsch, Peaper et al. 2011).  
It has been shown that the glycosylation of the MHC-I molecules in the ER is highly 
regulated. Nearly all monoglycosylated HC found in human cells are incorporated into the 
PLC and if deglycosylation is inhibited, their interaction with the PLC is significantly 
prolonged (Radcliffe, Diedrich et al. 2002; Wearsch, Peaper et al. 2011). A study using in vitro 
methods showed that glucosidase II could only trim free monyglycosylated HC and not 
those that were bound to the PLC (Wearsch, Peaper et al. 2011). This indicates that the 
glucose residues of the monoglycosylated MHC-I molecule become accessible to the 
glucosidase II first after its release from the PLC. After the last glucose residues has been 
removed, the MHC-I molecule can no longer associate with the PLC as its recruitment is 
dependent on the interaction with calreticulin which only binds to monoglycosylated 
proteins (Wearsch, Peaper et al. 2011). However, it has been proposed that if a 
deglycosylated MHC-I molecule is loaded with suboptimal peptide it can be rescued back 
into the PLC via the soluble enzyme UDP-glucose glycoprotein glucosyltransferase 1 
 
MHC Class I Quality Control 
 
171 
(UGT1) (Zhang, Wearsch et al. 2011). The UGT1 can selectively reglycosylate the 
suboptimally loaded/incorrectly folded MHC-I molecule, and after trimming by 
glucosidase I and glucosidase II the monoglycosylated MHC-I molecule can ones again 
enter the PLC, this what is called the calnexin/calreticulin cycle. After the MHC-I molecule 
has become correctly folded and loaded with an optimal peptide it will be deglycosylated 
and released from the calnexin/calreticulin cycle for transport from the ER to the cell 
surface for presentation (Radcliffe, Diedrich et al. 2002). The time spent in the calnexin-
calreticulin cycle can range from a few minutes to several hours, the more complex the 
folding of a protein, the more time it needs to spend. If a protein fails to reach mature 
conformation it is destined for ERAD (Klausner and Sitia 1990). Also for degradation tags 
the trimming of N-linked glycans has been shown to be of importance and calnexin has been 
implicated in the sequestering of proteins tagged for degradation (Liu, Choudhury et al. 
1997). 
4.1.3 Lack of calreticulin, but not calnexin, diminishes MHC-I quality control 
In normal human cells the PLC consist of calreticulin, tapasin, ERp57, TAP, maturing MHC-
I (Sadasivan, Lehner et al. 1996; Peaper, Wearsch et al. 2005). Ten years ago the hypothesis 
was that the abundant ERp57 found in the PLC was a consequence of its interaction with 
calreticulin or possibly calnexin (Oliver, Roderick et al. 1999). However, co-
immunoprecipitation from K42 cells (a calreticulin deficient embryonic mouse fibroblast cell 
line) showed complexes of calnexin together with ERp57, tapasin and HC suggesting an 
alternative PLC constellation lacking calreticulin (Gao, Adhikari et al. 2002). Co-
immunoprecipitation in lysates of K42 cells showed that ERp57 was associated with TAP, 
but that no calnexin could be detected in these precipitates, suggesting that neither calnexin 
nor calreticulin are essential for recruitment of ERp57 to the PLC (Suh, Mitchell et al. 1996; 
Gao, Adhikari et al. 2002). More recently it has been shown that ERp57 is directly disulfide 
conjugated to tapasin in the PLC (Peaper, Wearsch et al. 2005). 
Calnexin deficient mice are viable and they show no discernible effects on other systems, 
including the immune system, possible because calreticulin effectively replaces the calnexin 
function even at the earlier MHC-I HC maturation stages. In contrast, calreticulin deficiency 
negatively impacts both trafficking and localization of MHC-I molecules. In the absence of 
calreticulin the MHC-I molecules are not retained in the ER, and the transport of immature 
MHC-I to the cell surface is accelerated. In K42 cells, many MHC-I molecules would be 
loaded with suboptimal peptides, due to lack of calreticulin in the MHC-I quality control, 
and the pMHC-I complexes would fall apart either before or on the cell surface (Gao, 
Adhikari et al. 2002). It was shown that the peptide-receptive MHC-I molecules were not 
found in the cis-Golgi or ER as they would be in wild type cells; instead they were found in 
endosomes and lysosomes. Under these circumstances the suboptimally loaded MHC-I 
molecules are transported to the cell surface, where the pMHC-I complexes almost instantly 
disintegrate, and are readily endocytosed ultimately leading to a significant reduction in 
MHC-I mediated antigen presentation (Howe, Garstka et al. 2009). 
4.2 ERp57 oxidizes the MHC-I heavy chain and supports tapasin function 
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and Soling 1999; Silvennoinen, Myllyharju et al. 2004). ERp57 is mainly, but not exclusively, 
an ER resident protein (Turano, Coppari et al. 2002) with a C-terminal Gln-Glu-Asp-Leu 
(QEDL) retention signal (Urade, Oda et al. 1997) and two thioredoxin domains with CGHC 
motifs shared with ERp72, protein disulfide isomerase (PDI) and other members of the 
thioredoxin family. Not only have many names been designated to this protein but several 
different functions of ERp57 have also been suggested including thiol-dependent 
oxidoreductase (Bourdi, Demady et al. 1995; Hirano, Shibasaki et al. 1995), cysteine protease 
(Urade and Kito 1992; Urade, Nasu et al. 1992), carnitine palmitoyl transferase (Wada, Imai 
et al. 1995), a hormone induced protein of the brain (Mobbs, Fink et al. 1990; Mobbs, Fink et 
al. 1990) and in combination with calnexin and/or calreticulin as a chaperone for N-
glycosylated proteins in the ER (Oliver, van der Wal et al. 1997).  
In the ER, ERp57 has been shown to be associated with the PLC where it plays a critical role 
in the MHC-I maturation (Dong, Wearsch et al. 2009). It has also been shown to be involved 
in the quality control of other newly synthesized glycoproteins (Urade, Okudo et al. 2004; 
Khanal and Nemere 2007). In the PLC, ERp57 is covalently bound to tapasin via a disulfide 
bond between Cys95 of tapasin and Cys57 of ERp57, however the structural characterisation 
of the complex indicates that the heterodimer is also stabilised by non-covalent interactions 
between tapasin and the a and a’ domains of ERp57 (Dong, Wearsch et al. 2009). Calnexin 
and calreticulin, which both bind to ERp57 associate at the b and b’ domains of the protein 
(Russell, Ruddock et al. 2004; Kozlov, Maattanen et al. 2006). It has been suggested that the 
binding to calnexin and calreticulin is required for the recruitment of ERp57 into the PLC 
(Oliver, van der Wal et al. 1997; Oliver, Roderick et al. 1999). However, in more recent 
studies it has been proposed that ERp57 also on its own can recognize and bind some newly 
synthesized proteins such as MHC-I HC in the absence of calnexin and calreticulin (Zhang, 
Kozlov et al. 2009). An important function of ERp57 is its thiol-dependent reductase activity 
that catalyse the formation of protein disulide-bonds during the folding of glycoproteins in 
the ER (Tector and Salter 1995). However, in contrast, it has been shown that in the PLC and 
during the maturation of MHC-I, ERp57 has a more structural role by stabilising tapasin and 
the PLC (Garbi, Tanaka et al. 2006). The heterodimer of tapasin and ERp57 has also been 
shown to have a peptide editing function thereby playing a key role in the generation of 
mature and stable pMHC-I complexes that are to be presented on the cell surface (Wearsch 
and Cresswell 2007). 
An ubiquitous deletion of the ERp57 gene in mouse results in death in utero. To study the 
effects of ERp57 deficiency this problem was circumvented by generating a tissue specific 
deletion in the B cell compartment that resulted in B cells lacking the expression of ERp57 
(Garbi, Tanaka et al. 2006). The development and survival of the ERp57 deficient B cells 
were not affected nor was there any indication that the folding of glycoproteins such as the 
immunoglobulin, CD25, CD1d, CD19, CD23, CD72, CD40, CD80 and CD86 was reduced. 
This suggests that ERp57 is not essential for the basic B cell functions and glycoprotein 
folding in these mouse cells (Garbi, Tanaka et al. 2006). However, in another study the 
folding of specific glycoprotein substrates was shown to be reduced in the absence of ERp57 
(Jessop, Chakravarthi et al. 2007). Even though the general glycoprotein folding was not 
shown to be affected in the ERp57 deficient B cells there was a significantly lower surface 
expression of MHC-I molecules (H-2Kb showing a reduction of 50% whereas H-2Db was 
only slightly reduced) compared to non-B cells expressing wild type amounts of ERp57 
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(Garbi, Tanaka et al. 2006). This further confirms the importance of ERp57 as a key player in 
generation of stable mature MHC-I molecules. 
4.3 Tapasin optimizes the MHC-I peptide repertoire by releasing only stable pMHC-I  
Tapasin (TAP associated glycoprotein) was discovered more than a decade ago and has 
during the years been assigned a central role in the loading aspects of the MHC-I quality 
control (Sadasivan, Lehner et al. 1996). In 1994, the description of the human lympho-
blastoid B-cell line, termed LCL-721.220, marked the beginning of the discovery of tapasin. 
The LCL-721.220 did not have any HLA-A or HLA-B and only minor expression of HLA-C, 
and were devoid of full-length tapasin (Copeman, Bangia et al. 1998). The HLA-I cell surface 
expression of different HLA-I transfectants was monitored and found to be dependent on 
the particular HLA-I allomorph (Greenwood, Shimizu et al. 1994). For example, HLA-A*1 
and HLA-B*8 were reduced to 21% of the expression in a normal cell having tapasin, 
whereas HLA-A*2, HLA-A*3 and HLA-B*7 were reduced. The HLA-I cell surface expression 
was restored when LCL-721.220 was fused with either LCL-721.174 or Daudi; cell lines 
having tapasin. Thus, LCL-721.220 lacked one or several unknown mechanisms responsible 
for the maturation of MHC-I (Grandea, Androlewicz et al. 1995). At the same time, a 48 kDa 
protein with a yet unknown function was shown to co-immunoprecipitate with TAP in a 
wild type cell line (Ortmann, Androlewicz et al. 1994). In 1996, this 48 kDa protein was 
named tapasin (Sadasivan, Lehner et al. 1996), and it was shown by western blot to be 
absent in LCL-721.220 possibly explaining the defect in MHC-I maturation (Copeman, 
Bangia et al. 1998). Later, expression of tapasin in LCL-721.220 restored MHC-I cell surface 
expression and confirmed this hypothesis (Ortmann, Copeman et al. 1997). At that time, the 
true identity of tapasin was not known. The following year, the cDNA of the TAP-associated 
protein corresponding to tapasin was cloned, and it was found that tapasin is a 428 amino 
acid large, type-I transmembrane glycoprotein with a short cytoplasmic tail (Li, Sjogren et 
al. 1997; Ortmann, Copeman et al. 1997). 
In 1997, it was proposed that tapasin is a member of the Ig superfamily containing an IgC1-
SET domain (Ortmann, Copeman et al. 1997; Herberg, Sgouros et al. 1998). Subsequently, it 
was suggested that amino acids 284 - 401 mostly originating from exon 5 has an Ig-like 
structure (Mayer and Klein 2001). This was further elaborated on using homology modeling 
suggesting that 287 - 401 has an Ig-like fold (Turnquist, Petersen et al. 2004). After many 
crystallization attempts, the first protein crystal structure was reported of tapasin in a stable 
disulfide conjugate with ERp57 (Dong, Wearsch et al. 2009). ERp57 has been proposed to 
stabilize tapasin when covalently associated through a disulfide bond (Peaper, Wearsch et 
al. 2005). The structure reveals that tapasin has two ER luminal domains. Domain-1 is the N-
terminal domain spanning residues 1-269, and domain-2 spans the remaining residues 270-
381 in the luminal part of tapasin. 
To this date, it has not been possible to predict the structure of tapasin based on the amino 
acid sequence. This could be attributed to the fact that tapasin has a unique amino acid 
sequence especially within the now recognized domain-1. Related to the unique amino acid 
sequence the structure of tapasin domain-1 also has a unique 3-dimensional fold compared 
to other proteins. This domain consists mainly of anti-parallel beta-sheets. Interestingly, 
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within this domain are two beta-barrel-like structures that are tightly bound to each other. 
The stretch spanning the residues 77-102 contains a small alpha-helix (residues 83-90), but 
does not otherwise contain any secondary structure elements. The stretch contains the 
cysteine at position 95 and might serve as an extension from tapasin towards ERp57.  
4.3.1 Tapasin only integrates 2m-associated MHC-I HC into the PLC 
Tapasin directly interacts with at least three components inside the PLC; it bridges MHC-I 
and TAP, and is simultaneously covalently bound to ERp57 thereby serving as an important 
structural component in the PLC. Tapasin does only interact with 2m-associated MHC-I 
HC supported by observations showing that the MHC-I HC cannot be co-
immunoprecipitated together with tapasin in Daudi cells, a 2m negative cell line (Paulsson, 
Wang et al. 2001). Furthermore, the PLC is not assembled in Daudi cells, strongly suggesting 
that the MHC-I maturation takes place in successive stages inside the ER, and that 2m is 
required for interaction with tapasin and integration into the PLC (Lewis and Elliott 1998). A 
contrasting study reported that tapasin directly interacts with MHC-I in the absence of 2m 
(Rizvi and Raghavan 2006). In the absence of other cellular components it was shown that 
recombinant tapasin directly interacts with MHC-I HC alone or the MHC-I heterodimer. 
The study also showed that sufficient 2m would effectively disrupt the tapasin-MHC-I 
interaction. In this regard, it may be speculated that in this in vitro system sufficient amounts 
of 2m may stabilize MHC-I to such an extent, that it is no longer unstable and is therefore 
not able to interact with tapasin. 
4.3.2 In the PLC, tapasin keeps MHC-I peptide-receptive 
Exactly how MHC-I gets loaded with (the right) peptide in the ER is controversial. MHC-I 
incorporation into the PLC is mediated by tapasin structurally bridging MHC-I and TAP (Li, 
Sjogren et al. 1997; Ortmann, Copeman et al. 1997). In addition to serving as a structural 
component in the PLC, tapasin has also been suggested to facilitate peptide loading, edit the 
MHC-I peptide cargo, retain and recycle sub-optimally loaded pMHC-I complexes 
(Grandea, Lehner et al. 1997; Paulsson, Kleijmeer et al. 2002; Zarling, Luckey et al. 2003; 
Paulsson, Jevon et al. 2006). Here, we will describe what is currently known about the role of 
tapasin in MHC-I quality control within the PLC. 
To describe the chaperone and peptide-editor function of tapasin it is necessary to 
accurately define these terms. A chaperone is a protein that assists the folding of a target 
protein. Regarding tapasin, the only target protein identified is MHC-I, and the chaperone 
function of tapasin is to facilitate the folding of MHC-I. During MHC-I maturation, tapasin 
has been found to facilitate the assembly of MHC-I in the ER ultimately resulting in 
increased cell surface expression (Lauvau, Gubler et al. 1999; Zarling, Luckey et al. 2003; 
Everett and Edidin 2007). To support this notion, a study using recombinant tapasin and 
HLA-I showed that tapasin facilitates folding of HLA-I in the absence of other PLC proteins 
(Chen and Bouvier 2007). We have recently shown that tapasin has chaperone function, and 
that at least part of this chaperone function is located within the first 87 amino acids of 
tapasin (Tpn1-87) (Roder, Geironson et al. 2009; Roder, Geironson et al. 2011). A cell-free 
assay was developed to study the Tpn1-87 chaperone function on folding HLA-I under 
controllable conditions. We observed that Tpn1-87 facilitated the folding of HLA-I, and the 
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extend of the folding could be directly, but inversely, correlated with the intrinsic stability of 
the pMHC-I complex. Based on these observations a model for the tapasin chaperone 
function can be constructed in which, tapasin chaperones the MHC-I heterodimer by 
keeping it in a peptide-receptive state. A suboptimal peptide that only confers a low-
stability pMHC-I complex will either not release bound tapasin (and thus be retained in the 
ER), or the pMHC-I will quickly disintegrate, and tapasin will instantly re-associate to the 
MHC-I heterodimer. Only optimal peptides will confer a highly stable pMHC-I complex 
and cause the release of tapasin. 
Regarding the aforementioned peptide-editor function, it is here defined as tapasin catalyzing 
the exchange of peptides on MHC-I. More specifically, tapasin directly interacts with the 
MHC-I thereby keeping it in a peptide-receptive conformational state. Only when an 
optimal peptide is loaded onto the MHC-I will tapasin release the MHC-I as shown in a 
study using recombinant proteins (Rizvi and Raghavan 2006). Tapasin and ERp57 are 
disulfide linked in the PLC, and it was shown this tapasin-ERp57 disulfide conjugate 
catalyzes MHC-I peptide-exchange (Peaper, Wearsch et al. 2005). Interestingly, both tapasin 
chaperone and peptide-editor function can be thought of as consequences of the same 
underlying tapasin mechanism, which is tapasin assisted stabilization of MHC-I. Tapasin 
arrests the MHC-I in a conformation preventing the MHC-I from aggregation and 
degradation, the chaperone function. The same conformation also keeps the MHC-I in a 
peptide-receptive state, allowing the association and dissociation of peptides. Only an 
optimal peptide binding to the MHC-I is able to change the MHC-I conformation causing 
the release of MHC-I from tapasin. Taken together, chaperone and peptide-editor functions 
of tapasin could be considered the mere consequences of its interaction with the MHC-I. 
One consequence of keeping the MHC-I in a peptide-receptive conformation is giving an 
increasing diversity of peptides a chance to bind to the MHC-I. Of course, in the ER most of 
these peptides will be of suboptimal nature. In this line of reason, tapasin is expected to alter 
the pool of peptides presented by MHC-I. This was observed in one study that reported a 
reduced number of peptides presented on HLA-A*02:01 in the absence of tapasin (Barber, 
Howarth et al. 2001). This observation supports the theory presented here, because in the 
absence of tapasin suboptimal peptides will out-compete the optimal peptide for binding to 
HLA-A*02:01, and the suboptimal pMHC-I complexes will still be transported to the cell 
surface, because tapasin is not present to retain them in the ER.  
4.3.3 Tapasin mediates recycling of unstable pMHC-I back to the ER 
Assurance of mature and highly stable pMHC-I complexes on the cell surface in wild-type 
cells has generally been attributed to ER retention of immature MHC-I. The established theory 
arises from different experimental systems showing that tapasin retains MHC-I molecules in 
the ER until loaded with optimal peptides, i.e. peptides binding to MHC-I and resulting in 
stable pMHC-I complexes (Schoenhals, Krishna et al. 1999; Grandea, Golovina et al. 2000). 
In addition, a recycling mechanism of MHC-I from late secretory compartments back to the 
ER has been suggested to exist based on evidence from several studies (Hsu, Yuan et al. 1991; 
Bresnahan, Barber et al. 1997; Park, Lee et al. 2001; Paulsson, Kleijmeer et al. 2002). Shown in 
figure 2 are COP-I coated vesicles that recognize and bind to C-terminal KKXX-motifs in 
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Letourneur 1994). The findings that tapasin contains a C-terminal KKXX-motif and has been 
shown to have prolonged association with sub-optimally loaded pMHC-I complexes led to the 
investigation of tapasin involvement in COP-I transport (Paulsson, Kleijmeer et al. 2002). 
Tapasin was demonstrated to bind to COP-I via its KKXX-motif (Paulsson, Jevon et al. 2006). 
In cells expressing tapasin with the KKXX-motif mutated to AAXX, neither tapasin nor MHC-I 
were detected in association with COP-I, indicating a direct role for the tapasin KKXX-motif in 
mediating the MHC-I transport by COP-I coated vesicles. In the same cells, cell surface 
expression of MHC-I molecules was significantly increased, but MHC-I degradation was also 
increased suggesting escape to the cell surface of immature MHC-I. Thus, immature pMHC-I 
complexes having accidentally escaped the ER before being loaded with an optimal peptide, 
can be returned to the PLC in the ER for another round of peptide cargo optimization before 
being exported to the cell surface as mature and stable pMHC-I complexes. 
4.3.4 The maturation of different MHC-I allomorphs depends differently on tapasin 
A frequently used concept in the tapasin literature is tapasin dependency associated with each 
MHC-I allomorph. There has been a lack of previous consensus of this concept, and the use 
of dependency has been used referring to several types of distinct observations. In its strict 
sense, the dependency is how the cell surface expression of MHC-I depends on the presence 
of tapasin inside the cell. Thus, cell surface expression of HLA-I allomorphs that are highly 
dependent on tapasin will then be dramatically reduced in the absence of tapasin and vice 
versa. In this sense, HLA-I antigen presentation is controlled by tapasin to an extent 
depending on the HLA-I allomorph. To further investigate this dependency, we recently 
quantified the ability of Tpn1-87 to chaperone different pMHC-I complexes, see figure 4. 
HLA-B*44:02 has been shown to be almost completely dependent on tapasin, since HLA-
B*44:02 steady-state surface expression level is reduced by more than 90% in the tapasin 
deficient LCL-721.220 human cell line compared to the transfected homologues (Peh, 
Burrows et al. 1998). The same study also showed that HLA-B*27:05 surface expression was 
only slightly dependent on tapasin, whereas HLA-B*08:01 in this and another study was 
shown to be intermediate dependent on tapasin (Zarling, Luckey et al. 2003). 
 
 
Fig. 4. MHC-I residues related to tapasin dependency (a), and tapasin chaperoning of 
different pMHC-I complexes (b). 
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Regarding the specificity of the tapasin-MHC-I interaction, several reports have shown that 
entire regions and single residues on MHC-I and tapasin that are important in their 
interaction and function. The most well-studied single mutation was in HLA-A*02:01 where 
a threonine at position 134 was mutated to a lysine (T134K) (Lewis, Neisig et al. 1996; Peace-
Brewer, Tussey et al. 1996). The HLA-A*02:01-T134K mutant allomorph is unable to interact 
with tapasin, and this mutation can thus be used as a negative control in experiments 
studying the tapasin- MHC -I interaction. 
Notoriously, it is the amino acid sequence that makes MHC-I allomorph distinct. The amino 
acid at position 114 of HLA-B*44:02 and HLA-B*27:05 has been shown to be of crucial 
importance regarding tapasin dependence, the higher the acidity of this amino acid the 
higher the tapasin dependence (Park, Lee et al. 2003). HLA-B*27:05 and HLA-B*44:02 
(D114H) both have histidine at position 114, and are both tapasin-independent, while HLA-
B*44:02 and HLA-B*35:01 have aspartic acid at residue 114 and are demonstrated to be 
dependent on tapasin (Peh, Burrows et al. 1998; Park, Lee et al. 2003). It is very interesting 
that a single residue (in certain HLA-I allomorphs) can completely change tapasin 
dependency, and it is especially interesting that residue 114 has this effect since it is not surface 
exposed, but buried deep down in the peptide binding groove close to the apex of the F-
pocket. The tapasin interaction site on MHC-I is thought to be the surface exposed loop where 
the much discussed residue 134 is situated, and thus residue 114 is distal to the proposed 
tapasin interaction site, but is even though a strong determinant of tapasin dependence. 
4.3.5 Tapasin stabilizes TAP and increases peptide transport efficiency  
Tapasin binds directly to MHC-I, and form together with TAP the core of the PLC. The TAP-
tapasin complex interacts with MHC-I, calreticulin and ERp57 to form a fully functional 
PLC capable of loading peptides into the peptide-receptive MHC-I binding groove (Garbi, 
Tan et al. 2000; Gao, Adhikari et al. 2002; Williams, Peh et al. 2002; Garbi, Tanaka et al. 2006), 
see figure 2. The precise binding site to TAP has not yet been mapped, but it has been 
suggested that the first N-terminal transmembrane helix of TAP binds to the 
transmembrane domain of tapasin (Koch, Guntrum et al. 2006), supported by the fact that 
soluble human tapasin variants are defective in TAP association, also resulting in MHC-I 
that does not bind to TAP (Sadasivan, Lehner et al. 1996). As we will go in more detail with 
in a later section, TAP transports cytosolic peptides into the ER lumen. TAP exists as a 
TAP1/2 heterodimer, which was shown to be stabilized by tapasin (Garbi, Tiwari et al. 
2003). Furthermore, tapasin was shown to increase the peptide transport throughput by 
TAP (Li, Paulsson et al. 2000). Thus, in addition to localizing MHC-I close to the source of 
peptide transportation, tapasin also structurally bridges the PLC together while at the same 
time interacts with and keeps the MHC-I in a peptide-receptive conformation. 
5. The MHC-I binding peptide has been processed by many proteases 
5.1 The proteasome generates long peptides from degradable proteins 
Large multicatalytic protease complexes named proteasomes are located in the cytosol and 
degrade proteins as part of normal cellular turnover. The proteasome is essential for MHC-I 
antigen presentation, and inhibitors of the proteasome reduce the generation of peptides 
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(DRiPs) are polypeptides that never reach a functional state owing to errors in translation or 
folding. They are rapidly ubiquitylated during translation and have been shown to be a 
major source of peptides presented by MHC-I (Reits, Vos et al. 2000; Schubert, Anton et al. 
2000). The use of these newly translated proteins, facilitates rapid recruitment of effector 
cells to virally infected cells, resulting in a more efficient withdrawal of the infection.    
The proteasome contains IFN--inducible subunits. Under conditions of IFN-γ induction the 
1, β2 and β5 subunits are replaced by immunosubunits, low-molecular-mass polypeptide 2 
(LMP2), multi-catalytic endopeptidase complex-like 1 (MECL-1) and LMP7 respectively, 
resulting in assembly of new proteasomes called immunoproteasome (Loukissa, Cardozo et al. 
2000; Jamaluddin, Wang et al. 2001). Immunoproteasomes are concentrated around the ER, 
whereas constitutive proteasomes are distributed evenly in the cytoplasm and in the nucleus 
(Brooks, Murray et al. 2000). Immunoproteasomes, compared to constitutive proteasomes, 
have an increased capacity to cleave peptides after hydrophobic and basic residues but 
reduced capacity to cleave after acidic amino acids (Gaczynska, Rock et al. 1993; Gaczynska, 
Rock et al. 1994). Furthermore, immunoproteasomes generate peptides with an extended N-
terminal sequence that will facilitate transport into the ER (Cascio, Hilton et al. 2001; Knuehl, 
Spee et al. 2001). Even though immunoproteasomes favour the production of peptides 
presented by MHC-I molecules, they are not an absolute requirement (Arnold, Driscoll et al. 
1992; Yewdell, Lapham et al. 1994), and some antigenic peptides are even efficiently produced 
by the constitutive proteasomes only (Chapiro, Claverol et al. 2006). 
5.2 TAP transports cytosolic peptides into the ER and supports MHC-I quality control 
An essential part of the PLC is the heterodimeric TAP composed of the TAP1 and TAP2 
subunits, both containing an N-terminal transmembrane domain and a C-terminal cytosolic 
nucleotide-binding domain. TAP1 and TAP2 have 10 and 9 transmembrane helices, 
respectively, where the 6 C-terminal helices from each subunit build together to form the so 
called 6+6 TM core complex which has been shown to be essential and sufficient for ER 
targeting, assembly of the heterodimer, binding of peptide and peptide translocation (Koch, 
Guntrum et al. 2004). The translocation is a multistep process, beginning with association of 
peptides with TAP in an ATP-independent manner (Androlewicz, Anderson et al. 1993; van 
Endert, Tampe et al. 1994; Neumann and Tampe 1999). Peptides with a length of 8-16 amino 
acids are preferentially bound to TAP (van Endert, Tampe et al. 1994). Peptides with 8-12 
amino acids are transported most efficiently, although peptides longer than 40 amino acids are 
also transported, albeit with a lower efficiency (Androlewicz, Anderson et al. 1993; Koopmann, 
Post et al. 1996). The C-terminal amino acid and the first three N-terminal residues of the 
peptide have been shown to play a key role in TAP recognition (Scholz and Tampe 2005). 
Peptides with basic or hydrophobic amino acids at the C-terminus are particularly preferred 
by human TAP. Peptide binding to TAP is followed by a slow isomerization of the TAP 
complex that triggers an ATP-dependent peptide translocation across the ER membrane 
(Neefjes, Momburg et al. 1993; Shepherd, Schumacher et al. 1993; Scholz and Tampe 2005). 
5.3 Calreticulin and calnexin bind peptides – part of the peptide relay system 
As has been previously described both calnexin and calreticulin are multifunctional 
proteins. In addition to playing a key role in the maturation of MHC-I molecules via the 
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calnexin/calreticulin cycle it has also been shown that they are able to bind peptides. 
Neefjes and colleagues have shown that both the chaperones calnexin and calreticulin bind 
peptides in vitro (Spee and Neefjes 1997; Spee, Subjeck et al. 1999). Calreticulin has also been 
shown to bind peptides in vivo (Nair, Wearsch et al. 1999). Many other heat shock proteins 
have also been demonstrated to bind peptide and a model of peptide transfer along a line of 
chaperones from the cytosol to the lumen of the ER – the peptide relay system – has been 
suggested to be responsible for directing peptides towards MHC-I presentation (Srivastava, 
Udono et al. 1994). The complexes formed when chaperones bind peptide have been 
suggested to bind to heat shock protein receptors on the surface of professional APCs, 
which leads to en internalization of the complex. The peptide from the complex is then 
presented by the MHC-I resulting in the elicitation of a CTL response. It has also been 
shown that chaperone-peptide complexes can stimulate the APCs to secrete certain 
cytokines (Srivastava, Menoret et al. 1998).  
5.4 ERAP aminopeptidases trim ER peptides to fit the MHC-I peptide binding groove 
After the peptides have been transported by TAP into the ER they may be further trimmed 
by aminopeptidases such as ER aminopeptidases 1 and 2 (ERAP1 and ERAP2) (Saric, Chang 
et al. 2002; Serwold, Gonzalez et al. 2002; Saveanu, Carroll et al. 2005). Although both are 
members of the M1 family of zinc metolloproteases (Rawlings, Barrett et al. 2010) ERAP1 
and ERAP2 show striking differences in their substrate preferences. ERAP1 has a preference 
for large hydrophobic residues while ERAP2 prefers basic residues (Hattori, Kitatani et al. 
2000; Tanioka, Hattori et al. 2003; Saveanu, Carroll et al. 2005). In contrast to most other 
aminopeptidases, that are more or less restricted to cleaving peptides shorter than four 
residues, ERAP1 shows a strong increase in cleaving activity towards peptides that are 
between 10-16 residues long (York, Chang et al. 2002). As ERAP1 and ERAP2 cleave 
substrates with different preferential for the N-terminal residues ERAP1 and ERAP2 have 
been suggested to work in concert for trimming of MHC-I binding peptides (Saveanu, 
Carroll et al. 2005).  
The mechanism by with ERAP1 recognizes and cleaves peptides of a specific length has 
been debated. The crystal structure of ERAP1 (bound to bestatin) reveals a large cavity that 
would explain the preference for longer substrates compared to most other aminopeptidases 
(Nguyen, Chang et al. 2011). In this large cavity a catalytic site is found to which the N-
terminal part of the peptide binds. It has been proposed that in close proximity to this 
catalytic site a regulatory site is found to which the C-terminal part of the peptide is bound, 
this “double binding” ensures a closed conformation of the ERAP1 molecule resulting in 
effective cleaving of the peptide. However, if the peptide is too short the C-terminal will not 
reach the regulatory site and the “double binding” will not be achieved resulting in an 
ineffective cleaving of the peptide (Nguyen, Chang et al. 2011). 
The preference for longer immature antigenic peptide precursors supports the role of 
ERAP1 in the processing of antigenic peptides that are to be presented on MHC-I 
molecules, which preferentially bind peptides of eight to ten amino acid residues. It has 
been shown that over expression of ERAP1 enhances the presentation of antigenic 
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In agreement with this is the finding from ERAP1 siRNA knock down studies that 
showed a reduction in antigenic peptides presented by the MHC-I molecules (York, 
Chang et al. 2002). In mice ERAP1 deficiency gives a significantly reduced MHC-I 
expression on the cell surface (Yan, Parekh et al. 2006). ERAP1 is IFN- inducible as is 
many important APM components, putting ERAP1 in the same category (York, Chang et 
al. 2002). 
6. Perspectives 
Understanding the antigen processing and quality control of pMHC-I complexes is likely to 
significantly help us understand the criteria for why some MHC-I binding peptides are 
presented while others are not, and also why some peptides are able, and others are unable 
to function as CTL epitopes. The stability of pMHC-I complexes is likely to influence both 
positive and negative selection of responding CTLs implicating pMHC-I quality control as 
important in both autoimmune disease and as tumour antigens. Moreover, expression of 
many APM components is altered in many tumours and certain virus alter APM component 
activity and/or expression, and as a consequence change the MHC-I presented peptide pool 
both qualitatively and quantitatively. In conclusion further study of the APM and quality 
control of MHC-I will improve the identification of epitopes involved in both malignant 
neoplasms, viral diseases and in autoimmune diseases. 
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